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Abstract 
The failure to predict drug-induced toxicity reactions is still a major problem contributing to 
a high attrition rate and tremendous cost in drug development. Xenopus laevis embryos 
are amenable for the early stage medium to high throughput small molecule screens. We 
hypothesise Xenopus embryos can assist in vitro drug-induced toxicity safety assessment 
in the early phases of drug development before moving on to expensive preclinical trials in 
mammals. The objective of this study was to assess the use of Xenopus laevis embryos 
for the prediction of organ-specific toxicity. To do this I used drugs known to generate 
toxicity reactions in humans. First of all I determined that Xenopus embryos treated with a 
drug from the age of stage 38 until stage 45, was an appropriate assay for the prediction 
of drug-induced toxicity. The embryos expressed major drug metabolism enzymes 
including CYP2E1, CYP2D6, CYP3A4 and glutathione S-transferases, sulphotransferases 
and glucuronosyltransferases. They also expressed KCNH2, which encodes the α-subunit 
protein of the potassium ion channel KV11.1 that contributes to heart electrophysiology. 
For drug-induced liver injury, I used paracetamol treatment. Xenopus laevis embryos 
treated with paracetamol (0-5 mM) generated predicted paracetamol metabolites, had a 
dose-dependent depletion of free glutathione and increased expression of microRNA-122 
(miR-122) in tissue that did not contain the liver. To investigate drug-induced 
cardiotoxicity, I treated Xenopus embryos with doxorubicin (0-100 µM) and terfenadine (0-
50 µM). Embryo heart rates increased and decreased with these drugs respectively and 
arrhythmias occurred with both drug treatments. Embryos treated with doxorubicin had an 
increasing amount of arrhythmia that correlated with an increasing dose of doxorubicin 
treatment. Terfenadine treatment induced arrhythmia at a rate that was not concentration 
dependent. Wholemount in situ hybridisation (WISH) revealed the Xenopus embryos also 
express miR-208 specifically in the heart, similar to mammalian models. We conclude that 
Xenopus laevis embryos exhibit some similar characterisations of drug-induced 
hepatotoxicity and cardiotoxicity observed in mammalian models. These data indicate the 
Xenopus embryo could be a useful model to assess drug-induced toxicity and aid lead 
compound prioritisation in early drug development. 
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1 Chapter 1: Introduction 
1.1 General Overview of Drug Development 
On average it takes a compound 10-15 years to progress from the discovery phase to 
being registered and legally available on the market for the appropriate patients. This 
does not leave much time to recover the cost of development before the drug is taken off 
patent. The drug development process can differ slightly according to the pharmaceutical 
company and the type of compound being pushed through, but in general the pipeline 
consists of the following stages (Figure 1-1). 
 
 
Figure 1-1 Drug Development pipeline 
Typically, a drug will take 10-15 years in drug development from drug discovery until 
approval. The in vitro and in vivo models are used for pharmacokinetics studies and in 
drug safety assessment, which continues as the clinical studies are performed. The earlier 
a drug-induced toxicity reaction is identified for a drug candidate, the less time and money 
is wasted on the further development for a drug that has the potential to be a greater risk 
than benefit to the general population. Post-marketing surveillance is often when 
idiosyncratic adverse drug reactions are identified because they are too rare to be noticed 
in the clinical phase that is comprised of smaller cohorts.  
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To begin with, there is the discovery phase, a target has been identified and new chemical 
entities (NCEs) are put forward to determine which are good new potential therapeutic 
compounds for that target. Here, one is either looking at an entirely new therapeutic target 
for a disease model, or it could be the same target as a currently marketed medicine, and 
the aim is to find a NCE that is more efficient or has less side-effects. The “best” NCEs, 
termed lead compounds, are picked via analysis of their basic pharmacological properties. 
This is now often carried out by robotics so several tens of thousands NCEs can be 
processed at once, this is high throughput screening. For the last part of drug discovery, 
the lead compounds are optimised to generate more potent and more selective 
compounds, to be the best version of themselves with regards to their desired target. The 
compounds generated here are called drug candidates. Some preliminary toxicity studies 
are carried out during lead optimisation, however the majority of the toxicity studies begin 
in the preclinical phase of drug development.  
The aim of the preclinical phase is to generate data that will provide enough information to 
understand the properties of the drug candidates as much as possible before they 
progress into the clinical phase, into humans. The regulatory authorities such as the 
European Medicines Agency or the US Food and Drugs Administration, judge the plethora 
of information generated during the preclinical phase studies for a drug candidate and 
choose whether to allow it through to clinical phase studies in humans or not. The data 
submitted to the regulatory authorities is generated under the Good Laboratory Practice 
(GLP) code to ensure they are of a certain standard and this data is therefore deemed 
more reliable and trustworthy compared to non-GLP experiments (Sullivan, 1995). In 
addition to safety pharmacology and toxicological testing, the preclinical phase also 
involves pharmacokinetic studies, which consist of studies to look at the drug candidate 
adsorption, distribution, metabolism and excretion  (ADME). These additional studies are 
divided into primary and secondary pharmacology. Primary pharmacology investigates the 
drug candidate mechanism of action that is directly associated with the therapeutic target. 
Secondary pharmacology considers the mechanism of action not directly associated with 
the target (ICH (International Conference on Harmonization), 2014). The preclinical phase 
consists of in vitro and in vivo studies; the latter tends to follow the former. However, 
findings in the initial in vivo studies such as organ-specific toxicity can be evaluated 
retrospectively using target organ specific in vitro assays. Altogether, the preclinical phase 
will help to generate a first-in-human starting dose of the drug candidate, identify potential 
target organs for drug-induced toxicity and build a good idea of the parameters to be 
monitored in humans during the clinical phase to help to protect the phase I clinical phase 
healthy volunteers. 
 
 
3 
Finally, the successful drug candidate is submitted into the clinical phase, where it is 
administered to humans. The trials start with smaller groups of healthy volunteers in 
phase I clinical trials, and progress to phase III large, multiple groups of patients, that the 
drug candidate could provide a therapeutic use for.  
These 3 phases of drug development (drug discovery, preclinical and clinical) do not 
necessarily strictly occur one after the other, they sometimes overlap and preclinical 
studies are often continued whilst the clinical phase has begun. Furthermore, the length of 
time spent in each phase can be significantly different for a compound for which there is a 
great demand. An anti-cancer drug candidate that shows promise at extending the lives of 
cancer patients could spend a shorter amount of time in the preclinical phase and be 
pushed through to the clinical phase more quickly because it could be the only chance for 
some patients, who are willing to take on the potential risks associated with the drug 
candidate as the benefit could be a longer life. However for the majority of drug 
candidates, the regulatory authorities prefer a robust set of preclinical studies are carried 
out to assess the toxicological potential. 
1.2 Drug Safety Assessment in Drug Development 
The regulatory guidelines, for assessing the safety pharmacology of a drug candidate, are 
issued by the International Conference on Harmonisation (ICH). ICH was established in 
1990 in an attempt to integrate all of the existing regulations from different parts of the 
world such as Japan, the US and Europe. It is important to note that these are only 
guidelines and ultimately it is the drug company, not the regulator, which determines 
which safety studies are performed for a drug candidate in drug development. This is to 
help inject some flexibility into the drug development process and to encourage good 
experimental design for the studies that are necessary and justified for each individual 
drug candidate. Although there may be an initial catalogue of studies conducted for every 
drug candidate (Redfern et al., 2002), there is not a finite battery of studies that are, 
perhaps thoughtlessly, always conducted. Every drug candidate will have additional 
studies conducted in answer to their unique results from the initial studies. Overall the aim 
of the safety pharmacology studies is to investigate the potential undesirable 
pharmacodynamic effects of a substance on physiological functions in relation to 
exposure in the therapeutic range and above (ICH (International Conference on 
Harmonization), 2014). There are 2 main toxicological studies that are carried out: 
exploratory toxicology and regulatory toxicology. Exploratory toxicology studies typically 
consist of a single dose administered for 2 weeks at 2-day intervals. A large range of drug 
concentrations are used and the dose is increased throughout the 2 weeks and the 
studies are often not in accordance with GLP. These studies can help to determine which 
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organs are affected by the drug candidate and estimate the no toxic effect level (NTEL). 
These experiments provide preliminary, rough, quantitative information about the drug-
associated toxicity. On the other hand, regulatory toxicological studies are performed 
under GLP and GMP (good manufacturing practice) (Chorghade, 2006). The regulatory 
authorities and ethical committees require them to be performed before the drug 
candidate is given to humans, and they support marketing approval in parallel to clinical 
trials. The current major safety pharmacology ICH guidelines include ICH S6, S7A, S7B, 
S9 and M3. The so-called “core battery” of safety studies for compounds that are being 
developed for the purpose of human pharmaceuticals are found in ICH S7A (ICH 
(International Conference on Harmonization), 2014). Guideline ICH S7A encourages the 
design of studies that will test the effects of the drug candidate on the vital organ systems, 
usually cardiovascular, respiratory and central nervous systems. The ICH M3 (ICH 
(International Conference, 2009) focuses on the preclinical safety studies with regards to 
the conduct of human clinical trials and marketing authorization and the ICH S6 guidelines 
assess the evaluation of biotechnology-derived pharmaceuticals. The ICH S9 guidelines 
are helpful for anticancer drug candidate study design. The ICH S7B guidelines stipulate 
the preclinical testing strategy for the evaluation of the potential for delayed ventricular 
repolarization (ICH (International Conference on Harmonization), 2005). This is the one 
preclinical study that the regulatory authorities state must be investigated (Bowes et al., 
2012). An in vitro assay must be performed to investigate the effects of the drug candidate 
on the alpha subunit of the voltage-gated potassium ion channel (KV11.1) encoded by the 
gene human Ether-à-go-go-Related Gene (hERG). A drug candidate that interacts with 
this protein encoded by the hERG, a gene that is also known as KCNH2, will often be 
strongly associated with cardiotoxicity. The hERG channel and drug candidate 
relationship will be discussed later in this chapter. As well as the core battery of safety 
studies, other experiments that are popular in preclinical drug candidate safety 
assessment include genetic toxicity assays, studies that investigate drug-drug interactions 
and metabolite-mediated toxicity. The ability of the drug candidate to cause DNA damage 
(mutagenicity), chromosome aberration and chromosome breakage can be assessed 
using the Ames test (Ames et al., 1975; Maron and Ames, 1983), the micronucleus assay 
(Galloway et al., 1994) and clastogenicity assays respectively (Kirpnick et al., 2005). It is a 
good idea to investigate if a drug candidate interacts with a popular enzyme or membrane 
transporter protein that other existing drugs are known to inhibit or induce, such as 
cytochrome P450s and P-glycoprotein (Wienkers and Heath, 2005). And increasingly, the 
generation of reactive metabolites is important to investigate in drug development, 
particularly with regards to their association with organ-specific toxicity and idiosyncratic 
toxicity (Baillie et al., 2002). Many reactive metabolites are responsible for the formation of 
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adverse drug reactions (Park et al., 2005b) which can have a detrimental effect on a 
marketed drug. 
1.3 Problems with Drug Safety Assessment 
1.3.1 In Drug Development: Drug attrition 
It is widely acknowledged that in the past few decades, improved techniques such as 
high-throughput screening (Mayr and Fuerst, 2008), increasingly sensitive liquid 
chromatography mass spectrometry, (Feng, 2004; Kramer et al., 2007), combinatorial 
chemistry, faster DNA sequencing (Scannell et al., 2012) and improved X-ray 
crystallography has helped the drug discovery phase be more efficient. A larger number of 
NCEs are available to be screened quicker thus accelerating the time taken to identify a 
lead compound and subsequently reducing discovery phase costs. However there has 
been a decline in research and development (R&D) productivity (Pammolli et al., 2011) 
this is thought to be, in part, due to what has been referred to as “development-limiting 
toxicity” (Kramer et al., 2007), defined as a toxicity that has an undesirable safety margin 
and cannot be monitored, therefore it will affect the drug marketability.  
Toxicity associated with NCEs is a dominant cause for attrition in all phases of drug 
development (Kramer et al., 2007). Consequently, an effort has been made by 
pharmaceutical companies to move safety studies towards the early stages of 
development (Hamdam et al., 2013; Redfern et al., 2002) to identify and remove the 
compounds which are more likely to induce a toxicity phenotype as early as possible in 
drug development in an attempt to select the compounds which should be a better 
investment of time and money. Early safety assessment can help in the decision making 
process in lead generation, give chemists the opportunity to remove hazardous aspects of 
the lead compound during lead optimization, introduce risk assessment early in drug 
development and help to manage safety margins in preclinical and clinical development 
studies (Bowes et al., 2012). It is thought about 70 % of all drug attrition in drug 
development associated with safety concerns, occurs in the preclinical phase (Kramer et 
al., 2007). As a result, a more strategic and efficient assessment of safety pharmacology 
in the preclinical phase will increase the quality of the drug candidates selected for the 
clinical phase, they will be more likely to make it through to the marketing stage. 
1.3.2 After Drug Development: Adverse drug reactions 
An adverse drug reaction (ADR) is defined as a response to the application of a drug at a 
standard dose for therapeutic, prophylactic and diagnostic use that is considerably 
harmful and likely to become hazardous with continuous administration (Anonymous, 
1972; Edwards and Aronson, 2000). The drug treatment responsible for the ADR is 
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usually withdrawn or the dosage can be altered. ADRs are typically categorised into two 
types according to their mechanistic process. Type A are the most common ADRs and 
account for approximately 80% of all ADRs. They are predictable from the 
pharmacological properties of the implicated drug and are dose-dependent. Type B are 
idiosyncratic ADRs, and they tend to be more severe than type A and make up 10-15% of 
all ADRs. Type B can be further divided into immune and metabolic-mediated reactions 
(Gomes and Demoly, 2005; Pirmohamed et al., 2002) and they are more difficult to detect 
during drug development than type A ADRs. The reason for this can be put down to the 
fact that some type B ADRs only occur in 1 in 1000 to 1 in 10000 people, which when one 
considers the group size for human clinical trials is smaller, it is likely that these ADRs will 
be missed. There are additional, less common ADR types C, D and E: long-term adaptive 
changes, delayed effects and rebound effects when the drug is discontinued in patients 
respectively (Redfern et al., 2002). The delayed type D ADRs include examples such as 
carcinogenicity and teratogenicity and are investigated using preclinical toxicological 
studies. Type E is usually only detected during post-marketing surveillance. Type C ADRs 
occur with some drugs as a result of chronic use and dose accumulation. Some evidence 
exists for long-term methotrexate administration and it’s association with liver fibrosis, 
although the literature is not sure this is a valid association (Salliot and Van Der Heijde, 
2009). Antimalarial drugs and ocular toxicity have also been implicated as a type C ADR 
(Carr et al., 1968).  
ADRs are responsible for 1 in 16 UK hospital admissions, of which 2% are fatal. 
Pirmohamed and colleagues estimate that ADRs cost the NHS £499 million annually 
(Pirmohamed et al., 2004). Pharmaceutical companies stand to lose a significant amount 
of time and money if it becomes apparent that a compound causes moderate to severe or 
even fatal ADRs. It is particularly detrimental if the ADR is not discovered until the later 
stages of drug development such as the clinical phases, or after the compound has been 
approved and is in use in the general population. It is also in the patient’s best interest to 
reduce the number drugs that cause ADRs and associated drug attrition rate, not just for 
the obvious safety reasons, but also to guarantee there is an effective therapeutic drug 
option to treat the patient’s disease. Unfortunately, if a drug is the only effective treatment 
option, a patient will have to continue to use it even if drug-induced toxicity or 
hypersensitivity reactions are apparent. Therefore, it is important to remember that the 
decision to withdraw a drug also takes into account the availability of other treatments for 
that disease and the severity of the disease to be treated. Herein lies a similar challenge 
for pharmaceutical companies; determining when the potential adverse effects of a 
compound outweigh the therapeutic benefits to the targeted population of a specific 
disease (Stevens, 2006). Cancer is a good example of one such disease where patients 
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are more willing to tolerate risk of ADRs or a greater number of side effects associated 
with a drug, if the drug can extend their life.  
1.4 Drug-induced toxicity: Organ-specific 
1.4.1 Liver 
1.4.1.1 Structure and Function 
The human liver is located in the upper right part of the abdomen and extends across the 
centre to the upper left abdominal region. It is the largest visceral organ, the heaviest 
gland (approximately 1.4 kg) and the second largest organ to the skin in the human body 
(Tortora and Derrickson, 2014). The human liver divides into two lobes that are separated 
by a fold of mesentery called the falciform ligament, the inferior vena cava and the 
gallbladder. The right lobe is bigger than the left and has two functionally distinct lobes: 
the quadrate lobe and the caudate lobe, which are anterior and posterior respectively 
(Drake et al., 2012). The liver can be separated into approximately 1 million structural 
units called lobules. A lobule has a hexagonal shape that contains a central vein at its 
middle point and portal triads at its corners. A portal triad consists of connective tissue 
that envelops an artery, a vein and a bile duct. The population of hepatocytes supplied by 
1 portal triad is a hepatic acinus, which is divided into 3 zones: (1) periportal, (2) 
transitional and (3) perivenous. Zone 1 is closest to the portal triad vasculature and 
therefore receives highly oxygenated blood whereas zone 3 is close to the central vein 
and receives poorly oxygenated blood (Bacon et al., 2006).   
The three main components of the human liver are the hepatocytes, the bile canaliculi and 
the hepatic sinusoids. The hepatocytes make up about 80 % of the total volume of the 
liver and are therefore a major contribution to the overall function of the liver, they have 
metabolic, secretory and endocrine functions (Tortora and Derrickson, 2014). Hepatocytes 
secrete bile into the bile canaliculi, which are situated between neighbouring hepatocytes. 
The bile canaliculi aid the transportation of bile towards the gallbladder. Bile helps 
digestion in the duodenum of the small intestine, in particular, the emulsification and 
absorption of lipids. Oxygenated blood from the hepatic artery and deoxygenated blood 
from the hepatic portal vein is distributed into the blood capillaries found between 
hepatocytes known as hepatic sinusoids. This blood is then transported back to the right 
atrium of the heart via the inferior vena cava. 
As well as bile secretion, the liver also has role to play in many other vital human bodily 
functions, notably for this project, it is the key site of drug metabolism. Compared to other 
organs, the liver has a very high concentration of drug metabolising enzymes such as 
cytochrome P450s (CYP450s), which are found in the smooth endoplasmic reticulum. 
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Furthermore, drugs absorbed from the gastrointestinal tract are initially taken to the liver 
via the portal vein, this is known as first pass metabolism. If the liver and the 
gastrointestinal tract extract a drug effectively, it may never reach the systemic circulation. 
Consequently the liver can reduce drug bioavailability. The liver also functions to 
synthesise plasma proteins such as albumin as well as deaminate amino acids, which 
results in the generation of ammonia. When blood glucose is low, the liver can generate 
glucose from glycogen, specific amino acids, lactic acid and sugars, for example fructose 
and galactose. And vice versa, when blood glucose is high, the liver converts glucose to 
glycogen and triglycerides. Vitamins A, B12, D, E and K are stored in the liver alongside 
iron and copper. And finally, the liver contains Kupffer cells, which serve to phagocytise 
old red blood cells and white blood cells. 
1.4.1.2 Drug metabolism 
The liver contains a high concentration of the enzymes involved in drug metabolism. Drug 
metabolism is conventionally divided into phase 1 and phase 2 which are catabolic and 
anabolic respectively. Overall, the aim of drug metabolism is to decrease the lipophilicity 
of the drug and increase the polarity to excrete the compound quickly and avoid long-term 
exposure and excessive build-up of the compound. The kidneys find it easier to excrete 
polar compounds than non-polar compounds into urine. Phase 1 usually, although not 
always, precedes phase 2 and consists of oxidation, reduction and hydrolysis reactions 
that introduce a reactive, functional group to which a phase 2 conjugating system can add 
a substituent (Rang et al., 2016). The CYP450 enzymes are important for the phase 1 
oxidation reactions. They require the co-factor (reduced) nicotinamide adenine 
dinucleotide phosphate (NADPH) and molecular oxygen to ultimately transfer a single 
oxygen atom onto the drug substrate. In the human genome, 57 genes encode 18 
mammalian CYP450 families (Nebert et al., 2013) which are categorized according to 
their protein sequence homology. Most of the drug metabolising CYP450s belong to the 3 
families: CYP1, CYP2 and CYP3. The 8 major active CYP450 isoforms found in human 
hepatocytes have been described as CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, and CYP3A4 (Utkarsh et al., 2016). However, over half of all oral 
drugs are metabolised by the CYP2D6 and CYP3A4 isoforms in humans (Li et al., 1995). 
Two or more enzymes can catalyse the same type of oxidation, indicating a redundant 
and broad substrate specificity. In humans, genetic polymorphisms and diet account for 
major variations in CYP450 activity between individuals. Many single-nucleotide 
polymorphisms (SNPs) can be found in the gene encoding CYP2D6. Patients with the 
ultra-metaboliser CYP2D6 phenotype metabolise codeine to morphine quickly, and if 
given the “recommended common dose”, these patients could suffer brain damage or it 
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could even be fatal (Eichelbaum and Evert, 1996). Dietary and environmental factors can 
influence CYP450 activity by inhibiting and inducing the enzymes. Grapefruit juice is well 
known to contain a CYP450 inhibitor and herbal medicine St John’s wort induces CYP450 
activity. These environmental factors can be detrimental if a patient is taking a drug 
metabolised by CYP450s. 
Like phase 1 reactions, phase 2 anabolic conjugation reactions mainly take place in the 
liver, although some occur in the lungs and kidneys. Phase 2 reactions include 
glucuronidation, sulphation, acetylation, methylation, conjugation with amino acids and 
with the tripeptide glutathione (GSH). Conjugation usually results in a larger, inactive, 
more polar compound that is easier to excrete (Rang et al., 2016). The majority of the 
phase 2 conjugation reactions require enzymes, and isoforms exist for these too, much 
like the CYP450s. For example, glucuronidation involves the enzyme uridine 5'-
diphospho-glucuronosyl transferse (UGT), which transfers the glucuronosyl group of 
uridine 5’-diphosphoglucuronicacid (UDP-glucuronic acid) to target drug molecules, can 
be divided into 4 families in mammals: UGT1, UGT2, UGT3 and UGT8 (Mackenzie et al., 
2005). Sulphotransferases (SULTs) catalyze sulphation conjugation, they add a sulpho 
group from 3’-phosphoadenosine-5’-phosphosulfate (PAPS) to the target drug molecule. 
There are 13 known SULTs in humans that are divided into 4 families: SULT1, SULT2, 
SULT4 and SULT6 (Lindsay et al., 2008). 
1.4.1.3  Drug-induced Liver Injury (DILI) 
Drug-related liver injury (DILI), also known as drug-induced hepatotoxicity, is associated 
with impaired liver function and it is a common reason for drug candidate attrition in the 
late stages of drug development. It is also is leading cause of acute liver failure and the 
subsequent patient need for organ transplant. Consequently DILI is a big problem for the 
pharmaceutical industry as it can waste a lot of time and money invested in a drug 
candidate. It is also considered a major public health problem. DILI can manifest as 
different clinical pathologies (Table 1-1). The drug-induced liver pathological phenotype 
that occurs in a minority of patients is specific to the drug; that is to say that each 
hepatotoxic drug will usually present as certain type of liver injury, if a liver-specific ADR 
was to occur. DILI can be resolved following discontinuation of the culprit drug or it can 
continue even after withdrawal, this can result in death. Fatality from DILI is not unusual. 
Nearly all patients will develop DILI if the dose of the hepatotoxic drug is high enough; this 
is predictable and dose-dependent DILI (Dragovic et al., 2016). The problematic type of 
DILI is idiosyncratic DILI which is much more unpredictable and manifests according to 
each individual’s physiology, for example their immune response to the drug and genetic 
variants in isoenzymes (such as the previously mentioned CYP450s) which influences 
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their drug metabolism. The incidence of idiosyncratic DILI ranges from 1 in 1000 to 1 in 
100000 patients that have been given the recommended therapeutic doses. These 
idiosyncratic ADRs are considered rare and can have a latency period ranging from 5 to 
90 days (William M Lee, 2003). Therefore they are regularly not detected in the clinical 
phase of drug development. The rarity of idiosyncratic drug-induced hepatotoxicity makes 
it near impossible to detect in a relatively small cohort clinical trial size of approximately 
3000 patients (Larrey, 2002; William M Lee, 2003). Over half of acute liver failure cases 
are drug-induced (Larrey, 2002) and more than 600 drugs have been associated with 
hepatotoxicity (Park et al., 2005a) which has led to numerous drug withdrawals from the 
market and black box labelling. For example, out of 51 drugs withdrawn from the market in 
the United States, European, or Asian markets between the years 1998 to 2008, the 
primary reason for withdrawal in 29 % was DILI (MacDonald and Robertson, 2009).  
 DILI is particularly difficult to predict and is often not identified until post-marketing 
surveillance, when the drug has been approved and used for several years by a much 
more diverse population of people with different treatment durations and possibly different 
dose range exposure than that experienced by the controlled clinical phase population the 
drug candidate was tested on before it was approved. The mechanism of hepatotoxicity 
related to drug treatment is often not completely understood and consequently it is hard to 
investigate during early stage drug development, especially because frequently, there is 
no relationship between the drug pharmacokinetic properties and the incidence of 
hepatotoxicity. Factors that affect drug metabolism also contribute to the occurrence of 
DILI, such as age, gender, body-mass index, pregnancy, renal disease and liver disease 
(Hunt et al., 1992).  
Although the exact mechanism of DILI for each offending hepatotoxic drug is not always 
completely understood, a set of general mechanisms that contribute to DILI has been 
described (Table 1-2). The mechanisms described have been separated for clarity, but in 
reality a DILI reaction involves several mechanisms, which when combined, generate the 
liver injury and this leads to liver function impairment. Furthermore, there are additional 
mechanisms described in the literature, however not all the hypotheses have been 
completely proven. The mechanisms in Table 1-2 focus on the role of the hepatocyte in 
DILI; other cell types are involved as well. The Kupffer cells are resident liver 
macrophages that can be activated to stimulate the release of cytokines and therefore 
exacerbate DILI, possibly helping to push past the liver immune tolerance to an immune 
response (Godoy et al., 2013; Jonsson et al., 2000). This cytokine response, secondary to 
the primary antibody-mediated or cytolytic response drug-protein adducts, can also 
activate neutrophil-mediated hepatotoxicity. Neutrophils can adhere to and release 
proteases into hepatocytes, causing cell necrosis (Jaeschke et al., 2002). The cells that 
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store fat are known as the stellate cells. The stellate cells are also involved in DILI 
reactions, they can produce fibrosis or form granulomas (William M Lee, 2003).  
 
Table 1-1: Clinical presentation of DILI 
Clinical Title Observed Characteristics 
Fatty Liver with lactic 
acidosis 
Microvesicular steatosis, systemic 
mitochondrial dysfunction 
Nonalcoholic Fatty Liver  Microvesicular or macrovesicular 
steatosis with or without ballooning and 
steatohepatitis 
Acute Hepatic Necrosis  Collapse and necrosis of liver 
parenchyma  
Acute Liver Failure  Collapse and necrosis of liver 
parenchyma with INR (international 
normalized ratio) >1.5 and 
encephalopathy  
Acute Viral Hepatitis-like 
Liver Injury  
Early onset symptom of DILI, fatigue, 
lack of energy  
Autoimmune-like Hepatitis  Detectable autoantibodies and/or 
autoimmune features on liver biopsy 
specimen  
Cholestasis without 
Inflammation  
Severe itchiness with hyperbilirubinemia  
Cholestatic Hepatitis  Elevated serum levels of ALP and total 
bilirubin 
Immune-mediated 
hepatitis 
Skin rash 
Bile duct damage Insufficient quantity of interlobular bile 
ducts with cholestasis 
Sinusoidal disorders Obliteration of central veins 
Fibrosis and cirrhosis Variable degrees of collagenization 
Nodular regeneration  Formation of microscopic or 
macroscopic liver nodules  
Adapted from Navarro & Senior (2006) and Tujios & Fontana (2011)
Immune-mediated DILI is associated with genetic variance. Patients that have a particular 
human leucocyte antigen (HLA) haplotype encoding their major histocompatibility complex 
(MHC), can have a higher chance of developing DILI than patients that don’t have that 
haplotype. For example, flucloxacillin and amoxicillin-clavulanate -induced liver injury are 
associated with HLA-B*57:01 and the SNP HLA-DRB1*1501-DQB1*0602 respectively 
(Lucena et al., 2011; Monshi et al., 2013). Genetics can also contribute to the generation 
of chemically reactive metabolites (CRMs). Specific polymorphisms in the enzymes 
involved in phase 1 and phase 2 drug metabolism have potential to (1) increase the 
amount of CRMs produced to above average relative to the general population (2) reduce 
the efflux of CRMs from hepatocytes or (3) alter the metabolic pathway for a drug (Godoy 
et al., 2013). In addition, it is important to remember that although Table 1-2 describes the 
mechanisms of DILI in accordance with a drug, it is often the case that the drug metabolite 
(or CRM) not the parent drug is the small molecule responsible for the DILI reaction. 
1.4.1.4 The role of chemically reactive metabolites (CRMs) in DILI 
Through drug metabolism, a reactive metabolite can be generated. This reactive 
metabolite may be a temporary intermediate before the next drug metabolism reaction, 
however it can be enough to bind to intracellular proteins and provide a significant 
contribution to the generation of a DILI reaction. Although there are animal models that 
are good for testing the safety of stable metabolites, this is not true for reactive 
metabolites. The vast majority of DILI reactions detected, associated with drug 
metabolites that are detected once the drug is available for patient use, are due to 
reactive (not stable) metabolites (Stepan et al., 2011). This is due, in part, to the lack of 
understanding the mechanisms of CRM-mediated DILI. In general, a CRM can irreversibly 
and covalently bind to endogenous proteins in the human body. This can disrupt cellular 
pathways and generate an ADR phenotype. The total amount of dose that covalently 
binds is known as the “body burden” (Thompson et al., 2016). But covalent binding alone 
does not always result in an ADR, it can be regarded as a drug bioactivation marker, not 
necessarily a direct indication of toxicity (Park et al., 2011). It is because most drug 
biotransformation occurs in the liver, that the generation of reactive metabolites is often 
associated with a hepatotoxic ADR. The production of CRMs from a parent drug does not 
necessarily indicate an ADR will definitely occur. The human body can neutralise the 
CRM, for example with phase 2 metabolism conjugation to GSH. To assess the ADR 
generation potential for an individual CRM, the following factors need to be considered: 
(1) parent drug exposure in metabolic tissues, (2) the rate of parent drug conversion to a 
metabolite, (3) the accumulation of the metabolite, (4) the cell’s ability to neutralise the 
CRM and (5) the physicochemical properties of the metabolite. The CRM is usually 
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electrophilic as it is frequently the product of phase 1 oxidation from CYP450 enzymes. 
This electrophilic characteristic is exploited in drug development as a method of CRM 
detection. Radiolabeled or fluorescently tagged nucleophilic trapped agents, such as 
GSH, are identified using mass spectroscopy and can indicate the presence of CRMs 
generated from a parent drug candidate (Park et al., 2011; Prakash et al., 2008). Electron 
spin resonance spectroscopy can also be used to detect CRMs using a spin trapping 
agent, for example N-tert-butyl-α-phenylnitrone (Albano and Tomasi, 1987). The enzyme 
that is responsible for generating a CRM could also become inactive as a result of this 
interaction with the CRM. This time dependent inactivation of a drug metabolising enzyme 
is another method of CRM detection (Hollenberg et al., 2008).  
It has been speculated that a drug candidate with a high lipophilicity is more likely to form 
a CRM because a high fraction of it has to be eliminated by drug-metabolising enzymes 
(Thompson et al., 2016). An octanol-water partition coefficient (also known as logP) 
greater than 3 indicates the drug candidate has a high potential for causing DILI (Chen et 
al., 2013). Chen and colleagues state that when combined with a high dosage, that is 
≥100 mg/day, a logP≥3 drug candidate is very likely to cause a hepatotoxic ADR. This 
combination is known as a “rule of two”. Although a structure cannot predict the type, 
severity or incidence of an ADR, there are certain structures of drug candidates that are 
known to be more likely to generate CRMs and subsequently increase the risk of a DILI 
reaction developing; so-called “structural alerts”. These are established based on 
evidence of previously marketed drugs known to cause DILI reactions. Drug candidates 
are evaluated using in silico techniques to identify offending structural moieties (Hsiao et 
al., 2012; Liew et al., 2012).  
For all these methods of CRM generation detection, the most common in vitro protocols 
include the incubation of the drug candidate with liver microsomes, cytosolic fractions or 
S9 subcellular fractions (Thompson et al., 2016). Despite all the methods mentioned 
above the exact mechanisms of CRM-mediated DILI reactions remain elusive. Regulatory 
guidelines do not exist for the detection of drug bioactivation and the assessment of drug 
safety associated with the metabolic process (Park et al., 2011). It is difficult to make 
models that will detect CRM-mediated DILI potential for several reasons. The most 
obvious reason is that CRMs are reactive and therefore short-lived, most do not enter the 
circulatory system so the human body is only exposed to them for a short period of time 
and this makes CRMs difficult to detect, identify and quantify (Guengerich, 2005). CRM-
mediated DILI reactions also tend to be part of the idiosyncratic and rare type of ADRs, 
thus even detecting the phenotype in drug development is challenging (Stachulski et al., 
2013). Immune cells contain some drug-metabolising enzymes and so are also capable of 
generating CRMs. A CRM that is covalently bound to an endogenous protein to form an 
 
 
14 
antigenic determinant, can activate drug-specific T-cells and bring about an immune-
mediated ADR (Lavergne et al., 2008). There are 3 major mechanistic pathways for 
immune-mediated ADRs: (1) the hapten or pro-hapten hypothesis, (2) the 
pharmacological interaction concept and (3) the altered self-peptide repertoire hypothesis. 
Briefly, the hapten/pro-hapten hypothesis states that parent drug- or drug metabolite-
protein adducts are displayed as antigenic determinants on the MHC molecule by antigen 
presenting cells and trigger T-cells and a subsequent immune-mediated ADR (Brander et 
al., 1995). Drugs are too small to initiate an immune response, but by covalently binding to 
a protein the combination is large enough to be antigenic and can stimulate an immune 
response. A hapten compound is protein reactive whereas a pro-hapten compound 
requires drug metabolism to become a reactive molecule. In the pharmacological 
interaction concept, the parent drug or CRM binds non-covalently and reversibly to a 
peptide-MHC complex and a T-cell receptor to stimulate a T-cell response (Pichler et al., 
2011). The third hypothesis was demonstrated using abacavir as the culprit drug. 
Abacavir binds to HLA-B*57:01, changing the structure of the peptide groove and 
consequently altering the self-peptide repertoire for that MHC molecule. Different peptides 
can now bind to this abacavir-bound MHC molecule and activate a pathogenic-like T-cell-
mediated immune response known as abacavir hypersensitivity syndrome (Illing et al., 
2012; Norcross et al., 2012; Ostrov et al., 2012). This syndrome is associated with a rash. 
In general, the skin is more susceptible to pathogenic T-cells reactions than other organs 
and indeed, most ADRs seen in hospitalised patients are associated with an ADR skin 
phenotype (Hunziker et al., 1997). This susceptibility is thought to be because the skin 
has a large surface area, a dense network of dendritic cells and a large network of blood 
vessels (Clark et al., 2006).  
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Table 1-2: Mechanisms of DILI and associated examples 
Mechanism of DILI Type of Reaction Examples of 
Drugs 
1. Cell Swelling, Cell Rupture and Cell Lysis 
High energy drug reactions with CYP450 
can cause the drug to covalently bind to an 
intracellular protein. This can lead to 
intracellular dysfunction and subsequent 
actin disruption, loss of ionic gradients, 
change in calcium homeostasis and a 
decrease in the amount of ATP. All of these 
factors contribute to hepatocyte swelling, 
rupture and lysis, this manifests as liver 
injury, which can affect liver function. 
Hepatocellular 
Mixed Hepatocellular 
and Cholestatic 
Isoniazid 
Trazodone 
Diclofenac 
Nefazodone 
Venlafaxine 
Lovastatin 
2. Bile Transport Inhibition 
Drugs can bind to the transport proteins at 
the canalicular membrane or the 
surrounding actin. This can inhibit bile 
export or interrupt bile flow. 
Cholestasis 
Mixed Hepatocellular 
and Cholestatic 
Chlorpromazine 
Estrogen 
Erythromycin 
3.Immune stimulation 
A drug is too small to initiate an immune 
response, but it can covalently bind to a 
protein and form a drug-protein adduct. 
This larger product can travel to the 
hepatocyte surface and be recognised by 
the immune system; it is considered an 
antigen. This antigen can elicit an antibody-
mediated cytotoxic immune response via 
the adaptive immune system, or a direct T-
cell-mediated cytolytic reaction via the 
innate immune system. Both reactions can 
activate further cytokine activity and 
subsequent inflammation in the liver. 
However, as with other organs, the liver can 
tolerate and suppress an immune 
response. Liver injury only occurs if the 
Immunoallergic 
Granulomatous 
Autoimmune 
Fibrosis 
Halothane 
Phenytoin 
Sulfamethoxazole 
Methyldopa 
Methotrexate 
Flucloxacillin 
Ximelagatran 
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natural tolerance is overcome. 
4. Programmed Cell Death 
A drug can activate the caspase cascade 
via tumour necrosis factor α (TNFα) or Fas 
resulting in apoptosis: cell shrinkage and 
nuclear chromatin fragmentation. 
Apoptosis and/or 
necrosis are involved 
in almost all types of 
drug-induced adverse 
reactions 
Many drugs 
including 
paracetamol and 
ethanol 
5. Mitochondrial Dysfunction 
If a drug inhibits β-oxidation, binds to a 
respiratory-chain enzyme or the 
mitochondrial DNA, this can cause 
oxidative stress. Subsequently, anaerobic 
metabolism, lactic acidosis and triglyceride 
and reactive oxygen species accumulation 
can occur. The lack of fatty acid oxidation 
and associated triglyceride accumulation in 
the liver leads to microvesicular steatosis; 
tiny lipid vesicles in the cytoplasm of 
hepatocytes (Jaeschke et al., 2002). 
Microvesicular fat 
Steatohepatitis 
Valproic acid 
Nucleoside 
reverse 
transcriptase 
inhibitors 
Tetracycline 
Aspirin 
Troglitazone 
Amiodarone 
Adapted from Lee (2003), Kaplowitz (2005), Tujios & Fontana (2011) and Godoy et al 
(2013)  
1.4.1.5 Current in vitro models for Drug-induced Liver Injury 
At present, there is not a single in vitro test that alone, can assess all the potential 
mechanisms of DILI in a drug candidate. In preclinical drug development, a combination of 
in vitro assays are used and the results are combined to evaluate the overall potential risk 
of DILI for a drug candidate. However, even once the risk has been calculated, it is difficult 
to determine the scale of the risk – will the DILI reaction be fatal or is it the case that all 
drugs have some potential to cause DILI but in reality, the human body can control this 
and there will never be any symptomatic patients. The complexity and tolerance ability of 
the human body cannot be captured in relatively simpler in vitro assays that may only 
consist of 3 different cell types. Drug candidate DILI assessment could be accurate at 
predicting DILI reactions in humans, but the reaction could be a low level reaction that 
patients can tolerate, much like most drugs have side effects. In either case, a promising 
drug candidate with good therapeutic predictions could be unnecessarily removed from 
drug development. So, it is important to develop assays that can mimic the mechanisms 
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of human DILI as closely as possible, but it is more important to understand the limitations 
of these studies and interpret the results correctly. 
The advantages and disadvantages of some of the common in vitro cell models used to 
help predict DILI are summarised in Table 1-3. Traditionally, immortalized hepatic cell 
lines HepG2, Huh7 and HepaRG have been used for in vitro hepatotoxicity prediction 
assays because they are easy to use and share similarities with hepatocytes (Funk and 
Roth, 2017). Both the HepG2 and the Huh7 cell lines are derived from well-differentiated 
hepatocellular carcinomas, from 2 different patients. The HepaRG cell line is derived from 
a patient with a liver carcinoma and hepatitis C infection. The HepaRG cell line is 
considered a “step-up” from the HepG2 and Huh7 cell lines because unlike those cell 
lines, the HepaRG appears to be more sensitive to known DILI compounds and exhibits a 
change in oxidative stress, mitochondrial damage, and disorders of neutral lipid 
metabolism in the presence of them (Wu et al., 2016). However overall, the cell lines do 
not mimic the human drug-metabolizing enzyme system as well as primary human 
hepatocytes, and this is an important characteristic as some DILI reactions are dependent 
on the generation of CRMs, as previously described. 
For the preclinical hepatotoxicity studies, primary cultured human hepatocytes are 
considered the “gold standard” (Gomez-Lechon et al., 2010; LeCluyse, 2001). They are 
much closer physiologically to in vivo human hepatocytes and preserve good drug 
metabolism mechanisms. However, they are unstable, they rapidly de-differentiate, the 
quality is dependent on the donor and the quantity can be irregular if you do not have a 
reliable surgical source that can supply liver tissue routinely. The instability of the primary 
human hepatocytes is reflected in the quick deterioration of drug-metabolizing enzyme 
activity (e.g. CYP450s) and transporter function (e.g. ATP-binding cassette (ABC) 
transporters) (Funk and Roth, 2017; Rowe et al., 2013). The phase 1 metabolism enzyme 
rate of activity declines quicker than the phase 2 enzyme rate in what is known as the 
phase 1 to phase 2 “shift” (Richert et al., 2016). Primary human hepatocytes can be 
cultured between two layers of gelled collagen; this is known as the sandwich model. The 
sandwich-cultured hepatocyte model has been proven to be particularly useful in the 
assessment of the ability of the drug candidate to inhibit bile acid transport (Kostrubsky et 
al., 2003). The uncertainty of when researchers will be able to obtain fresh primary human 
hepatocytes has led to the optimisation of cryopreservation. However, cryopreserved 
hepatocytes have a reduced cell attachment ability and transporter expression and are 
therefore not always suitable for the sandwich model (Swift et al., 2010). Primary human 
hepatocytes can also be cultured in 3D models either by use of scaffolds, hollow-fiber 
bioreactors, or spheroids. Overall, the 3D models tend to be even more liver-like than 2D 
monolayer cell culture with regards to the gene expression, phenotype and cell surface 
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receptor expression (Godoy et al., 2013). In the 3D models that use scaffolds, the 
hepatocytes can grow around the scaffolds that provide an artificial extra-cellular matrix 
(ECM). The scaffolding can be made from synthetic or natural materials. The majority of 
scaffolds are inexpensive; the exception is 3D printed scaffolds. Spheroids can be 
generated using hydrogels, through self-assembly in non-adhesive wells (Friedrich et al., 
2009), with the help of a bioreactor (Chang and Hughes-Fulford, 2008) or via the hanging 
drop method (Kelm et al., 2003). Cell lines, as well as primary human hepatocytes, can be 
used to generate spheroids. Primary human hepatocyte spheroids are popular because it 
is thought they closely resemble the complex structure of the human liver, they can retain 
human liver proteomes, retain morphological and molecular phenotypes and maintain a 
good level of liver function (Bell et al., 2016; Messner et al., 2013).  
Hepatocytes and non-parenchymal cells can be co-cultured to recapitulate the interaction 
of the cells of the human liver. Co-culturing can be performed in the sandwich and the 3D 
models. The non-parenchymal cells have included sinusoidal endothelial cells, Kupffer 
cells and stellate cells. 
Finally, microfluidic in vitro systems appear to be an option that can combine the 
advantages of all the other in vitro models whilst providing solutions to the problematic 
disadvantages. Co-culture of human liver cells onto bio-compatible plastic material is 
combined with the addition of structures such as small channels, which can be perfused 
to, for example, remove the build up chemically reactive metabolites, or add oxygen to the 
cells (Novik et al., 2010). There is already a semi-automated 3D culture microfludic 
system called the HepaChip®. The HepaChip® is still being optimised, but it known to 
have good phase 1 and phase 2 enzyme activity compared to standard co-cultures and it 
could be useful as a holistic model to investigate specific mechanisms of DILI reactions as 
the ECM, co-culture cell ratio and metabolic activity can be easily changed to mimic 
particular DILI mechanisms (Godoy et al., 2013).  
All of the in vitro models described have limitations, outlined in Table 1-3, but they can all 
be useful by picking an appropriate model to assess each DILI mechanism (Table 1-4) so 
long as the limitations of the model are taken into account when analysing the results. 
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Table 1-3: Advantages and Disadvantages of in vitro models for DILI 
Cell model Advantages Disadvantages Reference 
HepG2 
Huh7 
• Technically easy to 
use 
• Stable phenotype 
• Experimentally 
reproducible 
• Genetic 
manipulation 
• No communication 
between different 
cell types 
• Low or partial 
expression of drug 
metabolising 
enzymes, hepatic 
transcription 
factors and 
nuclear receptors 
(Funk and 
Roth, 2017; 
Godoy et al., 
2013) 
HepaRG • Same cell-line 
advantages as 
HepG2 and Huh7 
• More stable, 
sensitive and 
superior 
predictability of 
known DILI 
compounds than 
HepG2 and Huh7 
• Higher levels of 
drug-metabolising 
enzymes than 
HepG2 and Huh7 
• Low CYP450 
expression (except 
CYP3A4) 
comparable to 
primary human 
hepatocytes 
(Lübberstedt et 
al., 2011; Wu et 
al., 2016) 
Primary human 
hepatocytes: 
monolayer 
• Retain the entire 
hepatic drug-
metabolizing 
enzyme equipment 
(phase I and 
phase II) in an 
integrated, 
functional and 
inducible form 
• Unstable - can 
only be used for 1-
2 day experiments 
• Not always readily 
available 
• High variation 
between batches 
• Require expert skill 
to isolate and 
(Gomez-
Lechon et al., 
2003) 
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maintain 
Primary human 
hepatocyte: 
sandwich culture 
• Formed and 
functional bile 
canalicular 
networks 
• Polarized 
excretory function 
• Cryopreserved 
hepatocytes are 
less suitable than 
fresh hepatocytes 
• Degradable 
• Inconsistent 
 
(Swift et al., 
2010) 
3D culture: 
hydrogel 
• Longer hepatocyte 
function observed 
than that with 
sandwich culture 
• Degradable 
• Central cells show 
signs of necrosis 
(Moghe et al., 
1997; Prestwich 
et al., 2007) 
3D culture: scaffold 
based 
• Overall 
inexpensive 
• Good porosity 
• Drug can bind to 
scaffold 
• Low throughput 
(Godoy et al., 
2013) 
3D culture: 
spheroids 
• Stable long-term 
culture of primary 
human 
hepatocytes 
• Functional bile 
ducts  
• Good cell-cell and 
cell-ECM 
interaction 
• Polarized cells 
• Difficult to organize 
co-cultures 
(Bell et al., 
2016) 
Co-cultures • Hepatocyte cell-
non-parenchymal 
cell communication 
• Not high-
throughput, labour 
intensive 
(Godoy et al., 
2013) 
Microphysiological 
systems: Liver-on-
a-chip 
• Physiological 
relevance - 
perfusion 
• Long-term 
 
• Limited 
widespread use as 
requires 
sophisticated 
equipment 
(Godoy et al., 
2013) 
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Table 1-4: Major DILI mechanisms and corresponding useful in vitro models 
DILI reaction mechanism In vitro assessment model Reference 
Drug metabolism: 
1. Lipophilicity 
2. The generation of 
CRMs 
• logP≥3 and a dose≥100 mg/day 
is indicative of a high risk factor 
for DILI 
• Cell-free glutathione (GSH)-
trapping assays 
• Covalent binding using a 
radiolabeled drug 
• Cytotoxicity assays using cell 
lines that overexpress the major 
CYP450s 
(Brink et al., 
2017; Chen et 
al., 2013; 
Thompson et 
al., 2016) 
Interference with 
transporters, for 
example: 
- Bile Salt Export 
Pump (BSEP) 
- Multidrug 
resistance-
associated 
protein 2 (MRP2) 
• Inverted membrane vesicles 
recombinantly expressing the 
respective transporter to 
measure transporter vesicles 
(Funk et al., 
2001; Funk 
and Roth, 
2017) 
Intrahepatic cholestasis • Sandwich model using primary 
human hepatocytes to measure 
the increase of bile acids and 
it’s effect on cytotoxicity and 
mitochondrial damage 
(Köck et al., 
2014) 
Mitochondrial 
dysfunction 
• Use isolated mitochondria 
• Measure cytotoxicity on primary 
human hepatocytes or cell lines 
grown under specific conditions 
e.g. replace the glucose with 
galactose in the media for 
hepG2 cells and they are more 
susceptible to drug-induced 
mitochondrial dysfunction 
(Marroquin et 
al., 2007) 
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Combination of all 
mechanisms 
• Primary human hepatocyte 
suspension and cell lines: 
- General cytotoxicity - measure 
lactate dehydrogenase (LDH) 
leakage, a change in ATP 
levels, the Resazurin assay 
- Other cytotoxicity – measure 
the level reactive oxygen 
species, free GSH decline and 
caspase activation 
(Richert et al., 
2016; Zhang 
et al., 2016) 
Adapted from the text of (Funk and Roth, 2017) 
 
Pharmaceutical companies have turned to optimising in vitro methods to predict and 
characterise DILI mechanisms because often, a hepatotoxic reaction is first detected in 
the clinical phase or the phase 4 post-marketing surveillance, of drug development in 
humans. Therefore the hepatotoxic reaction associated with the drug candidate was not 
significant, or just did not occur, in the animal models. For the liver especially, the current 
animal models have poor correlation with human toxicity reactions. In approximately 45 % 
of human DILI cases, the rodent and non-rodent species did not detect DILI in the 
regulatory toxicology studies performed in drug development (Olson et al., 2000). 
Nonetheless, as previously described in this chapter, the drug regulatory authorities 
require a drug candidate to be tested in non-rodent and rodent species before it is 
assessed for human clinical trials.  
1.4.1.6 Current in vivo and ex vivo models for Drug-induced Liver Injury 
An ideal animal model would undertake the same mechanism as humans towards the 
mechanism of DILI and the potential impairment of liver function that could follow 
(Shenton et al., 2004). However, as previously discussed in this chapter, the exact 
mechanisms that result in an idiosyncratic DILI reaction are largely unknown. A good 
animal model can be determined by using it to assess drugs that are known to be 
associated with DILI reactions and liver function impairment. The animal model should be 
able to distinguish between these hepatotoxins and drugs that have not been associated 
with any DILI reactions. As with the in vitro assays, the in vivo models can be separated 
into the mechanisms of DILI. 
For the immune stimulation mechanism, Halothane has been the popular model drug that 
is thought to act via stimulation of the adaptive immune system and consequently, it is the 
drug animal models are being developed against to detect this mechanism. An animal 
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model for this mechanism would require a drug candidate to sensitise their immune 
system, stimulate it upon re-challenge with the drug candidate, and overcome immune 
tolerance to overtly display an immune response that is manifested in the liver (Roth and 
Ganey, 2011). There are very few animal models for this mechanism; one example 
however, is the mouse model for flucloxacillin-induced cholestatic liver injury. Nattrass and 
colleagues used a CD4+ deficient mouse model, with a MHC-II αβ gene mutation to try to 
mimic sensitisation to the β-lactam antibiotic flucloxacillin (Nattrass et al., 2015). 
Flucloxacillin is thought to initiate hepatotoxicity through the activation of CD8+ T-cells, 
particularly in patients with the HLA-B*57:01 allele. This model found similarities to human 
flucloxacillin-induced liver injury such as elevated plasma DILI biomarkers and possible 
CD8+ T-cell-mediated hepatocyte apoptosis. However further investigation is needed to 
find an animal model that can be routinely used in drug development to represent the 
immune stimulation mechanism that leads to severe liver injury in humans. 
The mitochondrial dysfunction DILI mechanism, has in part, been captured in the 
superoxide-deficient-2 (SOD-2) heterozygous deficient mouse model. The reduction of 
SOD-2 available in the mouse cells, results in a mouse that has reduced mitochondrial 
function and the mice are more sensitive to drug-induced mitochondrial damage, 
especially from drug candidates that intensify oxidative stress (Roth and Ganey, 2011). 
Unfortunately, the liver injury in this model appears to be modest compared to that 
observed in humans and the duration of drug-candidate treatment required to get the 
hepatotoxic reaction varies (Corsini et al., 2012). Other mitochondrial dysfunction animal 
models have been developed, but they are more specific to the known hepatotoxic drug. 
Examples include fialuridine in woodchucks (Tennant et al., 1998), panadiplon in rabbits 
(Ulrich et al., 1998) and valproic acid in juvenile visceral steatosis (jvs) heterozygous mice 
(Knapp et al., 2008).  
As previously stated, drug metabolism is an important factor that can contribute to the 
generation of a DILI reaction. But there are differences in drug metabolism enzyme 
expression and activity between animals and humans, between animals themselves and 
interindividual variance within humans, which makes it difficult to develop an animal model 
that can detect DILI via CRM generation. An enzyme isotype that manifests as a reduced 
metabolism phenotype can result in an accumulation of the parent drug in the liver, to 
potentially toxic concentrations. On the other hand, a fast metaboliser enzyme isotype 
could generate a high concentration of reactive metabolites, which could lead to liver 
injury. To better translate these genetics factors from animal models into humans, 
transgenic mice have been developed that express human CYP450s. Chimeric mice with 
a humanized liver, generated via human hepatocyte transplantation, also have the 
potential to produce good translatable data. One popular ex vivo method to detect CRM-
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mediated liver injury is the isolation of liver subcellular fractions such as microsomes. 
Microsomes are not usually found in healthy human cells, they are typically isolated from 
human or rat hepatocytes via ultra-centrifugation. The high rotation speed (100000 xg) 
produces pellets that contain fragments of the endoplasmic reticulum, known as 
microsomes, which have a high concentration of CYP450 enzymes. Liver microsomes 
taken from a rodent model dosed with a radiolabeled drug can be assessed for drug 
protein-adduct formation by isolating proteins. Alternatively, a radiolabeled drug candidate 
that covalently binds could be measured indirectly using non-invasive autoradiography 
(Takakusa et al., 2008). Covalently bound drug or drug metabolite to intracellular proteins 
is an indication the drug candidate has the potential to cause liver injury. Furthermore, 
drug metabolite binding to GSH is also a risk factor that predisposes individuals to 
hepatotoxicity. Drug metabolites and drug protein-adducts or drug lipid-adducts can now 
be detected without the need for radiolabeling using mass spectrometry techniques. The 
amount of covalent binding in drugs known to be associated with DILI due to the 
production of reactive metabolites, has been estimated using antibodies to the reactive 
metabolite protein adducts and subsequent western blot or immunohistochemistry 
experiments (Bourdi et al., 2001).  
An animal model that only focuses on one DILI mechanism is often not enough to 
recapitulate the severity of liver injury that occurs in humans. Multiple determinants 
contribute to overcome liver tolerance including environmental factors such as 
inflammatory stress. A bacterial or viral infection in combination with a therapeutic dose 
can result in a DILI reaction. To mimic this in an animal model, the animal is co-treated 
with the culprit drug and lipopolysaccharide (LPS). LPS binds to the toll-like receptors 
(TLRs) on mammalian cells and initiates the expression and release of pro-inflammatory 
mediators, for example, cytokines, reactive oxygen species (ROS) and toxic proteases 
(Arbour et al., 2000). The LPS plus drug animal DILI model has successfully identified 
drugs known to be associated with DILI such as diclofenac, chlorpromazine, trovafloxacin 
and halothane, and perhaps more importantly, no severe or moderate DILI reaction was 
produced with drugs not associated with DILI. However, a positive result can sometimes 
depend on getting the timing between the administration of the drug and the LPS correct. 
It is different for every drug and between animal species, consequently, it is difficult to 
implement this animal model as a good throughput DILI detection model in drug 
development (Roth and Ganey, 2011). 
Rodents are usually the first animal species used in drug development, however zebrafish 
have also had some interest as a model for the prediction of DILI. Zebrafish possess 
similar drug metabolising enzymes to humans, including CYP450s, and accordingly, they 
follow similar drug metabolism pathways. Once validated and the limitations have been 
 
 
25 
determined, a zebrafish DILI model could be useful to bridge the gap between preclinical 
in vitro assays and rodent models (Vliegenthart et al., 2014b). 
1.4.1.7 Biomarkers: Drug-induced liver injury 
It is widely acknowledged that the current tests used in pharmaceutical industries to 
predict DILI are poor (Dragovic et al., 2016). Consequently, there has been a great effort 
in research to find biomarkers that are more sensitive and specific to DILI. A biomarker is 
defined as a characteristic that can be measured as an indicator of normal biological and 
pathogenic processes as well as pharmacologic response to a therapeutic dose 
(Biomarkers Definitions Working Group, 2001). A good organ-specific protein or gene 
biomarker should be approximately >10-fold higher than the maximal values of that gene 
(or protein) expression in any other tissue (Qin et al., 2016). Biomarkers are important in 
the preclinical and clinical phases of drug development, and in the clinic to diagnose and 
monitor disease. Many biomarkers have been used to try to detect DILI, however the 
sensitivity and specificity varies. The ideal biomarker for DILI should be non-invasive, is 
useful for the preclinical and clinical phases of drug development, specific to liver injury 
and easily detectable and measured through a uncomplicated laboratory assay (Antoine 
et al., 2009). It would also be useful if the biomarker reflected the state of liver function, 
because as mentioned previously, liver injury does not necessarily lead to impaired liver 
function. Here, I shall discuss the major DILI biomarkers that have been used in the past 
70-80 years. 
1.4.1.7.1 Alanine aminiotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP) and total bilirubin (TBL) 
The enzymes ALT, AST and ALP are all intracellular in a healthy patient. When there is 
liver disease or a DILI incident, these enzymes are elevated in the blood serum. 
Hepatocyte damage, presented as hepatocellular liver injury in the clinic, exhibits an 
elevation of the aminotransferases. Whereas the cholestatic liver injury phenotype, is 
reflected with a dominant ALP serum increase, followed by raised TBL levels.  In the 
mixed hepatocellular and cholestatic liver injury phenotype, both ALT and ALP levels are 
significantly greater than the healthy norm (William M Lee, 2003). However a liver biopsy 
and histological analysis would be the only way to know for certain what type of liver injury 
has occurred. The R formula, when measured at the onset of DILI, can help identify the 
type of liver injury, R= ALT (upper limit of normal, ULN)/ ALP (ULN). R≥5 indicates a 
hepatocellular liver injury phenotype, R≤2 indicates a cholestatic liver injury and finally 
2<R<5 is a mixed phenotype (Aithal et al., 2011; Benichou, 1990). ALT is predominantly 
present in liver cells and at low concentrations elsewhere in the human body. In contrast, 
AST can be found in the red and white blood cells, skeletal muscle, the heart, lung, brain, 
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kidney and pancreatic tissue as well as the liver. It is for this reason, elevated serum ALT 
is more specific to liver injury than an AST increase (Giboney, 2005; Robles-Díaz et al., 
2016). However overall, ALT, AST and ALP can all be affected by other factors, none of 
these enzymes are entirely specific to DILI reactions. For example, hyperthyroidism 
(Cooper et al., 1979) and bone disease (King, 1953) can cause an increase in serum ALP, 
and serum ALT and AST can be elevated after exercise (Fowler et al., 1962). 
Furthermore, another limitation of the liver enzymes as biomarkers are the short half lives. 
ALT and AST have short circulation half lives at 47 h and 17 h respectively. Hy’s Law 
dictates that an AST or ALT>3 xULN with TBL> 2xULN indicates a hepatocellular DILI 
reaction, which has a 10-50 % high risk of mortality without liver transplantation 
(Zimmerman, 1999, 1978). But there has been a great effort in research to find a 
biomarker that is more specific to DILI reactions. The following biomarkers are some of 
the proposed biomarkers. 
1.4.1.7.2 Glutamate dehydrogenase (GLDH) 
GLDH is a mitochondrial enzyme abundant in the liver. It is more specific to the liver than 
ALT and AST, however some GLDH can be found in the kidney and in skeletal muscle. 
An increase in circulatory GLDH is indicative of mitochondrial dysfunction, a loss of 
mitochondrial membrane integrity and subsequent hepatocellular necrosis (Robles-Díaz et 
al., 2016). However GLDH can also be influenced by other factors, for example, it has 
been reported that the GLDH circulatory levels increase with subcutaneous heparin 
injections (Harrill et al., 2012).  
1.4.1.7.3 Cytochrome c 
Cytochrome c shuttles electrons between complexes II and IV of the electron transport 
chain. It is a small heme protein located in the inner membrane of the mitochondria. It is 
not liver-specific, but it is a biomarker for mitochondrial dysfunction that leads to apoptosis 
(Hu et al., 1999; Miller et al., 2008). Pathological mitochondria membrane 
permeabilisation causes the release of cytochrome c into the cytosol where it activates 
caspase-mediated apoptosis. Eventually cytochrome c is transferred into the serum and it 
can also be detected in urine. Saturated GSH conjugation or the binding of a reactive 
metabolite to a mitochondrial protein can lead to cytochrome c release into the serum 
(Antoine et al., 2009).  
1.4.1.7.4 High-mobility group box-1 (HMGB1) 
HMGB-1 is a nuclear protein and inflammatory mediator. Increased levels of serum 
HMGB-1 correlate with drug-induced liver injury. Its proinflammatory activity and 
stimulation of immune activation is mediated through signalling the toll-like receptor (TLR) 
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and receptor for advanced glycation end-products (RAGE) signalling (Antoine et al., 2012; 
Kubes and Mehal, 2012). HMGB-1 can recruit macrophages to the site of liver injury via 
TLR4 and RAGE. HMGB1 in the hypoacetylated form is released into the plasma from 
damaged cells that have compromised mitochondria. If the culprit drug or drug metabolite 
impairs mitochondria, the cellular production of ATP is reduced, and the cell death is a 
necrotic phenotype (as opposed to apoptotic) (Scaffidi et al., 2002). The hyperacetylated 
form of HMGB-1 is released from active immune cells.  
1.4.1.7.5 Keratin-18 (K18) 
Keratin-18 is an intermediate filament, it contributes to cell structure and support and it is 
present in the epithelial cells of the liver, although it is not liver-specific (Cummings et al., 
2006). K-18 accounts for approximately 5 % of total hepatic protein. It is a caspase target 
during apoptosis and is released into the blood from unhealthy cells in a fragmented form 
and a full-length form indicating apoptosis and necrosis respectively (Schutte et al., 2004).  
1.4.1.7.6 MicroRNA-122 (miR-122) 
Micro ribonucleic acids (miRNAs) are non-coding RNAs, approximately 22 nucleotides 
long, and they regulate messenger RNA (mRNA) usually through binding to the mRNA 3’ 
untranslated region (UTR) (Bartel, 2004). MiRNAs are stable and involved in a wide 
variety of physiological and pathological processes in humans and other animal species. 
In healthy humans they can found inside cells and extracellularly. MiRNAs can also be 
cell- and tissue-specific and their abnormal presence in extracellular body fluids can 
indicate cell damage has occurred. Inflammation and different types of cancer can be 
identified through the detection of specific miRNAs in body fluids such as breast milk, 
urine and cerebrospinal fluid, in amounts that are not usually found in a healthy human 
(Brase et al., 2010; Osaki et al., 2014; J. feng Wang et al., 2010).  Consequently miRNAs 
are widely accepted as good biomarkers (Weber et al., 2010). MiR-122 expression is 
specific to and highly expressed in the liver; 70 % of total human liver miRNA is miR-122. 
It is more specific to the liver than ALT, and can be useful in early phase human trials, 
where hepatotoxic drug candidates can go undetected if ALT is the biomarker in use 
(Thulin et al., 2014). When miR-122 is detectable in the blood, it can be a sign of 
hepatotoxicity. Circulating miR-122 has been identified in the early stages of 
hepatocellular damage and at lower doses compared to ALT (Antoine et al., 2013; Wang 
et al., 2009), Often, biomarkers for DILI are not detectable until the later stages of liver 
injury, when the prognosis can be worse. Circulating miR-122 is significantly increased in 
patients with diagnosed acute liver injury associated with paracetamol administration 
compared to patients that are taking paracetamol but do not present with acute liver injury 
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(Starkey Lewis et al., 2011). In other words, miR-122 has a good specificity for DILI 
identification. 
1.4.2 Heart 
1.4.2.1 Structure and Function 
The human heart is a pyramid or cone-like shape, the apex extends to the left, anteriorly 
and inferiorly, towards the diaphragm and the base is opposite. The heart is in the 
mediastinum anatomical region of the human body, so between the sternum and the 
vertebral column, and from the first rib to the diaphragm. About two thirds of the mass of 
the heart is to the left of the midline. It about the size of a human fist: 12 cm long and 9 cm 
wide at it’s widest point and 6 cm thick (Tortora and Derrickson, 2014). Cardiac muscle 
tissue is known as the myocardium, and it is the middle layer of the heart wall. The outer 
layer is called the epicardium and the inner layer is known as the endocardium. The 
myocardium layer contributes to 95 % of the heart wall and is responsible for the heart 
pumping movements, it is made up of cardiac muscle fibres. A cardiac muscle fibre 
contains 1 or 2 nuclei and is connected to a neighbouring fibre by an intercalated disc, 
which consists of desmosomes and gap junctions that are important for the propagation of 
action potentials and the coordination of atrial or ventricular contraction. In the human 
body, the heart consists of four chambers: two atria and two ventricles. The right side is 
separated from the left via the interatrial and interventricular septa. The ventricles have 
thicker walls than the atria and the left ventricle wall is thicker than the right. Blood is 
pumped into the atria of the heart first, through the atrioventricular valves, and then the 
ventricles pump blood out of the heart. The right atrioventricular valve is the tricuspid 
valve and the left is the bicuspid valve. The right atria and right ventricle receive 
deoxygenated blood from the body (from the inferior and superior vena cava) that is 
pumped to the lungs (via the pulmonary arteries), and the left atria and left ventricle pump 
oxygenated blood from the lungs (via the pulmonary veins) to the body (through the 
aorta). The pulmonary artery and aorta have semilunar valves, which prevent the flow of 
blood back into the heart ventricles. The atrioventricular and semilunar valves open and 
close according to the change in blood flow and the change in pressure exerted from atrial 
and ventricular contractions, in turn, contractions are controlled by the generation of action 
potentials. The autorhythmic cells of the sinoatrial node, located in the right atrial wall, 
repeatedly and spontaneously depolarise to overcome a threshold and trigger an action 
potential that causes the contraction of both atria. This action potential is conducted 
through the atrial muscle fibres to the atrioventricular node, located in the interatrial 
septum. During this conduction the atria have emptied their blood volume into the 
ventricles. From the atrioventricular node, the action potential enters the bundle of His, 
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then the right and left bundle branches towards the heart apex, and into the Purkinje 
fibres that extend up the walls of the ventricles. Ventricular contraction occurs. The action 
potential of a cardiomyocyte can be described in 5 phases (Figure 1-2). In a human, the 
baseline membrane potential is approximately -90 mV. In phase 0, the rapid entry of Na+ 
through voltage-gated sodium channels depolarises the membrane potential to +20 mV. 
This Na+ influx stimulates phase 1, where the transient potassium channels open to 
instigate rapid repolarisation via K+ efflux. However the repolarisation plateaus as L-type 
Ca2+ channels and slow delayed rectifier K+ channels open to allow Ca2+ influx and K+ 
efflux respectively in phase 2. The plateau is overcome in phase 3 when additional K+ 
rectifier channels open to increase the K+ efflux and bring the membrane potential back to 
-90 mV, phase 4 (Li et al., 2016). 
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Figure 1-2: Action potential of a cardiac myocyte 
Schematic of an action potential of a cardiac myocyte. In phase 0, sodium ions (Na+) enter 
the cell through voltage-gated Na channels for rapid depolarisation. Rapid repolarisation 
follows through the movement of potassium ions (K+) out of the cell in phase 1. In phase 
2, calcium ions (Ca2+) entered the cell through L-type Ca channels which is counter-
balanced by the efflux of K+ to result in a plateau. More K+ channels opened in phase 3 for 
further repolarisation until the membrane potential reaches the baseline of -90 mV in 
phase 4. 
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The movement of action potentials across the human heart produces an electrical current 
that can be detected, using an electrocardiograph, which generates an electrocardiogram 
(ECG) (Figure 1-3) The P wave is atrial depolarisation, the QRS complex is ventricular 
depolarisation and the T wave is ventricular repolarisation. The QT interval is defined as 
the start of the QRS complex until the end of the T wave. In a healthy human, the QT 
interval is approximately 350-440 ms and a QT interval >500 ms is indicative of an 
unhealthy individual (Li et al., 2016). A genetic predisposition can be the cause of a QT 
prolongation, or it can also be the result of a drug the patient is taking. 
 
 
Figure 1-3: Electrocardiogram (ECG) trace 
Schematic of the ECG trace for a human heart. The P wave is atrial depolarisation, the 
QRS complex is ventricular depolarisation and the T wave represents ventricular 
repolarisation. The QT interval is the time between the beginning of the QRS complex 
until the end of the T wave. Adapted from Rang et al (2016) and Li et al (2016). 
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1.4.2.2 Drug-induced cardiotoxicity 
Drug-induced cardiotoxicity is a leading cause of drug attrition in drug development and 
the removal of drugs from the market after approval. Of the primary reasons for drug 
withdrawal in the US, Asia and European markets between 1998-2008, 33 % were due to 
cardiotoxicity (MacDonald and Robertson, 2009). This percentage includes drugs that 
were specifically marketed for antiarrhythmic therapeutic use as well as drugs that were 
developed for an entirely different therapeutic use, such as the antihistamine drug 
terfenadine. Cardiotoxicity can be split into 2 different types: (1) functional cardiac injury, 
where a change in the mechanical function of the myocardium is observed and (2) 
structural cardiac injury, a loss of cellular or subcellular parts of the heart or impaired heart 
or vasculature morphology, such as extracellular matrix remodelling. There are many 
different cardiotoxic effects including: myocardial dysfunction, ischaemia, hypotension, 
hypertension, QT interval prolongation, arrhythmias and thromboembolism. A drug that 
alters the contractility of the heart, can cause a reduced cardiac output that leads to 
toxicological peripheral tissue hypoperfusion; this is the ultimate functional cardiotoxic 
effect, These drug-induced cardiotoxicity effects can be observed immediately after drug 
administration or not until months or years after the start of drug therapy (Cross et al., 
2015). 
Delayed repolarisation, represented by QT prolongation on an ECG, is a surrogate marker 
for proarrhythmia for a drug candidate in drug development. Excluding anti-arrhythmics, 
over 100 drugs are known to cause QT prolongation (De Ponti et al., 2001). A large 
number of these drugs have a long history of safe use, consequently, QT prolongation 
does not always lead to drug-induced cardiotoxicity.  The QT interval is the electrical 
systole of the ventricles in the heart. A prolonged QT interval equates to a prolonged 
action potential that will delay the ventricular repolarisation. In the majority of drug-induced 
QT prolongation, one cause is the inhibition of the rapidly activating delayed rectifier 
potassium ion current (IKr). The IKr current can be inhibited through blocking the voltage-
dependent potassium channel. In this channel there is the protein known as KV11.1, which 
is an alpha subunit of the channel encoded by the hERG (human Ether-à-go-go-Related 
Gene). The alternative, more official name for this gene, is KCNH2.  This KCNH2 encoded 
alpha subunit is the major subunit for IKr and each subunit contains 6 α-helical 
transmembrane segments (Sanguinetti et al., 1995). Some drugs such as amiodarone 
and terfenadine inhibit not only the IKr current, but also the slow delayed rectifier current 
(IKs), which also contributes to delayed ventricular repolarisation (Kodama et al., 1997; 
Salata et al., 1995). The KV7.1 voltage-gated potassium channel is the dominant channel 
type involved in the IKs current. The primary pore-forming alpha protein subunit of the 
channel is encoded by the KCNQ1 gene in humans (Jost et al., 2007). Like hERG, the 
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inhibition of this channel is associated with a long QT interval. Genetic mutations in the 
KCNQ1 gene are associated with long QT syndrome, hence the alternative name for the 
KV7.1 channel is KVLQT1 (Obiol-Pardo et al., 2011). Compounds that specifically block 
the KV7.1 type potassium channel alone, have been identified in drug development such 
as the Hoechst/Aventis compound chromanol 293B and Merck-Sharpe&Dohme 
benzodiazepine derivatives L-735,821 and L-768,673 (Busch et al., 1996; Salata et al., 
1996; Selnick et al., 1997). In addition to QT prolongation, these compounds are 
associated with T wave abnormalities and a longer action potential duration.   
As mentioned previously, QT prolongation drug candidate potential must be measured in 
an in vitro assay during preclinical drug development, as outlined in the ICH S7B 
regulatory drug development guidance document. A drug candidate must be evaluated to 
determine if it is a potent hERG channel blocker, to the point where it is deemed sufficient 
to have the potential to cause arrhythmia. However not all drugs that inhibit the hERG 
channel cause QT prolongation. Verapamil is a potent hERG channel blocker, but is not 
associated with QT prolongation (Redfern et al., 2003; Zhang et al., 1999). There is 
evidence that drug-induced IKr inhibition is a risk factor for Torsade de pointes (TdP). TdP 
can be identified on an ECG as continuously changing QRS complexes that indicate extra 
ventricular beats as a result of early depolarisation initiated in the Purkinje fibres or 
midmyocardial cells (Dessertenne, 1966). TdP can lead to potentially life threatening 
ventricular tachycardia. Drugs associated with TdP in humans are often present in the 
blood plasma at a concentration that is similar to that which is needed to block the hERG 
channel (Redfern et al., 2003). In addition to hERG channel blocking, a drug candidate is 
also tested for its ability to inhibit of the IKs current or the KV7.1 channel. 
1.4.2.3 Current in vitro models for Drug-induced Cardiac Injury 
As mentioned previously, ventricular repolarisation is governed not only by the opening of 
the hERG channel and associated K+ efflux, but many other voltage-gated channels are 
also involved. Ventricular repolarisation occurs when the net outward current exceeds the 
net inward current in phase 3 of the action potential and the sodium and calcium voltage-
gated channels contribute to this (Colatsky et al., 2016). Consequently, it makes sense to 
investigate drug candidate interaction with these channels in preclinical drug 
development, in addition to hERG blocking potential. This is the basis of the 
comprehensive in vitro proarrhythmia assay (CiPA) initiative. Once introduced, the ICH 
S7B document effectively removed the risk of approving drugs that cause TdP. However, 
a hERG channel blocker may not necessarily lead to QT prolongation, and QT 
prolongation does not always generate a TdP phenotype. Indeed, sometimes QT 
prolongation is not sufficient for TdP formation and an early after-depolarisation (EAD) is 
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required as well. Delayed repolarisation can stimulate a net inward current during the 
action potential plateau and cause an EAD. As a result, the low specificity of the hERG 
channel inhibition test has caused premature and inappropriate termination of good 
therapeutic drug candidates; it has generated false positives.  
The CiPA method, consists of 3 elements: (1) in vitro evaluation of drug effect on multiple 
individual currents using human ion channels in a heterologous expression system, (2) 
integration of the information from (1) into in silico computational reconstruction of a 
human ventricular myocyte to assess proarrhythmic liability and (3) confirm any effects 
found, by investigating ionic currents identified using in vitro electrophysiological 
techniques in human stem cell-derived cardiomyocytes (hSC-CMs) (Cavero and 
Holzgrefe, 2014; Sager et al., 2014). For the first element, 7 ionic channel currents are 
assessed: the L-type Ca2+, the depolarising late and fast Na+ channel currents, these are 
the inward depolarising currents. The last 4 currents are outward repolarising currents and 
are made from K+ channels they are: the slow delayed rectifier channel, the rapid delayed 
rectifier channel, transient K+ channel and the inward rectifier channel (Colatsky et al., 
2016; Sager et al., 2014).  All of the ionic currents are assessed via automated patch 
clamp platforms expressed in the heterologous expression systems such as human 
embryonic kidney cells or Chinese hamster ovary cells. The disadvantage of this 
comprehensive ion channel screening tool is that the channel expressed in the 
heterologous systems can have different drug-binding kinetics and a different mode of 
channel inhibition to the wild-type channel, such is the case with the hERG channel 
expression (Di Veroli et al., 2014). However the use of hSC-CMs in the third element has 
many advantages. The hSC-CMs can detect drug candidate effects not observed in 
heterologous expression systems, for example, modulation of IKr via intracellular 
secondary messengers, oxidative stress and altered calcium handling (Clements, 2016; 
Mewe et al., 2010). hSC-CMs are stable in culture, therefore they can also be used to 
study the drug candidate long-term effects on hERG channel expression.  
Prior to the CiPA initiative, Kramer et al (2013) investigated the use of models that 
measure the drug candidate multiple ion channel effects (MICE). They used 32 
torsadogenic and 23 non-torsadogenic drugs to test which combination of ion channel 
assays can improve on the 70 % predictivity for cardiotoxicity associated with a positive 
hERG channel result alone. They discovered that the best MICE model involved testing 
the drug candidate blocking potency for a combination of hERG and the voltage-
dependent calcium channel Cav1.2 (Kramer et al., 2013). The reason for this is that if a 
drug candidate blocks the hERG channel, the negative repercussions can be offset by 
simultaneous Cav1.2 blocking (Bril et al., 1996).  
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Manual patch clamp is considered the gold standard for hERG screening; it has a high 
predictive power and can measure the drug candidate effects on hERG channel function. 
However, it is too slow and costly to allow for the quick screening of a large amount of 
compounds in drug development, and requires a trained electrophysiologist (Murphy et 
al., 2006). One alternative method to detect drug candidate hERG channel inhibition is to 
investigate the ability of the drug candidate to compete with a known compound that binds 
to hERG channel. The rubidium efflux assay is one example of this method. In this assay, 
cells expressing the hERG channel (endogenous or otherwise) are loaded with rubidium 
ions (Rb+), that can be the radioisotope, 86Rb. The rubidium ions replace the potassium 
ions inside the cell. The cells are incubated with the drug candidate to be tested and 
subsequently a high concentration of potassium ions. The potassium ions depolarise the 
cells and open the hERG channel. Within minutes, the supernatant is collected and the 
content of rubidium ions is measured using atomic absorption spectroscopy or scintillation 
counting for 86Rb. A low amount of rubidium ions in the supernatant is an indication the 
drug candidate has a high affinity to the hERG channel, and is a hERG channel inhibitor 
(Chaudhary et al., 2006; Cheng et al., 2002). In the [3H]dofetilide assay, hERG channel 
inhibition is detected through the ability of the drug candidate to compete with the potent 
hERG channel antagonist, dofetilide (Redfern et al., 2003). A similar assay uses 
[3H]astemizole, another potent hERG channel blocker, to measure drug candidate hERG 
channel potency (Chiu et al., 2004). Finally, fluorescent voltage-sensitive dyes offer 
another method to measure cardiotoxicity in vitro. A voltage-sensitive fluorescent dye, 
such as bis-(1,3-dibutylbarbituric acid)trimethine oxonol, can reflect the change in 
membrane potential for sodium and potassium ion voltage-gated channels (Tang et al., 
2001). The alteration of this mechanism in the presence of a drug candidate can indicate 
its potential for hERG channel inhibition and the induction of a cardiotoxic reaction. 
1.4.2.4 Current in vivo and ex vivo models for Drug-induced Cardiac Injury 
Ex vivo female rabbit heart preparations are a popular model for drug candidate 
cardiotoxicity assessment. There 2 major methods: the ventricular wedge preparation and 
the Langendorff Screenit model. Both models retain the structure and electrophysiology of 
the ventricle. The wedge preparation is maintained with an arterial perfusion, the left 
circumflex branch of the coronary artery whereas the Langendorff heart has a perfused 
aorta (Liu et al., 2006; Valentin et al., 2004). The Langendorff-perfused heart can be 
coupled to an automated computerized system that can measure the concentration-
dependent electrophysiological effects of the drugs. This is the Screenit system. Both the 
rabbit ventricular wedge and Langendorff heart preparations are useful to define the 
mechanisms involved in proarrhythmia including QT prolongation, early after 
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depolarisation and transmural dispersion of repolarisation. In addition, the isolation of the 
heart is advantageous to study drug-induced cardiotoxicity because the drug is not 
exposed to hormonal and other physiological processes that are unique to the animal, not 
relevant to humans, and therefore could produce inaccurate cardiotoxicity assessment 
results. One disadvantage of these models is the need for a technical expert. 
Furthermore, these rabbit preparations have a different electrophysiology to humans, so it 
is hard to assess the proarrhythmic risk of a drug candidate using these assays (Gintant 
et al., 2016). Purkinje fibers isolated from dogs or pigs, can be used to assess the 
proarrhythmic potential of drug candidates. Gintant and colleagues demonstrated that 
drugs associated with QT prolongation and TdP in humans, cause a concentration-
dependent prolongation of the action potential duration in isolated Purkinje fibers. Non-
cardiotoxic drugs did not significantly alter the action potential duration (Gintant et al., 
2001).  
Zebrafish have a fully functional cardiovascular system at 48 hpf that consists of a 2 
chambered heart (1 atrium and 1 ventricle, separated by an atrioventricular valve) which 
expresses the zebrafish equivalent of the hERG channel (zERG). The amino acid 
sequence produced from the human and zebrafish ether-a-go-go related genes are 99 % 
conserved (Langheinrich et al., 2003). Although the zebrafish does not have a pulmonary 
system, it is still considered a useful model to aid the assessment of a drug candidate 
cardiotoxic potential. The zebrafish embryos are transparent, a major advantage because 
the heart rate and rhythmicity can be visually determined in a live, whole mount embryo. 
De Luca and colleagues took advantage of the zebrafish transparency and generated a 
model system called Zebrabeat that can analyse variations in heart rate. In this model, a 
zebrafish double transgenic line was used that labelled endothelial and andocardial cells 
with green fluorescent protein (GFP) and red blood cells with red fluorescent protein 
(DsRED). The embryos were anaesthetised to remain stationary and the heart rate was 
recorded using a resonant laser-scanning confocal microscope coupled to a software 
called Zebrabeat that can recognise the GFP-labelled heart outline and the flow of 
fluorescent red, red blood cells. They were able to detect variation in heart 
contraction/relaxation and quantify red blood cell content in the heart chambers (De Luca 
et al., 2014). This model demonstrates the potential practicality of non-mammalian models 
in drug development. 
One animal model limitation, is the difference in the physiological mechanisms of 
ventricular repolarisation between species (Gintant et al., 2016). In humans, dogs and 
rabbits, this is mediated by IKr. However guinea-pigs use IKr and IKs currents for ventricular 
repolarisation, and rats have minimal IKr, they rely on Ito. 
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1.4.2.5 Biomarkers: Drug-induced cardiotoxicity 
Similar to biomarkers for DILI, there is room for improvement in biomarkers that have a 
high sensitivity and specificity for the prediction and detection of drug-induced 
cardiotoxicity. Many current biomarkers are not sufficient for early diagnosis and it has 
been suggested that a multiple biomarker strategy would be ideal (Osaki et al., 2014).  
1.4.2.5.1 Cardiac myoglobin, creatine kinase-muscle/brain isoenzymes, and 
troponins 
Cardiac troponin I is a protein specific to myocardial cells and as such, an altered 
concentration of troponin I in patient plasma indicates myocardial injury. It is a specific and 
sensitive biomarker that has a high diagnostic and prognostic value and considered the 
classic gold standard for the detection of myocardial injury (Adams et al., 1994; Cardinale 
et al., 2004; Osaki et al., 2014). Elevated plasma cardiac troponin I is associated with an 
increased risk of patients developing left ventricular dysfunction following a high dose of 
chemotherapy such as anthracyclines. Similarly, cardiac troponin T release into plasma, 
or into the media from cardiotoxic drug-treated cardiomyocytes, can also indicate 
cardiotoxicity, however it is not sufficient for the detection of late onset cardiotoxicity 
(Holmgren et al., 2015). But the cardiac troponins have a couple of disadvantages as 
biomarkers. One disadvantage is that they are rapidly cleared from the plasma after 24h 
and consequently they are not always reliable (Nishimura et al., 2015). Also, patients with 
chronic kidney disease but no cardiac symptoms have elevated plasma cardiac troponin 
(Ahmadi et al., 2014). 
As well as cardiac troponins, cardiac myoglobin and creatine kinase-muscle/brain 
isoenzymes are routinely used for the assessment of myocardial injury and subsequently 
could be useful for the identification of drug-induced cardiotoxicity.  
1.4.2.5.2 Heart-specific micro-RNAs 
MiR-208 expression is specific to the heart and it was first demonstrated as a plasma 
biomarker of drug-induced cardiac injury in rats treated with isoproterenol (Ji et al., 2009). 
Many cardiovascular diseases are associated with specific miRNA plasma expression for 
example, plasma elevated miR-2 is associated with a reduced heart rate, widened QRS 
interval and a clinical presentation of a shortened PR interval (De Rosa et al., 2014). MiR-
1, miR-133a, miR-208a and miR-499 are all elevated in plasma after acute myocardial 
infarction in rats (G.-K. Wang et al., 2010), Furthermore, rats treated with the cardiotoxic 
compounds isoproterenol and allylamine generated a significant elevation of plasma miR-
208-3p (Glineur et al., 2016). Overall, miR-208 appears to be the most promising and 
heart-specific miRNA biomarker for drug-induced cardiotoxicity (Nishimura et al., 2015). In 
humans, it is specifically the miR-208a-3p, which is often shortened to miR-208. 
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1.4.2.5.3 Drug candidate interaction with hERG channel and subsequent 
association with QT interval prolongation 
As previously mentioned, drug hERG channel activity is associated with TdP and QT 
prolongation. Inhibition of the hERG channel correlates with an increased risk of TdP, QT 
prolongation and subsequently, an increased risk of arrhythmia. Drugs that bind to the 
hERG (KV11.1) channel slowly or drugs that dissociate from the channel faster, are less 
cardiotoxic compared to drugs that bind to the channel faster (Yu et al., 2015). The 
interaction of a compound with the hERG channel can be evaluated with hERG channel 
expressing cells mathematical modelling. A 30-fold difference between the drug candidate 
hERG IC50 and the maximum plasma concentration (Cmax) is regarded as the minimum 
margin required for safety when testing the cardiotoxicity of a drug (Redfern et al., 2003). 
The difference between these 2 measurements can be used to predict TdP incidence and 
arrhythmogenesis. However, there is a 30 % discordance between a positive hERG 
channel inhibition result and TdP generation (Kramer et al., 2013). Exceptions to this drug 
safety guideline include drugs that are associated with TdP despite a large difference 
between the hERG IC50 and Cmax including amiodarone (1400-fold) and nifedipine (35700-
fold). Furthermore, verapamil has only a 2-fold difference but is not associated with QT 
prolongation or TdP (Redfern et al., 2003). 
1.5 An ideal preclinical animal model for the prediction of drug-
induced toxicity 
In order to be able to evaluate a new animal model, it would be useful to determine what 
the ultimate ideal animal model for the prediction of drug-induced toxicity would be. First 
and foremost, a good study design is necessary when working with animal models in drug 
development. It is good practice ethically, so that each animal tested contributes reliable 
and useful data, but also scientifically, the experiments conducted should be designed to 
have clear endpoints and good statistical power. A clear endpoint will help determine if the 
animal has indicated a drug-induced toxicity reaction or not. An ideal safety animal model 
would have a similar clinical and anatomic pathology to humans. The drug metabolism 
and pharmacokinetics (DMPK) should also be similar because this can have a big impact 
on whether a drug-induced toxicity reaction will be generated, and determines the validity 
of the animal model for the evaluation of drug safety in humans (Redfern et al., 2002). 
The animal model should be able to distinguish between drugs associated with human 
toxicity and those not. Furthermore, any drug-toxicity reactions generated in the animal 
would ideally have been generated via the same mechanisms as in humans (Roth and 
Ganey, 2011). The development of a reaction should have a similar time of onset in the 
animals compared to what happens in humans. In addition, an excellent animal model 
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would demonstrate similar risk factors to humans that contribute to the generation of a 
drug-induced toxicity reaction.  
1.5.1 Where is the gap? 
Traditionally, drug candidates are tested on rodents and at least one non-rodent species, 
often the dog, before they are administered to humans. It has long been established that 
the concordance between animal and human drug-induced toxicity reactions is not as 
high as it should be to sufficiently predict the toxicity of a new drug candidate in humans. 
In a retrospective study of 150 compounds from 12 pharmaceutical companies, 221 
human toxicity events were generated in the clinical phase of drug development. In non-
rodents, 63 % predicted these toxicity events and there was a concordance of 43 % for 
rodents. The best correlation was observed for haematological, cardiovascular and 
gastrointestinal toxicities, and the worst was with cutaneous reactions (Olson et al., 2000). 
This study highlights the need for a better toxicity predictive model or multi-model system 
that is sensitive, reproducible and relevant to carry out an improved quantitative and 
qualitative assessment of drug safety. This applies to in vitro experiments, as well as in 
vivo. There is a conscious effort in research to try to fill this gap and ultimately save 
pharmaceutical companies time and money. As mentioned previously in this chapter, this 
would subsequently benefit patients and the healthcare system too. In general, there is a 
need for a model that is not expensive, and does not require long and complicated 
techniques. This model should be readily available and suitable for high throughput 
experiments to be conducted at the beginning of drug development. In addition, there is a 
also a need for a model that can help study the delayed effects of drug candidates. 
Generally, the most popular safety pharmacology studies involve a single dose that is 
analysed up to 24 h (Redfern et al., 2002). 
This project is funded by the UK National Centre for 3 Rs (NC3Rs). The major objective 
for the NC3Rs is to look for technologies that can replace, reduce and refine the use of 
animals for scientific purposes (NC3Rs, 2017; Prescott and Lidster, 2017). Overall, they 
aim to reduce the use of experiments that are irrelevant to humans and increase the 
efficiency of research and quality of study design. We hypothesise, the Xenopus laevis 
can help fill the gap for some of the ideal characteristics of an animal model for the 
prediction of drug-induced toxicity. The Xenopus can also contribute to the ideology of the 
NC3Rs as we shall explain below. 
1.6 Xenopus laevis 
Xenopus are non-mammalian, African clawed frogs that can develop ex utero at different 
rates according to the temperature at which they are incubated. At 25°C, a Xenopus 
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embryo can develop into an adult in 12 months, this is the temperature that elicits the 
fastest development rate. At <12°C the embryos will die however, between 12°C and 
25°C, the embryos will develop at a rate proportional to the temperature. Consequently, 
the age of a Xenopus embryo cannot be given in hours post fertilisation (hpf), instead, the 
age can be identified using the developmental stages set out by Nieuwkoop and Faber 
(these can also be found on the NIH-funded website xenbase.org) (Nieuwkoop and Faber, 
1994). The Xenopus embryos are easy to house, they can be obtained in large numbers 
following hormone stimulation and they are amenable for medium to high throughput 
small molecule screens. The Frog Embryo Teratogenesis Assay Xenopus (FETAX) uses 
developing Xenopus embryos to assess the teratogenic potential of small molecule 
compounds, therefore, it is possible that the Xenopus can help to detect drug-induced 
toxicity. At late stage development (stage 38-45) the Xenopus heart, liver and kidney are 
functional and adding compounds at this stage would assess drug-induced toxicity unlike 
the FETAX assay, which measures the affect on embryological development. 
Furthermore, toxicity can be assessed in embryos prior to coverage by the Animal 
Scientific Procedures Act and only a small amount of the compound to be tested would be 
required; this is important because in lead compound selection, the amount of compound 
available could be quite small. Toxicity assessment using the Xenopus combined with in 
vitro pharmacological cytotoxicity profiling and mathematical modelling can provide early 
in vivo testing without the need for early mammalian testing. This will be consistent with 
the ideology of the NC3Rs: reduction in the number of tests to be eventually conducted in 
mammalian experiments. The Xenopus could help prioritise the lead compounds and 
provide more information than in vitro safety tests. The Danio rerio (zebrafish) has already 
had some success as a possibly useful in vivo model for the assessment of drug-induced 
toxicity; this is encouraging for a Xenopus model which more anatomically similar to 
humans than Danio rerio. It is likely that a combination of both non-mammalian models 
could be used to help identify drug-induced toxicity potential in NCEs at early stage 
development. For this project, we used the Xenopus laevis species as the adults and the 
embryos are bigger than the Xenopus tropicalis, which was the other species available in 
our laboratory. From a practical point of view, the larger size makes the Xenopus laevis 
easier to handle and physically manipulate that is advantageous for techniques such as 
imaging and wholemount in situ hybridisation. However, the Xenopus laevis genome is 
allo-tetraploid compared to the diploid genome of the Xenopus tropicalis, so genetic 
alterations can be more challenging. 
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1.6.1 The Xenopus laevis liver 
The Xenopus liver has the same cell types as found in humans including hepatocytes, 
stellate cells, Kupffer cells and sinusoidal endothelial cells (Blitz et al., 2006). The 
Xenopus hepatic tissue is generated from an area of suprablastoporal endoderm, which is 
close to the Spemann’s organiser region (Chalmers and Slack, 2000). Similar to 
vertebrates, the liver is derived from the endoderm of the future gut tube, close to where 
the stomach and duodenum will meet (Nieuwkoop and Faber, 1994). By the age of stage 
37-39, the Xenopus liver is a sac-like structure, with thick walls that fold inwards and fill 
the liver cavity with hepatocytes. Also at this time, the liver and biliary ductal systems are 
developing and the gall bladder is a thin-walled sac structure (Blitz et al., 2006).  
1.6.2 The Xenopus laevis heart 
The adult Xenopus laevis heart has 3 chambers: 2 atria and 1 ventricle and an outflow 
tract that extends from the ventricle, carrying blood from the heart to the body (Figure 1-
4). The Xenopus ventricle is similar to the mammalian left ventricle (Hempel and Kühl, 
2016). In the Xenopus embryo, a linear heart tube forms at stage 30, this consists of a 
bulbus cordis, ventricle, atrium and sinus venosus. From stage 35 onwards, the heart tube 
starts beating and the atrium is divided into left and right atria. Chamber specification is 
complete at stage 39, the outflow valve is matured by stage 41 and stage 44 is the 
maturation of the atrioventricular valve. By stage 46, the embryo has a fully functional 3 
chambered heart (Bartlett et al., 2004; Nieuwkoop and Faber, 1994). The heart rate of 
Xenopus embryos is closer to that of the human than to the mouse (Blitz et al., 2006). 
Mice have a heart rate of 300-600 bpm (beats per minute) and Xenopus embryos have a 
heart rate of approximately 130 bpm at 22°C (Bartlett et al., 2004; Dhillon et al., 2013).  
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Figure 1-4: Xenopus heart 
A schematic of the Xenopus heart at approximately stage 46 from a ventral view. The atria 
are slightly behind the ventricle. Blood flows from the atria into the ventricle, where 
oxygenated and deoxygenated blood mixes and exits the heart via the outflow tract. 
1.7 Rationale 
It is clear that there is room for new models and the improvement of existing models used 
to help predict drug-induced toxicity in humans. In accordance with the principles of the 
NC3Rs, the Xenopus laevis could be a useful model in the early preclinical phase of drug 
development to aid drug candidate prioritisation through drug-induced toxicity 
experiments. 
Our project aims are to: 
• Characterise the functional capacity of Xenopus laevis embryos in relation to drug 
metabolism and drug toxicity 
• Optimise and adapt assays used in other drug toxicity models to the Xenopus 
system 
• Investigate organ-specific toxicity in Xenopus embryos with drugs that are 
associated with hepatotoxic, cardiotoxic and nephrotoxic reactions in humans 
In summary, in chapter 3 we carried out preliminary drug screens using the Xenopus 
laevis embryos. In chapters 4 and 5 we looked at drugs associated with hepatotoxicity 
and cardiotoxicity respectively in humans. We adapted existing in vitro experiments to 
assess the similarity of the drug response in the Xenopus embryos to humans, and we 
created new experiments that take advantage of the useful characteristics of the Xenopus 
laevis embryos. Our results show there are a lot of exciting potential directions for further 
experiments the Xenopus laevis embryos with regards to the prediction of drug-induced 
toxicity in drug development. Some suggestions for this are outlined in chapter 6. 
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2 Chapter 2: Materials and Methods 
2.1 Xenopus laevis egg collection 
Xenopus laevis females were primed 5-10 days prior to egg collection with 100 units of 
Pregnant Mare Serum Gonadotrophin (PMSG) into one dorsal lymph sac. Approximately 
16 hours prior to egg collection, the primed females are injected with 500 units of human 
chorionic gonadotrophin (hCG, Chorulon®) into both dorsal lymph sacs. Embryos were 
obtained by in vitro fertilisation (IVF). Testes were isolated from a euthanized male frog 16 
hours before egg collection. The male was anaesthetised in 300mL of 0.5 mg/mL tricaine 
(MS-222) dissolved in distilled water (dH2O). The testes were kept at 4°C overnight in 
testes buffer. 
On the day of egg collection, the eggs were obtained from the abdomen of the primed and 
induced female frogs through manual abdominal massage over a clean petri dish. The 
testes were crushed in 1 mL of 1X Marc’s Modified Ringers (MMR) and spread on the 
eggs for 5 min at 18°C. 0.1x MMR covered the eggs for a further 20 min and the vitelline 
membrane was removed using 250 mL of 2 % (w/v) L-cysteine pH 8.0 (1X MMR). The 
eggs were washed further with 1X MMR and 0.1X MMR to remove the cysteine and then 
they were developed to the stage required for drug screening. Embryos were left to 
develop in 0.1X MMR solution on a petri dish coated with bovine serum albumin at 23°C. 
Stages were identified according to Nieuwkoop & Faber (1994). 
Solutions: 
• 10X MMR: 1 M NaCl, 20 mM KCl, 10 mM MgCl2, 20 mM CaCl2, 50 mM HEPES 
(pH 7.5) 
• Testis buffer: 80% (v/v) fetal bovine serum, 20% (v/v) 1X MMR 
• PMSG (Intervet): 1000U/ml PMSG prepared in solvent and stored at 4°C 
• Chorulon® (Intervet): 1000U/ml Chorulon prepared in solvent and stored at 4°C 
All experiments were performed in compliance with the relevant laws and institutional 
guidelines at the University of East Anglia. This research has been approved by the local 
ethical review committee according to UK Home Office regulations. 
2.2 Embryo fixing 
The required stage of development was determined according to Nieuwkoop & 
Faber (1994). Once the embryos reached their desired stage they were fixed using 
MEMFA (3.7% (v/v) formaldehyde, 1X MEM salts (0.1 M MOPS, 2 mM EGTA, 1 mM 
MgSO4, pH7.4) made up with dH2O. They were then dehydrated in 100 % ethanol (EtOH) 
and left at -20°C for storage. 
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2.3 Photographing embryos 
When we were ready to photograph the embryos for phenotype identification, the fixed 
embryos were re-hydrated using a serial gradient of EtOH (phosphase buffered saline 0.1 
% tween-20, PBST) to 100 % PBST. A clean petri dish was coated with a 2 % (w/v) 
agarose gel and the embryos, suspended in 100 % PBST, were photographed. For the 
stage 38 embryos, we captured the lateral view. The ventral and lateral views were 
captured for stage 45 embryos where possible. 
2.4 RNA isolation and cDNA synthesis 
2.4.1 1. mRNA: TRIzol® method 
After incubation until the stage required, 10 embryos were placed in a 1.5 mL eppendorf 
tube, all fluid was removed and they were then snap frozen in liquid nitrogen for at least 2 
h. The sample frozen dried embryos could be stored at -80°C if need be. 
Samples were kept on ice and all reagents were kept ice cold. 1 mL of TRIzol® was 
added to the dried embryos. All animal tissue was broken by vortexing until homogenised. 
Then 500 µL of Chloroform was added and centrifuged at 4°C to separate proteins/lipids, 
DNA and RNA. The aqueous upper phase containing RNA was put into a new 1.5 mL 
eppendorf tube. To precipitate RNA: 500 µL of isopropanol, 50 µL of 5 M NaCl and 2 µL of 
glycogen-blue were added. After centrifugation at 4°C the supernatant was removed and 
replaced by 70 % EtOH prepared in RNase free water to wash RNA. After centrifugation 
at 4°C the EtOH was removed and the pellet was dissolved in 45 µL of RNase free H2O. 
At this step, the RNA could be stored at -80°C. 
5 µL 10X DNase buffer and 1 µL of DNase I (Roche) were added to each RNA sample. 
Samples were then incubated at 37°C for 30 min. To this, 50 µL of nuclease-free H2O was 
added. Sample final volume was 100 µL. To extract RNA: 100 µL of acidic 
phenol/chloroform was then added. After centrifugation at 4°C the aqueous upper phase 
was put into a new 1.5 mL eppendorf tube. To precipitate RNA 70 µL of isopropanol, 7 µL 
of 5 M NaCl and 1 µL of glycogen-blue were added. This was centrifuged at 4°C. Then the 
supernatant was removed and replaced by 70 % EtOH prepared nuclease-free to wash 
RNA. After centrifugation at 4°C the EtOH was removed and the pellet was resuspended 
in 20 µL of nuclease-free H2O. The concentration was determined by spectrophotometry 
(Nanodrop) and sample was stored at -80°C. 
First strand cDNA Synthesis was performed using SuperScript II Reverse Transcriptase. 
For reverse transcription, 1 µg RNA and 1 µl Oligo(dT) (Promega) 12-18 primer were 
mixed and brought up to 11 µL using nuclease-free water. The mixture was heated to 
70°C using a PTC- 100 Peltier Thermal Cycler (BIO-RAD) for 10 min before being put 
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back on ice where 4 µL 5X First-Strand Buffer (Sigma, UK), 1 µL 10mM dNTPs (Roche 
UK), 1 µL RNasin (40U/µL; Roche, UK), 1 µL of SuperScript II Reverse Transcriptase 
(200U/µl; Invitrogen, UK) and 2 µL 100 mM DTT (Sigma, UK) were added to each tube. 
The samples were incubated at 42°C for 1 h, enzymes were deactivated at 65°C for 5 min 
and 30 µL nuclease-free water was added to make a total of 50 µL cDNA. 
2.4.2 2. miRNA: miRCURYTM RNA (Exiqon) method 
RNA extraction was completed using the miRCURYTM RNA Isolation (for tissue) kit 
according to manufacturer’s instructions. Embryo tissue was placed into a 2 mL eppendorf 
tube and snap frozen in liquid nitrogen. To homogenise the tissue, 300 µL of Lysis 
Solution was added to the sample and vortexed for 5 min. 600 µL of RNAse Free Water 
and 20 µL of proteinase K was added to the lysate and incubated at 55°C for 15 min and 
spun for 1 min at 14000 x g. 450 µL of 95 % EtOH was added and the lysate solution was 
passed through a column by centrifuging for 1 min at 14000 x g. 3X 400 µL of Wash 
Solution was subsequently passed through the column at 14000 x g for 1 min to wash the 
resin. The resin was then dried by a 2 min spin at 14000 x g. The RNA was eluted by 
adding 50 µL of nuclease-free water to the column and spun for 2 min at 200 x g followed 
by 1 min at 14,000 x g. RNA was quantified using a standard spectrophotometer, 260/280 
and 260/230 ratios of 1.8-2.0 indicated good quality RNA. 
To make cDNA the Universal cDNA synthesis kit II (Exiqon) was used: 2 µL of 5 ng/µL 
RNA was added to 2 µL 5 x Reaction Buffer, 5 µL nuclease-free water and 1 µL Enzyme 
mix. This was incubated at 42°C for 60 min then at 95°C for 5 min and cooled to 4°C. The 
cDNA was stored at -20°C.  
2.5 RT-PCR 
The amplification of templates was performed using a thermocycler. Total PCR reaction 
was 10 µL containing 10-50ng of template cDNA 1 µM of each forward and reverse 
primer, 1X of BioMix™ (2X reaction mix containing ultra-stableTaq DNA polymerase, 
Bioline). An initial denaturation step of 95°C for 3 min was followed by a denaturation of 1 
min at 95°C for the start of the cycle. The annealing step was carried out at an annealing 
temperature calculated by subtracting 5°C from the primer melting temperature, for 1 min. 
This was followed by 1 min of extension step at 72°C (according to the expected size of 
the PCR product, 1 min/1 kbp) 25-35 cycles (depending on the level of expression of the 
gene of interest) of denaturation, annealing and extension were carried out. Amplified 
products were fractionated in 1 % (w/v) agarose Tris/Borate/EDTA (TBE 1X: 45 nM Tris-
Borate, 1 mM EDTA (ethylenediaminetetraacetic acid), pH 8.0) gel electrophoresis with 
 
 
46 
0.0001 % (v/v) of 10 mg/mL ethidium bromide and visualised under UV light using a UV 
transilluminator (BIO-RAD). 
2.6 qRT-PCR 
The cDNA was diluted 1 in 80; we determined this was the optimum concentration to use 
in preliminary experiments. The reaction was performed in MicroAmp optical 96 well plate 
(Applied Biosystems). The final volume was 15 µL containing 5 µL of the diluted cDNA, 
0.5 µL of miRCURYTM LNA PCR Primer mix (Exiqon) or 10 µM mrp2 (forward and 
reverse), 7.5 µL of 2x SYBR® Green PCR Master Mix (Applied Biosystems) and 2 µL of 
RNase free water. A 7500 real-time PCR instrument (Applied Biosystems) was used 
under the following conditions: 50°C for 2 min, 95°C for 10 min, 95°C for 10 s (for miRNA) 
or 15 s (for mRNA) cycles X40 and 60°C for 1 min. We used miR-103 as a quantitatitve 
control for miR-122 expression of paracetamol-treated embryos. To measure mrp2 
expression, we used ornithine decarboxylase 1 (odc1) as a quantitative control. Samples 
were plated in triplicates (technical replicates). Samples derived from embryos produced 
from different mothers were our biological replicates. 
2.6.1 qRT-PCR statistical analysis 
Gene expression was analysed using the Livak method (Livak and Schmittgen, 2001). An 
average CT value was taken from the technical replicates, this was normalised to miR-103 
or odc1 expression and also to the untreated samples (embryos that received no drug 
treatment). The fold change was determined using the formula: 2^-ΔΔCT, this number 
was converted into a logarithmic (log10). Mann-Whitney tests were performed between gut 
and tail tissues from embryos treated with the same concentration of drug to determine 
statistical significance. These were performed using Graph Pad Prism 6. 
2.7 Wholemount in situ hybridisation (WISH) 
2.7.1 1. mRNA probe synthesis: for Cardiac Troponin 1c and alpha-1-
microglobulin/bikunin precursor (AMBP) 
2.7.1.1 Purification of PCR product 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, UK) 
according to manufacturer’s instructions. The concentration was determined by 
spectrophotometry (Nanodrop). Ligation reactions were carried out according to the ratio 
of vector and insert. 
This ratio was calculated as follows: 
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Ligation reactions were carried out according to two conditions of ratio 3:1 and 1:1. The 
reaction mixture was as follows: 10-100 ng of PCR products, 0.5 µL of pGEM®-T Easy 
Vector, 5µl of 2x ligase buffer (Promega), 1 µL of Ligase T4 DNA (3U/µL, Promega) made 
up to 10 µL with nuclease-free H2O. The reaction was then incubated for 2-3 h at RT. 
Ligation reaction was then transformed into competent bacteria by the method outlined 
below. 
2.7.1.2 Preparation of competent cells 
A 5 mL culture of DH5α Escherichia coli was grown overnight in Luria Broth (LB) at 37°C 
and with shaking. 1 mL of this culture was added to 200 mL of LB medium and grown at 
37°C with shaking until optical density (OD600) reached 0.3 to 0.4. At this point the 
culture was divided into 3X 15 mL Falcon tubes and put on ice for 15 min. The cells were 
centrifuged at 4°C for 15 min at 6000 x g. The supernatant was discarded and the 
bacterial pellet was resuspended in 16 mL filter sterilized TB I buffer. Cells were put on ice 
for 15 min, centrifuged at 4°C at 20000 x g for 30 min. The supernatant was discarded 
and the pellet was resuspended in 4 mL of sterilized TB II. Aliquots were stored at -80°C. 
Materials: 
• TB I pH 5.8: 0.1 M RbCl2, 0.068 M MnCl2H2O, 0.01 M CaCl2, 1 M KAc pH 7.5, 37.5 mL 
Glycerol adjust to 250 mL and pH using 0.2 M HAc 26 
• TB II: 0.5 M MOPS pH 6.8, 0.01 M RbCL2, 1.04 M CaCl2 H2O, 37.5 mL Glycerol adjust to 
250 mL aliquoted and stored at -80°C 
2.7.1.3 Transformation 
5 µL of plasmid was added into 200 µL of competent E.coli cells, left on ice for 30 
min and heat shocked at 42°C for 90 s. 300 µL of LB media was added and cells were left 
for 1 h at 37°C. 300 µL of transformation mix was plated out onto LB agar containing the 
required antibiotic overnight at 37°C. 
2.7.1.4 DNA midiprep 
Colonies from the transformation were incubated in 50 mL LB/carbenicillin liquid media 
overnight at 37°C with rocking. Plasmid DNA was isolated using Qiagen midi plasmid 
purification kit (Qiagen, UK) according to manufacturer’s instructions. 1 µL of the final 
product was analysed by gel electrophoresis and the sequence of the gene of interest 
was confirmed by sequencing with 0.1 µM M13 forward and reverse primers (Sanger 
Sequencing Service, Source BioScience). The Midi preparation of the plasmid was diluted 
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10 times and 1 µL was used for the PCR reaction, 1X of BioMix™ (2x reaction mix 
containing ultra-stableTaq DNA polymerase, Bioline) was added for a total volume of 10 
µL. A thermocycler was used to perform the reaction under the following conditions: an 
initial denaturation step of 95°C for 3 min was followed by a denaturation of 1 min at 95°C. 
The annealing step was carried out at an annealing temperature of 55°C for 1 min. This 
was followed by 1 minute of extension step at 72°C. 25 cycles denaturation, annealing 
and extension were carried out. Amplified products were fractionated in 1 % (w/v) agarose 
Tris/Borate/EDTA (TBE 1x: 45nM Tris-Borate, 1mM EDTA, pH8.0) gel electrophoresis 
with 0.0001% (v/v) of 10mg/ml ethidium bromide and visualised under UV light using a UV 
trans-illuminator (BIO-RAD). 
2.7.1.5 DNA quantification 
DNA was quantified using a standard spectrophotometer, 260/280 and 260/230 ratios of 
1.8-2.0 indicated good quality DNA. 
2.7.1.6 Probe synthesis 
Probe was synthetised with a promoter specific RNA polymerase (T7, Sp6 or T3) the 
following reaction conditions were used: 1 µL PCR template, 2 µL dithiothréitol (DTT, 
Promega), 1 µL Digoxigenin (DIG) labeled UTPs (Roche), 1 µL RNase inhibitor 
(Promega), 2 µL (40U) RNA polymerase (Promega) 4 µL 5x transcription buffer 
(Promega) made to a final volume of 20 µL with nuclease-free H2O. The reaction was 
incubated at 37°C for 3 h. Any remaining DNA template was removed by adding 1 µL of 
DNase I (Roche) and incubating for 30 min at 37°C.  
2.7.1.7 Purification of probes 
30 µL of nuclease-free H2O were then added to the 20 µL of the probe synthesis PCR 
product purify the probe. Probes were purified by using Illustra MicroSpin G-50 Columns 
(GE healthcare life sciences) according to manufacturer’s instructions. 5 µL of probe was 
analysed on a 2 % (w/v) agarose to confirm probe integrity. 5 µg of purified probe was 
added to approximately 10 mL of hybridisation buffer depending on probe quality 
(determined on a 2 % (w/v) agarose gel) and stored at -20°C. 
2.7.2 2. XenmiR probes: miR-122 and miR-208 
Probes obtained from Exiqon arrived as 1 nmol dried pellets. We resuspended the pellet 
in 40 µL nuclease-free water, and added 10 µL of this into 12.5 mL hybridisation buffer to 
generate a final concentration of 20 nM. 1 mL of this probe solution was used in the WISH 
for the miRNAs. 
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2.7.3 WISH staining protocol 
Embryos were rehydrated from 100 % EtOH by using a serial gradient of EtOH (PBST) 25 
% to 100 % PBST for 5 min each followed by 2 x 5 min PBST washes, all with rocking at 
room temperature (RT). Embryos were then treated with 10 µg/mL proteinase K (no 
rocking) for varying times depending on the embryo stage age.  
Xenopus stage 38 – 10 min and stage 45 – 20 min. 
Xenopus embryos were then subsequently washed 2X PBST for 5 min and incubated in 
3.7 % (v/v) formaldehyde/PBST for 45 min without rocking. Next, the embryos were 
washed with 50 % hybridisation buffer (PBST) followed by 100 % hybridisation buffer both 
for 10 min. Then embryos were prehybridised in 100 % hybridisation buffer for 4 h at 
hybridisation temperature (48°C for XenmiR probes: miR-122 and miR-208, and 65°C for 
mRNA probes: AMBP and cardiac troponin 1c). The embryos were incubated with 
XenmiR probes for 24 h and overnight with mRNA probes, at their respective 
temperatures. 
Probes were removed and stored at -20°C and embryos were washed with fresh 
hybridisation buffer for 10 min followed by 2X 15 min washes with wash solution and 1X 
10 min wash in 50% maleic acid buffer, 0.1 % tween-20 (MABT)/50% wash buffer. All 
steps were completed at the correct hybridisation temperature for the XenmiR and mRNA 
probes as stated. Next, 2X 30 min washes in 1X MABT (0.1 % tween-20), 1X 1 h wash in 
2 % (w/v) Boerhinger Mannhein blocking reagent BBR in MABT (BMB) and a 4 h wash in 
20% (v/v) goat serum in 2 % (w/v) BBR, all at RT. BBR solution was replaced with 
antibody solution containing anti-Dig antibody (Roche, 150 U) (1:3000) made in 20 % (v/v) 
goat serum and 2 % (v/v) BBR at 4°C overnight. All steps with rocking. 
Antibody solution was removed and embryos were washed 5X 1X MABT for 60 min each 
at RT and incubated 1 last 1X MABT wash overnight at 4°C with rocking. The colour 
reaction was then carried out by washing the embryos in fresh alkaline phosphate buffer 
twice for 10 min at RT with rocking. Embryos were then put in NBT/BCIP in alkaline 
phosphate buffer (4.5 µL/mL NBT, 3.5 µL/mL BCIP) protected from light using foil, until 
the desired level of colour was reached. Embryos were placed in 5X TBST solution 
overnight if needed to remove background staining and then photographed. 
Materials for WISH: 
• PBS – 10X: 2.5 g NaH2PO4.H2O, 11.94 g NaHPO4.H2O, 102.2 g NaCl 
• PBST – PBS with 0.1 % (v/v) tween-20 
• Proteinase K (10 µg/mL): 1 µL proteinase K, 1 mL PBST 
• Hybridisation buffer: 50 % (v/v) formamide, 5X SSC, 1 mg/mL Torula RNA, 100 µg/mL 
Heparin, 1X Denharts solution, 0.1 % (v/v) tween-20, 0.1 % (w/v) CHAPS, 10 mM EDTA 
• Washing buffer: 50 % (v/v) formamide, 1X SSC, 0.1 % (v/v) tween-20 
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• MABT (1X): 100 mM Maleic acid, 150 mM NaCl, 0.1% (v/v) tween-20, (pH 7.5) 
• BMB (10%): 10% (w/v) in BMB preheated (50°C), 1X MAB, stirred until dissolved and 
then autoclaved, aliquoted and stored at -20°C. 
• Alkaline phosphatase buffer: 100 mM Tris (pH 9.5), 50 mM MgCl2, 100 mM NaCl, 0.1% 
(v/v) tween-20. 
• BCIP: 50 mg/mL in 100% DMF 
• NBT (Nitro Blue tetrazolium): 75 mg/mL in 70 % dimethylformamide (DMF) 
• TBST: 125 mL 1 M Tris pH 7.5 40 g NaCl, 1 g KCl and 450ml with dH2O. Autoclaved 
then add 50 mL of tween-20. 
• MEMFA: 10 % (v/v) MEM salts, 10 % (v/v) formaldehyde 
• MEM salts: 0.1 M MOPS, 2 mM EGTA, 1 mM MgSO4, pH 7.4 
2.8 Sectioning 
2.8.1 Cryostat with OCT compound 
Embryos were fixed in MEMFA for 1 week, washed 2X 5 min with PBST and placed in 
30% (w/v) sucrose overnight at 4°C. Embryos were transferred to cryo30 
moulds filled with optimal cutting temperature (OCT) compound and left for 4 h at RT. 
Embryos were positioned appropriately for sectioning, frozen gradually in isopentane 
surrounded by dry ice for 30 min and then left overnight at -20°C. Embryos were 
sectioned to 15 µm thickness using the LEICA CM 1950 Cryostat and sections were 
placed on 5 % TESPA slides. Slides were washed 3X 5 min washes in PBS and 
coverslips were mounted using hydromount.  
2.8.2 Microtome with wax 
Embryos were fixed in MEMFA for 1 week, washed 2X 5 min with PBST and then 
dehydrated using a serial gradient to 100 % EtOH. 3X 100 % EtOH to remove PBST 
completely then put into 100 % histoclear (National Diagnostics) in glass vials in a 65°C 
oven for 10 min. Add wax in the ratio 1:1 with 100 % histoclear, incubate for 1 h at 65°C. 
3X wax washes at 65°C to remove histoclear. Transfer embryos and wax to moulds and 
allow to set at RT for at least 1 h. Embryos were sectioned using a microtome to a 10 µm 
thickness onto 5 % TESPA slides and adhered to slides using water and manual pressure 
and dried at RT. Slides were washed 2X 5 min washes in histoclear to remove wax and 
mounted using hydromount and coverslips. 
2.8.3 Hematoxylin and Eosin staining 
After sectioning, the OCT or wax was removed from the slides as stated above. 
Hematoxylin (Sigma, UK) was diluted 1:1 in dH2O and filtered using filter paper, ready for 
 
 
51 
use. Eosin Y (Sigma, UK) stock solution contained 0.1 % (w/v) dissolved in dH2O with 3 
drops of acetic acid. 100 mL of this stock was added to 700 mL of 80 % EtOH (dH2O) and 
this solution was filtered using filter paper, ready for use. Acidic alcohol contained 396 mL 
of 95 % EtOH and 4 mL HCl. Test slides were conducted for the day to adjust the staining 
times for a optimal H&E stain. Approximately, the sections (without excess OCT or wax) 
were treated with 5 min hematoxylin, rinsed in dH2O for 30 s, 5X dips in the acidic alcohol 
followed by another 30 s dH2O rinse. Then, eosin treatment for about 30 s, dehydration 
with 75 % to 100 % EtOH (dH2O) and 2X 10 s in histoclear. Mounted using hydromount 
and coverslips. Images were taken using a Zeiss CCD upright microscope with colour 
camera. 
2.9 Treatment with drugs 
2.9.1 Chapter 3 Drug screens 
The following drugs were used for the chapter 3 screens Paracetamol (Acetaminophen; 
Sigma, UK), Indomethacin (Santa Cruz Biotechnology), Cisplatin (Santa Cruz 
Biotechnology), Gentamicin (Gentamicin sulfate; Santa Cruz Biotechnology), doxorubicin 
(doxorubicin hydrochloride; Sigma, UK), daunorubicin (daunorubicin hydrochloride; 
Sigma, UK), tobramycin (Santa Cruz Biotechnology), AMAP (N-acetyl-meta-aminophenol; 
Sigma, UK), diclofenac (diclofenac sodium salt; Sigma, UK). For these drugs, all of the 
concentrations (0.78 µM – 100 µM) contained 0.5 % DMSO (v/v). 1 well in a 96-well plate 
contained 125 µL of 2X final concentration of drug. Embryos at their desired stage 
according to Nieuwkoop & Faber (1994), were added to the well containing the drug 
solution, 1 embryo/well, with 125 µL 0.1X MMR. The final total volume of each well was 
250 µL. For 1 biological replicate (n=1), we used 5 embryos for each drug concentration. 
Consequently 5 biological replicates (n=5) used a total of 25 embryos. The plates were 
sealed with Breathe-Eazy® Sealing membranes (Sigma, UK) to prevent evaporation, but 
allow the exchange of gases. For both stage 15 – stage 38 and stage 38 – stage 45 
screens, the embryos were incubated at 23°C throughout drug treatment. Embryos were 
fixed and photographed as previously mentioned.  
2.9.2 Chapter 4 and 5 screens 
All drugs in these chapters were dissolved in 0.1X MMR alone. Except terfenadine, all 
final concentrations of terfenadine contained 0.5 % DMSO (v/v) (0.1X MMR). The 
untreated embryos for terfenadine experiments (0 µM terfenadine) also contained 0.5 % 
DMSO (v/v) (0.1X MMR). 1 well in a 96-well plate contained 125 µL of 2X final 
concentration of drug. Embryos at their desired stage according to Nieuwkoop & Faber 
(1994), were added to the well containing the drug solution, 1 embryo/well, with 125 µL 
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0.1X MMR. The final total volume of each well was 250 µL. For 1 biological replicate 
(n=1), we used 7 embryos for each drug concentration. Consequently 5 biological 
replicates (n=5) used a total of 35 embryos. 
2.9.3 The preparation of samples for the measurement of miR-122 expression 
using qRT-PCR  
Stage 38 embryos were treated with paracetamol as described above until stage 45. At 
stage 45, the embryos were placed into a clean petri of 0.5 mg/mL tricaine (0.1X MMR) 
and incubated at 23°C for 1 h. Embryos were dissected into tail and gut tissue using a 
simple razor. The dissection technique was confirmed by analyzing the expression of the 
liver-specific marker AMBP. AMBP was expressed in the gut tissue dissected but not in 
the tail tissue. 
 
1 biological replicate is defined as using 1 adult frog mother. In other words, a result 
generated from embryos that have the same mother, was only counted as 1 biological 
replicate. 
2.9.4 1-aminobenzotriazole (ABT) and paracetamol 
2.9.4.1 Pre-incubation 
62.5 µL 6 mM 1-ABT was put into 1 well of a 96-well plate with 1 embryo and 62.5 µL 
0.1X MMR to make a final concentration of 3 mM 1-ABT. This was incubated at 23°C for 2 
h. Then 62.5 µL of 4X final concentration of paracetamol was added with 62.5 µL of 6 mM 
1-ABT to create a final volume of 250 µL/well. This was incubated for a further 70 h, until 
the embryos were stage 45 at 23°C. The embryos were processed with the GSH assay 
method. 
2.9.5 N-acetyl cysteine (NAC) and paracetamol 
2.9.5.1 1. Pre-incubation 
62.5 µL 1 mM NAC (Sigma, UK) was put into 1 well of a 96-well plate with 1X stage 38 
embryo and 62.5 µL 0.1X MMR to make a final concentration of 0.5 mM 1-ABT. This was 
incubated at 23°C for 2 h. Then 62.5 µL of 4X final concentration of paracetamol was 
added with 62.5 µL of 1 mM 1-ABT to create a final volume of 250 µL/well. This was 
incubated for a further 70 h, until the embryos were stage 45 at 23°C.  
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2.9.5.2 2. Concurrent treatment 
62.5 µL 2 mM NAC, 62.5 µL 4X final concentration of paracetamol, 125 µL 0.1X MMR and 
1X stage 38 embryo were combined in 1 well of a 96-well plate. Final volume was 250 
µL/well. The plate was incubated at 23°C for 72 h, when the embryos were stage 45. 
2.9.5.3 3. 24 h NAC treatment prior to harvest 
125 µL of 2X final concentration paracetamol and 125 µL 0.1X MMR were combined into 
1 well of a 96-well plate with 1X stage 38 embryo. This was incubated at 23°C for 48 h. At 
48 h we added 25 µL 6 mM NAC and 25 µL 2X final concentration of paracetamol to make 
a final volume of 300 µL/well with 0.5 mM NAC. This was further incubated for 24 h at 
23°C until the embryos were stage 45. 
 
All the embryos were processed with the GSH assay method at stage 45. 
2.9.6 Doxorubicin and dexrazoxane 
62.5 µL 4X final concentration doxorubicin, 62.5 µL 4X final concentration dexrazoxane, 
125 µL 0.1X MMR and 1X stage 38 embryo were added to 1 well of a 96-well plate and 
incubated for 72 h at 23°C, until they were stage 45. Final volume was 250 µL/well. The 
doxorubicin to dexrazoxane ratio was 1:10 respectively. 
2.10 Measuring free GSH 
2.10.1 Sample preparation 
At the end of the incubation period, embryos that were treated with the same conditions 
were transferred into 1 eppendorf and put on ice. As much as possible, the incubation 
solution was removed and 125 µL 10 mM HCl was added. Embryos were homogenized 
using the vortex and an eppendorf pestle. Then, they were centrifuged at 14000 x g for 5 
min at 4°C. 25 µL of the supernatant was transferred to another tube to be kept at -80°C 
for protein quantification using the Bradford assay, this was replaced with 25 µL 6.5 % 
(w/v) 5-sulfosalicylic acid hydrate (SSA). Remove all of the supernatant including the SSA 
and keep at -80°C until perform the GSH assay. 
2.10.2 GSH assay 
Standard GSH concentrations: 0, 1, 2, 5, 10, 20, 30 and 40 nmol/mL were made up on the 
day of the experiment using GSH buffer and 0.1 mM GSH (Sigma, UK) and kept on ice. 
20 µL of the standard or sample was mixed with 200 µL Assay Reagent in 1 well of a 96-
well plate and incubated for 5 min. 50 µL/well 13 U/mL GSH reductase (diluted in GSH 
buffer) and the plate was read immediately at 405 nm absorption using the GloMax® 
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Explorer System spectrophotometer (Promega). 11 readings were taken at 15 s intervals. 
The reading with best standard curve was used to calculate the sample results (nmol/mL).  
Solutions: 
• GSH buffer: 143 mM NaH2PO4 and 6.3 mM EDTA dissolved dH2O 
• Assay Reagent: 0.28 mg/mL NADPH (Sigma, UK) and 0.4 mg/mL DTNB (5,5-
dithio-bis-(2-nitrobenzoic acid; Sigma, UK) dissolved in GSH buffer 
2.10.3 Bradford assay  
Standard concentrations were made up using BSA dissolved in 10 mM HCl: 0, 0.1, 0.2, 
0.4, 0.8, 1.2, 1.6, 2 and 4 mg/mL. The assay was completed according to the 
manufactuer’s instructions (BIO-RAD). 5 µL of each sample was added to 1 well of a 96-
well plate with 25 µL of reagent A + S (1 mL reagent A + 20 µL reagent S) and 200 µL of 
reagent B. This was incubated for 15 min at RT. The plate was read at 595 nm absorption 
using the GloMax® Explorer System spectrophotometer (Promega). 
 
GSH results (nmol/mL) were divided by the BCA result (mg/mL) for the same sample to 
give the final result (nmol/mg). 
2.11 Heart rate assay 
I created and developed the method to detect heart rate in Xenopus embryos as detailed 
below. The method was originally adapted from Bartlett and colleagues (2004). 
2.11.1 Anaesthetic assays 
Untreated embryos were developed until the age of stage 45, when they were placed into 
0.1, 0.2 0.3, 0.4 or 0.5 mg/mL (0.1X MMR) tricaine in a clean petri dish and incubated at 
23°C for 1 h. We used 3 embryos and 3 biological replicates for each concentration in this 
anaesthetic assay: 9 embryos for each concentration in total. After this incubation, the 
embryos were kept in tricaine solution in the petri dish, placed so that the ventral side was 
in view and filmed in black and white using a Pulnix TM-840 CCD camera on top of a 
Zeiss CCD upright microscope. The camera was optimized to record 50 frames per 
second (fps) of 720p resolution, we recorded the embryo heart beat for 30 s.  
2.11.2 Drug treatment: doxorubicin and terfenadine 
Embryos were dosed with 0-100 µM doxorubicin or 0-50 µM terfenadine from stage 38 
until stage 45 in a 96-well plate as described in “treatment with drugs”. 7 embryos were 
used for each concentration and we conducted 3 biological replicates: 21 embryos in total 
for each concentration. At the age of stage 45, the embryos from the same drug 
concentration were pooled together and put into a final concentration of 0.2 mg/mL 
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tricaine in a clean petri dish along with a fresh solution of the concentration of drug they 
were receiving. They were incubated for 1 h at 23°C before they were filmed in black and 
white using a Pulnix TM-840 CCD camera on top of a Zeiss CCD upright microscope. The 
camera was optimized to record 50 frames per second (fps) of 720p resolution, we 
recorded the embryo heart beat for 30 s. 
2.11.3 Post-treatment doxorubicin recovery 
After the doxorubicin-treated embryos were filmed as above, the embryos that received 
the same concentration of doxorubicin were pooled together and were transferred into a 
clean petri dish containing only 0.1X MMR media. They were incubated at 23°C for a 
further 72 h. After 72 h, they were transferred into a clean petri dish containing a final 
concentration of 0.2 mg/mL tricaine and incubated at 1 h for 23°C. After 1 h, the embryos 
were filmed as previously mentioned in black and white using a Pulnix TM-840 CCD 
camera on top of a Zeiss CCD upright microscope. The camera was optimized to record 
50 frames per second (fps) of 720p resolution, we recorded the embryo heart beat for 30 
s. 
2.11.4 Video analysis 
The black and white video MP4 recordings were imported into Adobe Media Encoder CC 
2017 and converted into a sequence of TIFF images, so 1 image is created for each 
frame. A 30 s video would create 1500 images. This TIFF image sequence is imported 
into ImageJ using the Time Series Analyzer V3 plugin. We identified the atrium and 
ventricle of the Xenopus embryo and created a circular region of interest (ROI) that was 
70 pixels wide on top of each of these heart chambers. We also created a control third 
ROI of the same size that was placed in an area outside of the embryo in the images. 
Using the ImageJ plugin, we processed all the images to generate the average intensity 
within each ROI for every frame, which we pasted into Microsoft Excel. In excel, we 
converted the frame numbers into real time seconds, and normalized the atrium and 
ventricle ROI averages to the third ROI average. Occasionally in the recording, the entire 
image becomes brighter or darker and affects the intensity readings for the atrium and the 
ventricle. Consequently, the third ROI can be used to correct this. 
The average ROI intensity was plotted against seconds. The higher the intensity number, 
the closer the pigment is to black on the greyscale, which equates as blood filling the 
chamber. We used the ventricle data to calculate the heart rate. The number of peaks in 
30 s on the ventricle graph was counted manually and we converted this into beats per 
min (bpm). An arrhythmic heart beat was identified as irregular peaks and troughs in the 
graphs created from the atrium and ventricle ROIs. We validated the arrhythmic beat by 
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observing the heart beating in real time in the video. An irregular beat on the graph always 
correlated with an arrhythmic beat observed in the video. 
An average heart rate (bpm) for 1 concentration from 1 biological replicate was taken. 
Subsequently we averaged the 3 biological replicates and calculated the standard error 
across these 3 replicates. 1 biological replicate is defined as using 1 adult frog mother. In 
other words, a result generated from embryos that have the same mother, was only 
counted as 1 biological replicate. 
An example of a heart rate assay video, video analysis and representative graphs for 
normal heart beat rhythm and arrhythmia is shown in the Appendix Figures A-1 and A-2. 
2.12 Mass spectrometry analysis of paracetamol (APAP) and 
paracetamol metabolites 
2.12.1 Preparation of samples 
Stage 38 embryos were treated with paracetamol as described above until stage 45. At 
stage 45, the embryos used for drug treatment were pooled into 1 eppendorf and put on 
ice to reduce the movement of the embryos. The incubation medium was removed and 
put into a new eppendorf.and we snap froze the embryos in liquid nitrogen. Samples were 
stored at -80°C until they were analysed. These samples were analysed in the MRC 
Centre for Drug Safety Science at University of Liverpool by Dr. Mark Bayliss. The method 
for analysis was described recently in Eakins et al (2015).  
We measured paracetamol and paracetamol metabolite content in our samples using high 
performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Test 
samples were treated with acetonitrile, to remove matrix-based interferences. They were 
diluted with water prior to analysis by LC-MS/MS on a Sciex API 4000 (Warrington, UK) 
equipped with a Turbo V™ electrospray source (ESI). The gradients were based on 
mobile phases containing 0.1% (v/v) formic acid in both water (A) and acetonitrile (B). 
Separations were performed on a 2.6 µm Kinetex® XB-C18 column (50 × 2.1 mm ID) 
obtained from Phenomenex (Macclesfield, UK), at a temperature of 40 °C and a flow-rate 
of 0.5 mL min−1. The following gradient was used: 0 min 0% B, 0.3 min 0% B then 2.3 
min 50% B. The column was flushed with 100% B, and then returned to 0% B using a 
flow-rate of 0.7 mL min−1, giving a programmed cycle time of 4.2 minutes. A panel of 
deuterated internal standards was employed. The MS was operated in negative ion mode 
for measuring the major paracetamol metabolites (APAP-glucuronide, APAP-sulphate, 
APAP-NAC, APAP-glutathione, APAP-methoxy and APAP-cysteine) and high 
concentrations of paracetamol and it was operated in positive ion mode for measuring the 
remaining metabolite and low concentrations of APAP (Eakins et al., 2015).  
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2.12.2 Analysis of HPLC-MS/MS 
Where ratio of an analyte inside the embryo versus the analyte in the incubation medium 
is <0.02, results for the embryo represent mainly concentrations in residual medium that is 
still coating embryos. We analysed 5 embryos for each paracetamol concentration, these 
embryos were generated from 1 adult female frog and used in the same paracetamol drug 
screen. Consequently, this experiment comprises of 1 biological replicate, therefore were 
could not perform any statistical analysis. 
2.13 Positive control 
Where possible, literature has been described to be able to compare the data we have 
generated with the Xenopus embryos to existing results from similar experiments. Within 
the experiments conducted with the Xenopus embryos, a negative control was included. 
However we were not able to conduct the experiments with a positive control, for 
example, an organism to which a reproducible response is established. In future 
experiments, it would be ideal to conduct the Xenopus experiments in parallel to a more 
established animal model such as zebrafish or a rodent. 
2.14 Statistical analysis 
Statistical tests were carried out using GraphPad Prism 6.0 software. I chose the 
appropriate test to use according to the parameters of the data and the comparisons I 
wanted to analyse. An ordinary one-way ANOVA was used for investigating the difference 
of the treated groups compared to the untreated embryos and Mann-Whitney non-
parametric tests were used to compare unpaired treatment groups. For the paired data 
sets a parametric paired T test was performed. 
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3 Chapter 3: Characterisation of the Xenopus laevis 
embryo as a model for drug-induced toxicity 
3.1 Introduction 
Over the past 15 years the Wheeler laboratory, plus others, have shown that the Xenopus 
laevis embryos are amenable to medium throughput drug screens (Tomlinson et al., 2012; 
Wheeler and Brändli, 2009; Wheeler and Liu, 2012). Up to 5 embryos, that are stage 45, 
can fit into 1 well in a 96 well plate. This is advantageous because compared to other 
animal models such as rodents, the Xenopus model assay could test many drug 
candidates at one time and only a small amount of the compound would be required 
which suits early stage testing in drug development where often only a small amount of a 
drug candidate is available. Rodents are traditionally the first animal model used in drug 
development for preclinical drug safety studies and instinctively, they could be considered 
more relatable to humans than the non-mammalian Xenopus laevis. However, studies 
show that the correlation between rodent studies and other animal studies is not good. 
Only 4 in 24 toxicities were detected in animals that occurred in humans (Heywood, 
1990). Another study found that for 114 drug-induced toxicity cases, only 6 had direct 
animal correlation (Spriet-Pourra and Auriche, 1994). In conclusion, there is definitely 
room for an improvement of the current practice for drug safety studies in drug 
development. There is a space for an animal model that can predict drug-toxicity 
reactions, or more likely, the solution may be to use a variety of animal models for which 
we really understand the use and limitations. Furthermore, although a non-mammalian 
model such as Xenopus may initially seem irrelevant for humans, many zebrafish models 
have proven there is some translation (Zon and Peterson, 2005).  
To begin our investigation into the use of Xenopus laevis embryos as a model for the 
prediction of drug-induced toxicity, we decided to use a known Xenopus toxicity assay 
(previously mentioned in chapter 1) called the FETAX as a starting point. The FETAX can 
suggest the impact the drug candidate has on embryonic development. Next, we used 
Xenopus embryos at the age we believe is more relevant to drug-induced toxicity: stage 
38 until stage 45. In both of these assays we decided to use drugs that are known to 
cause organ-specific toxicity in humans. The key mechanisms of action for these drugs 
are summarised in Table 3-1. The mechanisms of action for drug-induced toxicity with 
respect to paracetamol and doxorubicin will be discussed in more detail in chapters 4 
and 5 respectively. 
Gentamicin is an aminoglycoside which is a class of antibiotics that consists of 2 or more 
amino sugars with a glycosidic linkage to an aminocyclitol ring (Weinstein et al., 1963). 
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Gentamicin is one of the most nephrotoxic aminoglycoside antibiotics. It is largely 
excreted unchanged via glomerular filtration in the kidneys (Gyselynck et al., 1971). This 
is because it is not lipophilic and therefore it is not readily absorbed into most tissues. But 
is does accumulate in the kidney proximal tubule epithelial cells (Vandewalle et al., 1981). 
Gentamicin enters these cells through the receptor megalin (Dagil et al., 2013). It is 
estimated 5 % of the gentamicin parent drug administered builds up in these cells which is 
a key step that leads to the generation of nephrotoxicity (Mingeot-Leclercg and Tulkens, 
1999). Gentamicin-related toxicity occurs in 10-20 % of patients and presents as non-
oliguric renal failure in the clinic. Although when gentamicin is stopped, the renal failure is 
reversed in almost all patients. Gentamicin is also associated with ototoxicity. The megalin 
receptor is present in the cochlea of the inner ear as well as in the kidneys, consequently 
the ears are susceptible to gentamicin-induced cell death (Mizuta et al., 1999).  
Indomethacin is an anti-inflammatory drug, originally introduced to treat rheumatoid 
arthritis (Lione and Scialli, 1995). It inhibits prostaglandin synthesis in all tissues, however 
it especially affects the gastric prostaglandins. This is thought to be because the parent 
drug is the active component (it doesn’t need to be activated like a prodrug). Therefore, 
with oral administration, it immediately affects the gastric prostaglandins causing 
gastrointestinal irritation and ulcer formation (Wilson and Kaymakcalan, 1981). Under 
physiological conditions, the gastric prostaglandins aid the formation of gastric mucus and 
inhibit acid secretion. Indomethacin also induces mitochondrial stress through the 
inhibition of complex I, and together with the interference of the gastric prostaglandins, the 
intestinal mucosal epithelia become more permeable thus making it easy for bacteria to 
penetrate the mucosa (Watanabe et al., 2011). This will recruit inflammatory cells, activate 
the innate immune system and overall cause more injury to the initial injury site (Boelsterli 
et al., 2013). 
Cisplatin is a highly effective anticancer chemotherapeutic agent but it is unfortunately 
associated with dose-limiting nephrotoxicity (Arany and Safirstein, 2003). Renal 
impairment typically begins a few days after the first dose (Miller et al., 2010). 
Approximately 20-30 % of patients taking cisplatin present with acute kidney injury 
(Goldstein and Mayor, 1983; Madias and Harrington, 1978). The exact mechanism of 
therapeutic action is not known. In an aqueous environment, the cisplatin compound 
becomes a positively charged electrophile that reacts with DNA to form inter- and intra-
strand crosslinks consequently inhibiting DNA synthesis and cell replication (Wang and 
Lippard, 2005). Tumour cells are less capable at DNA repair and therefore they are more 
sensitive to the mechanisms of cisplatin than healthy cells. It is thought that cisplatin 
particularly targets mitochondrial DNA. The renal proximal tubule cells contain a high 
density of mitochondria so this could be the reason for the high frequency of kidney-
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specific toxicity associated with cisplatin. Cisplatin is metabolised by various enzymes to 
generate highly reactive thiols that are more potent toxins than the parent drug itself 
(Townsend et al., 2003). Positively-charged cisplatin metabolites accumulate in 
negatively-charged mitochondria. Furthermore, cisplatin-induced tubular epithelial cell 
injury activates TLR4-mediated inflammatory cell recruitment (Zhang et al., 2008). As with 
most anticancer drugs, cisplatin is associated with a number of organ-specific toxicities in 
addition to nephrotoxicity namely ototoxicity, gastrotoxicity and myelosuppression 
(Hartmann and Lipp, 2003). However nephrotoxicity is the dominant organ-specific 
phenotype for patients administered cisplatin. 
To help validate our Xenopus toxicity assay, we looked at drugs that are not well known to 
be associated with toxicity in addition to the organ-specific toxic compounds named 
above. Tobramycin, also known as nebramycin, is an aminoglycoside antibiotic that was 
discovered in approximately the same decade as gentamicin (Stark et al., 1967). 
Tobramycin is associated with some nephrotoxicity but not as much as gentamicin (Begg 
and Barclay, 1995; Luft et al., 1978). It has the same therapeutic mechanism of action as 
gentamicin. Consequently, in order to validate an animal model for the prediction of 
nephrotoxicity, tobramycin is often used as a counter drug to gentamicin. Daunorubicin is 
an anthracycline antibiotic that has a similar therapeutic mechanism of action to 
doxorubicin, but is has a lower incidence of cardiotoxicity than doxorubicin (Dorr et al., 
1991). For this reason it is often used in conjunction with more potent cardiotoxic 
compounds to validate a new animal model for the prediction of cardiotoxicity. Pouna and 
colleagues (1996) tested a number of anthracycline drugs including doxorubicin and 
daunorubicin to investigate the value of an isolated perfused rat heart for preclinical drug 
safety studies. In this model daunorubicin was significantly less cardiotoxic that 
doxorubicin, this reflects the incidence observed in humans (Pouna et al., 1996). N-acetyl-
meta-aminophenol (AMAP) is the alleged non-toxic isomer of paracetamol. However 
toxicity to this compound does occur in some animal models. Overall the incidence of 
AMAP toxicity appears to be species-specific (Hadi et al., 2013). Consequently, we 
decided to see if we could see the difference between paracetamol and AMAP in the 
initial drug screens in this chapter using the Xenopus embryos. AMAP is discussed in 
more detail in chapter 4. 
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Table 3-1: A summary of the key mechanisms of action for drugs known to be 
associated with drug-induced toxicity. 
Drug name Therapeutic mechanism Toxicity mechanism Reference 
Gentamicin Aminoglycoside antibiotic  
Bactericidal for Gram 
negative and some Gram-
positive bacteria e.g. 
Pseudomonas aeruginosa 
and Mycobacterium 
tuberculosis respectively. 
Blocks the initiation of DNA 
synthesis by binding to the A 
site of 16s ribosomal RNA 
(rRNA) within the 30S 
subunit. This interferes with 
physiological ribosome-RNA 
interactions and transfer 
RNA specificity during 
translation and causes 
bacterial cell death.   
Nephrotoxic and ototoxic 
Accumulates in the 
lysosomal and endosomal 
vacuoles in the epithelial 
cells of the proximal 
tubule. Gentamicin 
overloads the lysomes and 
ruptures causing high 
concentrations of 
gentamicin and acid 
hydrolases to enter the 
cytoplasm. This disrupts 
cell structure and function 
causing non-oliguric renal 
failure. 
Gentamicin also causes 
the degeneration of hair 
cell death of the inner ear 
causing the loss of high 
and low frequency 
hearing. The mechanism 
for this is the interference 
with mitochondrial 
ribosomals, causing 
mitochondrial dysfunction 
and cell death. 
(Begg and 
Barclay, 
1995; 
Fourmy et 
al., 1996; 
Hutchin 
and 
Cortopassi, 
1994; 
Mingeot-
Leclercg 
and 
Tulkens, 
1999; 
Silverblatt 
and 
Kuehn, 
1979) 
Indomethacin NSAID 
Analgesic, antipyretic and 
anti-inflammatory drug. 
Nonselective inhibitor of 
COX-1/2 that blocks the 
synthesis of prostaglandins. 
Gastrointestinal toxicity 
Parent drug specifically 
inhibits gastric 
prostaglandin synthesis. It 
also induces endoplasmic 
reticulum stress and 
mitochondrial stress, 
(Boelsterli 
et al., 
2013; 
Watanabe 
et al., 
2011) 
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consequently exacerbating 
the site of inflammation 
and necrosis. 
Diclofenac NSAID 
Analgesic, antipyretic and 
anti-inflammatory drug.  
Weak COX-2 selective.  
Hepatotoxic  
The metabolites from 
oxidative reactions and 
phase II gluconide 
metabolite derivatives are 
involved in the generation 
of diclofenac-induced liver 
injury. The exact toxicity 
mechanism is unknown, 
however there is an 
involvement of 
mitochondrial dysfunction. 
(Gómez-
Lechón et 
al., 2003; 
Syed et al., 
2016) 
Doxorubicin Anthracycline cytotoxic 
antibiotic  
Doxorubicin intercalates with 
the DNA and inhibits 
topoisomerase II activity 
consequently blocking DNA 
synthesis and cell 
replication, this induces cell 
death.  
Cardiotoxic 
Doxorubicin can cause 
cumulative, dose-related 
cardiac damage through 
the generation of free 
radials. Damaged cardiac 
tissue can cause 
dysrhythmias and lead to 
heart failure. 
 
(Gu et al., 
2015; 
Singal and 
Iliskovic, 
1998) 
Cisplatin Anticancer alkylating-like 
agent 
Tumour cells tend to have 
insufficient DNA repair 
mechanisms. Cisplatin can 
covalently bind to DNA, 
cause intrastrand cross links 
and thus inhibit DNA 
synthesis and replication. 
This can trigger tumour cell 
death. It is thought 
Nephrotoxic 
The nephrotoxicity 
associated with cisplatin is 
proportional to the dose. 
The high density of 
mitochrondrial DNA in 
proximal tubular cells 
indicates this is why 
cisplatin-induced toxicity is 
particularly noticeable in 
the kidney. 
(Miller et 
al., 2010; 
Wang and 
Lippard, 
2005) 
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mitochondrial DNA is more 
susceptible than nuclear 
DNA. 
 
Paracetamol NSAID 
Analgesic and antipyretic but 
weak anti-inflammatory drug 
compared to other NSAIDs. 
It is often not classed as 
NSAID because it is a very 
weak COX inhibitor. The 
exact therapeutic 
mechanism for the analgesic 
effect is unknown but it could 
be due to an indirect action 
of the cannabinoid receptors 
(CB1). 
Hepatotoxic 
The major metabolic 
pathway produces stable 
metabolites via 
sulfotransferase and 
glucuonyl transferase 
enzymes. However the 
minor metabolic pathway, 
catalyzed by CYP2E1, 
CYP1A2 and CYP3A4, 
generates the reactive 
metabolite NAPQI (N-
acetyl-ρ-benzoquinone). If 
a dose greater than the 
recommended therapeutic 
dose is ingested (>4 
g/day), this metabolite 
accumulates and can 
damage hepatocytes and 
instigate cell death 
through the generation of 
reactive oxygen species, 
stimulation of Ca2+-
activated degradative 
enzymes and lipid 
peroxidation. NAPQI is 
particularly damaging 
when there is a reduction 
in the neutralising agent 
GSH (glutathione). 
(Bertolini et 
al., 2006; 
McGill and 
Jaeschke, 
2013) 
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Prior to the investigation into the use of Xenopus embryos towards the prediction drug-
induced toxicity, we decided it was important to characterise the capabilities of the model. 
Drug metabolism can often play a crucial role in the generation of a drug-induced toxicity 
reaction. In humans, for the majority of drugs, the body alters the molecular structure of 
the parent compound administered with the aim to excrete the drug safely and quickly. 
The host organism can also affect the distribution of the drug through body compartments, 
so-called pharmacokinetics. However the body’s reaction to a drug, under certain 
circumstances, is what leads to a drug-induced toxicity reaction. A drug associated with 
toxicity reactions is not inherently toxic itself, rather it is the way the body reacts to it that 
generates a toxicity reaction. For example the body can generate a metabolite that is 
reactive and responsible for the generation of drug-induced toxicity reactions, such is the 
case with paracetamol and it’s metabolite NAPQI (Table 3-1 and chapter 4). The body 
can also favour the transport of a drug into a specific body compartment that can lead to 
detrimental accumulation for example cisplatin accumulation in proximal tubule epithelial 
cells results in nephrotoxicity. Environmental factors including age and diet can also 
influence the body’s ability to safely excrete drugs. One famous example is that grapefruit 
reduces the expression of CYP3A4 in the gut (Bailey et al., 1998). Overall the way an 
organism reacts to a drug is important in determining an animal model that can predict 
drug-induced toxicity in humans. 
Drug metabolism and the generation of chemically reactive metabolites (CRMs) are 
discussed in detail in chapter 1. CYP450 enzymes are a superfamily of haem proteins 
that have distinct but sometimes overlapping substrate specifities. Of 315 drugs tested, 57 
% were predominantly cleared through the action of CYP450s in humans. The CYP450 
isoenzyme that metabolised the most drugs was CYP3A4 (50 % of the drugs) then it was 
CYP2D6 (20 %), CYP2C9 and CYPC19 (15 %) and <15 % included CYP2E1, CYP2A6 
and CYP1A2 (Bertz and Granneman, 1997). CYP450 enzymes catalyse drug oxidation 
reactions via the mechanism summarised in Figure 3-1. The major enzyme involved in 
phase II drug metabolism is the uridine-5'-diphospho-glucuronyl transferase (UGT). The 
UGT superfamily consists of 22 proteins in humans, of which the UGT1A and UGT2B 
subfamilies are particularly involved in drug renal elimination (Rowland et al., 2013). The 
remaining key phase II enzymes are summarised in Table 3-2. 
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Figure 3-1: The monooxygenase CYP450 enzyme cycle. 
Drugs that are metabolised by CYP450 enzymes undergo an oxidation reaction where 
they lose an electron and gain an oxygen atom. Iron is present in CYP450 enzyme in the 
ferric (Fe3+) or ferrous state (Fe2+). This figure is adapted from Rang et al (2016). 
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Table 3-2: Summary of the major phase II metabolism enzymes  
Adapted from (Nassar et al., 2009) 
Reaction Conjugating agent Enzyme Target 
functional 
group 
Glucuronidation Uridine 5'-diphospho 
(UDP)-glucuronic 
acid 
UDP-glucuronyl 
transferase (UGT) 
-OH 
-COOH 
-NH
2
 
-SH 
Acetylation Acetyl Coenzyme A Acetyl transferase -OH, -NH
2
 
Amino acid 
conjugation 
-­‐ Glycine -­‐ Glutamine, -­‐ Taurine 
Acyl transferase -COOH 
Methylation S-adenosyl-
methionine 
Methyl transferase -OH, -NH
2
 
Sulphation 3’-
phosphoadenosine-
5’-phosphosulphate 
(PAPS) 
Sulphotransferase -OH, -NH
2
 
Glutathione 
conjugation 
Glutathione Glutathione-S-
transferase 
Electrophiles 
 
3.2 Aim 
To establish the appropriate stages of Xenopus laevis embyronic development for the 
investigation of Xenopus as a drug-induced toxicity model. 
3.3 Hypothesis 
From stage 38 to stage 45, the Xenopus laevis embryo is sufficient for the detection of 
drug-induced toxicity. 
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3.4 Results 
3.4.1 Initial drug dose response screens 
3.4.1.1 1. Stage 15-stage 38 Xenopus laevis embryos 
In the drug discovery screens I generally tested compounds between stages 15 and 38 as 
this correlates with major organogenesis in the embryo. Stage 15 (18 hpf at 23°C) 
Xenopus embryos were treated with 0.78-100 µM of drug and harvested at stage 38 (36 h 
incubation). The embryos that survived to the age of stage 38 were photographed, and 
divided into phenotype groups. Embryos treated with paracetamol (n=5) developed an 
increasing variation of phenotypes that deviated from the normal stage 38 phenotype 
(“wildtype”) (Figures 3-2A and 3-3A). In particular, the frequency of the developmentally 
delayed phenotype (orange bar) correlated with paracetamol concentration 12.5-100 µM. 
For embryos treated with the alleged non-toxic paracetamol isomer AMAP (n=3), the most 
frequent phenotype was the wildtype (blue bar) (Figures 3-2B and 3-3B). The incidence 
of an developmentally delayed embryo was less frequent in the embryos treated with 
AMAP compared to paracetamol. Gentamicin-treated embryos produced variable 
phenotypes in all of the concentration groups (n=4) (Figures 3-2C and 3-3C). The 
incidence of any particular phenotype did not correlate with the concentration of 
gentamicin the embryos received. In humans, tobramycin is the less nephrotoxic drug of 
the same class as gentamicin (the aminoglycosides). In the embryos treated with 
tobramycin the over incidence of abnormal phenotypes (not wildtype) was less compared 
to the gentamicin-treated embryos (n=2) (Figures 3-2D and 3-3D). The wildtype 
phenotype negatively correlates with 12.5-100 µM doxorubicin treatment (n=3) (Figures 
3-2E and 3-3E). For embryos treated with indomethacin, there was not a concentration-
dependent abnormal phenotype (n=3) (Figures 3-2F and 3-3F). The frequency of the 
wildtype phenotype decreases for embryos treated with 25-100 µM indomethacin. 
Cisplatin induced a variety of abnormal phenotypes including developmentally delayed, 
bent tail (pink bar), shortened body length (black bar) and oedema (green bar) in embryos 
treated with 25-100 µM concentrations (n=3) (Figures 3-2G and 3-3G). The wildtype 
phenotype frequency decreased in embryos treated with the same cisplatin concentration 
range. Finally, for embryos treated with diclofenac the overall incidence of any phenotype 
was significantly reduced with 50-100 µM concentrations (n=2) (Figures 3-2H and 3-3H). 
The absence of phenotypes at the higher concentrations correlates with the low 
percentage of embryos photographed. Only 40 % and 0 % of the embryos treated with 50 
and 100 µM diclofenac respectively survived to be photographed. The most common 
abnormal phenotype observed in embryos treated with diclofenac is developmental delay.  
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Figure 3-2: Stage 15 – stage 38 dose-response 0.78-100 µM drug screens. 
Stage 15 Xenopus laevis embryos were incubated for 36 h with paracetamol (A), AMAP 
(B), gentamicin (C), tobramycin (D), doxorubicin (E), indomethacin (F), cisplatin (G) or 
diclofenac (H). Photographs were taken of the embryos that survived to age of stage 38 
and embryos that displayed the same phenotype were grouped together, a representative 
embryo of the phenotype is depicted in this figure. A representation of each of the 
phenotypes has been labelled. The phenotypes included wildtype, no head, oedema, bent 
tail, developmentally delayed, shortened body and abnormal eye. The percentage of 
embryos that produced this phenotype out of the total embryos tested is indicated. 
3.4.1.2 2. Stage 38-stage 45 Xenopus laevis embryos 
For these screens, stage 38 embryos were incubated with 0.78-100 µM drug for 72 h. The 
surviving stage 45 embryos were photographed and I noted the incidence of abnormal 
and wildtype phenotypes. Compared to the stage 15-stage 38 screens, the overall 
incidence of abnormal phenotypes in the stage 45 embryos was lower due to 
organogenesis being near completion. The wildtype phenotype was the most popular 
observed phenotype. For embryos treated with paracetamol (Figures 3-4A and 3-5A) and 
gentamicin (Figures 3-4B and 3-5B), the second most common phenotype was oedema. 
The frequency of this phenotype does not correlate with drug concentration for both 
paracetamol and gentamicin. There are less abnormal phenotypes in embryos treated 
with tobramycin compared to gentamicin (n=2) (Figures 3-4C and 3-5C). The wildtype 
phenotype frequency decreases with increasing doxorubicin concentration from 25-100 
µM (n=3) (Figures 3-4D and 3-5D). The oedema phenotype for doxorubicin-treated 
embryos occurs throughout the concentration spectrum. Embryos treated with 100 µM 
doxorubicin produced developmentally delayed and shortened body length phenotypes. 
The embryos treated with 100 µM indomethacin did not survive (Figures 3-4E and 3-5E). 
The wildtype phenotype was the most popular for indomethacin-treated embryos, and the 
incidence was not concentration-dependent for the 0.78-25 µM indomethacin treatment 
groups (n=1). However for embryos treated with 50 µM indomethacin, the most common 
phenotype observed was a shortened body length. At this concentration the embryos also 
produced a bent tail phenotype. All stage 38 embryos treated with a concentration of 
cisplatin within the range 0.78-100 µM, produced a wildtype phenotype at stage 45 (n=1) 
(Figures 3-4F and 3-5F). For diclofenac, the wildtype phenotype was only observed in 
embryos treated from 0.78-12.5 µM (n=1) (Figures 3-4G and 3-5G). The only phenotype 
observed in embryos in the 25 and 50 µM diclofenac treatment group was a shortened 
body length. None of the 100 µM diclofenac-treated embryos survived to the age of stage 
45 to be photographed. Stage 38 embryos that were treated with a concentration of 
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daunorubicin within the range 0.78-100 µM all displayed wildtype phenotypes (n=1) 
(Figures 3-4H and 3-5H). 
3.4.2 Characterisation of Xenopus embryo drug metabolism machinery 
In all the future experiments for the investigation of the use of Xenopus embryos for the 
prediction of drug toxicity, I will use embryos aged stage 38 until the age of stage 45. I 
isolated RNA from whole stage 38 and stage 45 embryos and looked for the expression of 
major enzymes that are involved in drug metabolism in humans. The Xenopus CYP2E1, 
CYP2D6 and CYP3A4 isoenzymes were expressed in stage 38 and stage 45 embryos 
(n=5) (Figure 3-6A). The Xenopus gene that is the equivalent of the human KCNH2 gene 
was also present in both stage 38 and stage 45 embryos (Figure 3-6A). The KCNH2 
gene encodes the alpha subunit of the potassium ion channel known as the hERG 
channel. The hERG channel is associated with a significant amount of drug-induced 
cardiotoxicity reactions in humans. Embryos that expressed the 3 CYP450 isoforms we 
looked for, also expressed the major enzymes that are involved with human phase II drug 
metabolism (Figure 3-6B). In particular, I looked for the major phase II enzymes that are 
important for paracetamol metabolism including the glutathione S-transferases (GSTs): 
GSTP1, GSTT1 and GSTM1. We measured the presence of sulphotransferase enzymes 
SULT1A1 and SULT2A1. And finally, I looked for UGT1A6 and UGT1A1, which are the 
major UDP-glucuronsyl-transferase enzymes that produce paracetamol-glucuronide 
conjugates. For these phase II enzymes I used 2 sets of primers designed for 2 different 
regions of the Xenopus laevis gene. Overall, all of these phase II enzymes were 
expressed in RNA isolated from whole stage 38 and stage 45 embryos (n=5). 
3.4.3 Atlas of stage 45 Xenopus laevis  
To our knowledge, there is not an existing atlas for Xenopus laevis embryos. 
Consequently, I decided to produce an atlas to help identify the structures within the 
embryos in future experiments. Untreated stage 45 embryos were sectioned transversely 
(Figure 3-7) and along the sagittal plane (Figure 3-8) (n=10). For the transverse sections, 
I sectioned from anterior to posterior until the end of the gastrointestinal region. This is 
because that is the area of the organs I am interested in for hepatotoxicity and 
cardiotoxicity in the future experiments of this projects. In the sagittal sections of the stage 
45 embryos one can clearly see the length of the whole embryo. 
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Figure 3-3: Incidence of phenotypes for the stage 15 to stage 38 screen. 
The frequency of phenotypes observed after a 36 h 0.78-100 µM drug incubation in the 
stage 15-stage 38 screens (Figure 3-2) were plotted as a percentage of the total embryos 
tested for that drug. The stage 15 embryos were treated with paracetamol (A), AMAP (B), 
gentamicin (C), tobramycin (D), doxorubicin (E), indomethacin (F), cisplatin (G) or 
diclofenac (H). The wildtype phenotype (blue bar) indicates the phenotype is that of an 
untreated stage 15 that is incubated for 36 h. 
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H. Daunorubicin 
 
Figure 3-4: Stage 38 – stage 45 dose-response 0.78-100 µM drug screens. 
Stage 38 Xenopus laevis embryos were incubated for 72 h with paracetamol (A), 
gentamicin (B), tobramycin (C), doxorubicin (D), indomethacin (E), cisplatin (F), diclofenac 
(G) or daunorubicin (H). Photographs were taken of the embryos that survived to age of 
stage 45 and embryos that displayed the same phenotype were grouped together, a 
representative embryo of the phenotype is depicted in this figure. A representation of each 
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of the phenotypes has been labelled. The phenotypes included wildtype, no head, 
oedema, bent tail, developmentally delayed, shortened body length and abnormal eye. 
The percentage of embryos that produced this phenotype out of the total embryos tested 
is indicated. 
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Figure 3-5: Incidence of phenotypes for the stage 38 to stage 45 screen. 
The frequency of phenotypes observed after a 72 h 0.78-100 µM drug incubation in the 
stage 38-stage 45 screens (Figure 3-4) were plotted as a percentage of the total embryos 
tested for that drug. The stage 38 embryos were treated with paracetamol (A), gentamicin 
(B), tobramycin (C), doxorubicin (D), indomethacin (E), cisplatin (F), diclofenac (G) or 
daunorubicin (H). The wildtype phenotype (blue bar) indicates the phenotype is that of an 
untreated stage 45 that is incubated for 72 h. 
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Figure 3-6: RT-PCR for drug metabolism enzymes in untreated Xenopus laevis 
embryos. 
The expression of major drug metabolism enzymes in RNA isolated from whole stage 38 
(i) and stage 45 (ii) untreated embryos. For the phase I enzymes (A) 1 representative gel 
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is displayed (n=5). Histone 4 (H4) was the positive control, water (W) was the negative 
control. For the phase II enzymes (B) 2 representative gels are shown for each stage 
(n=5). For the phase II enzymes, 2 primer sets designed for different sections of the gene 
are displayed, for example, lanes 4 and 5 are both amplicons for GSTP1 but using 2 
different primer sets. The CYP450 enzymes were the positive controls and the negative 
control was water (W). 
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Figure 3-7: Transverse sections of untreated stage 45 Xenopus laevis embryos. 
Transverse sections (15 µm) arranged in order from anterior to posterior (A to K) as 
shown in (L) . The sections were either left without stain (i) or stained with H&E (ii). 
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Figure 3-8: Sagittal sections of untreated stage 45 Xenopus laevis embryos. 
Sagittal sections (15 µm) taken from the region shown in (F). The sections were either left 
without stain (i) or stained with H&E (ii). Sections from approximately the same area are 
grouped together, for example, the sections in (A) are almost the same but with and 
without stain counterparts. 
 
 
 
103 
3.5 Discussion 
In our laboratory, Xenopus embryos have been used for chemical and drug screens 
before (Tomlinson et al., 2012; Wheeler and Brändli, 2009; Wheeler and Liu, 2012). 
Therefore, we decided to test a known assay called the FETAX, which measures the 
effect of drugs on embryonic development as previously mentioned in chapter 1. The 
Frog Embryo Teratogenesis Assay Xenopus (FETAX) uses Xenopus embryos up to the 
age of stage 38 and it is thought to analyse small molecule teratogenicity. However, in 
terms of drugs, a teratogen is an agent that can disturb the development of the embryo or 
foetus. Teratogens halt the pregnancy or produce a congenital malformation (a birth 
defect). Classes of teratogens include radiation, maternal infections, chemicals, and 
drugs.  The changes seen in the stage 15 to stage 38 screens I have measured in this 
project do not reflect teratogenicity, but rather they demonstrate developmental changes. 
To begin with, I decided to use the same concentration range for all the drugs, 0.78-100 
µM. To perform the FETAX, I used stage 15 Xenopus laevis embryos and incubated them 
at 23°C with the drugs for 36 h (Figure 3-2). Typically, an untreated stage 15 embryo 
develops to the age of stage 38 after a 36 h incubation period at 23°C. Embryos that had 
the same phenotype were grouped together and we took a photograph of one of them, to 
represent the group. Each drug tested in the stage 15 to stage 38 screens produced at 
least 3 different abnormal phenotypes. There was not an obvious phenotype that 
indicated the toxicity of the drug. For example, the drugs associated with hepatotoxicity, 
paracetamol and diclofenac, did not exhibit one particular abnormal phenotype. 
Furthermore the most common abnormal phenotype observed for all the drugs was the 
developmentally delayed phenotype. The developmentally delayed phenotype was 
defined as an embryo that looks younger than stage 38 after the 36 h drug incubation. 
The high frequency and non-specificity of this phenotype for all the drugs tested suggests 
that any compound interference at this age will slow down embryonic development. 
Furthermore there was a greater variation of abnormal phenotypes produced in the stage 
15-stage 38 screens compared to the stage 38-stage 45 screens. I believe this is because 
the older embryos have more functional organs and mature systems compared to the 
younger embryos. Unlike stage 15-38 embryos, organogenesis has more or less finished 
in stage 45 embryos, and therefore they are better equipped to process drugs. The stage 
38-stage 45 embryos can tolerate the drugs better than the younger embryos. However, 
like every organism, the embryos have a limit, and this is reflected in the dose-dependent 
decrease in the wildtype phenotype for the higher concentrations of doxorubicin, 
diclofenac and indomethacin in the stage 38-stage 45 screens (Figure 3-5). The absence 
of a wildtype phenotype decline in these screens with drugs such as cisplatin, 
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paracetamol and gentamicin, that are associated with organ-specific toxicity in humans, 
suggests the 0.78-100 µM concentration range is not high enough. I cannot be certain that 
I am treating the embryos with a concentration that is high enough to induce organ-
specific toxicity if there is an absence of significant mortality in the highest concentrations 
of cisplatin, paracetamol and gentamicin administered. To be clear, mortality does not 
necessarily indicate drug-specific toxicity, however a concentration of the drug just below 
that which causes death, is likely to be the dose that induces drug-specific toxicity. That is 
if the animal model is capable of generating a drug-induced toxicity reaction similar to that 
observed in humans.  
Expression analysis using RT-PCR identified many of the drug metabolism enzymes 
characterised from human studies that play a major role in drug-induced toxicity (Figure 
3-6). The drug metabolism enzymes I looked for are expressed at the embryo age that I 
will use to perform the toxicity screens for this project. Furthermore it is promising that the 
gene, KCNH2, which encodes the alpha subunit protein of the hERG channel (KV11.1) is 
expressed. This is promising for characterising the use of the embryos for the prediction of 
drug-induced cardiotoxicity. As previously mentioned in chapter 1, the hERG channel is a 
voltage-gated K+ channel that has a physiological role in the generation of the delayed 
rectifier current (IKr). This current is important for cell membrane repolarisation for the 
cardiac action potential. Some drugs associated with cardiotoxicity in humans bind to and 
block this potassium channel, which can lead to arrhythmic heart beats. I assumed that if 
the drug metabolism enzyme is expressed at stage 38 and stage 45, they will also be 
expressed at the stages in-between. The RT-PCR results in this chapter were generated 
from embryos that were not treated with any drugs. In the future, we would like to 
investigate the change in expression of drug metabolism enzymes in treated embryos. For 
example CYP2E1 expression in embryos treated with paracetamol. CYP2E1 is the major 
enzyme responsible for the production of the reactive metabolite that is important for the 
generation of paracetamol-induced hepatotoxicity in humans. This is discussed in more 
detail in chapter 4. The Xenopus CYP2E1 does not necessarily metabolise paracetamol 
at the same rate or to generate the same reactive metabolite produced by the human 
CYP2E1. In zebrafish, CYP3A65 is responsible for the production of the paracetamol 
reactive metabolite (Chng et al., 2012). The presence of mRNA expression does not help 
us to understand the activity of the enzyme. Drug metabolism enzyme activity can be 
crucial for the animal to be able to generate a drug-specific toxicity reaction, particularly 
when it is known that the toxicity reaction is mediated by a drug metabolite. In future 
experiments, I would look to measure the activity of the Xenopus CYP450, GST, UGT and 
SULT enzymes that could be involved in drug metabolism. We only measured the 
expression of the major enzymes involved in human drug metabolism. I would look to 
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investigate the expression of more drug metabolism enzymes in the Xenopus embryos to 
understand the potential usefulness and limitations of the model. 
In the following chapters, I investigated drug-induced hepatotoxicity and drug-induced 
cardiotoxicity in the Xenopus laevis embryos. I decided to create an atlas to help identify 
structures, such as the heart and the liver (Figure 3-7). I chose to look at stage 45 
embryos, because that is the age the embryos will be analysed at after drug incubation. 
The transverse sections were arranged in order from anterior to posterior in order to help 
determine at which level a section is taken from in future experiments. The different body 
compartments of the embryo are more apparent in the sections stained with hematoxylin 
and eosin (H&E). The sagittal sections demonstrate that one advantage of the Xenopus is 
that because of its small size, we are able to take a section of the full body. We could 
observe the effect of the drug on the tissue surrounding the target organ for drug-induced 
toxicity. This is not possible with larger animals, for which a costly magnetic resonance 
imaging (MRI) scan might be the equivalent. 
3.6 Conclusion 
Overall, from these results, I believe that the stage 38-stage 45 Xenopus laevis embryo 
screen has the potential to predict drug-induced toxicity as opposed to drug-induced 
teratogenicity. In the following chapters that explore organ-specific toxicity, tor the most 
part, we decided to incubate the stage 38 embryos with the drug of interest and harvest 
the embryos at stage 45. It has been determined that up until and including the age of 
stage 45, the Xenopus laevis embryos do not feel pain, and consequently embryos 
younger than stage 46 are not subjected to home office restrictions. Furthermore the 
stage 45 embryos still fit comfortably into the wells of a 96 well plate to allow medium 
throughput screening. In conclusion, this drug screen protocol could be useful in terms of 
practicality for early preclinical drug safety studies in drug development. 
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4 Chapter 4: Assessing the use of Xenopus as a model 
for the prediction of Drug-induced Liver Injury using 
paracetamol as the model hepatotoxin 
4.1 Introduction 
4.1.1 Paracetamol-induced Liver Injury 
It is estimated that paracetamol-induced liver injury is accountable for the majority of acute 
liver failure cases in developed countries. It contributes to 80 % of the liver failure cases 
associated with drugs. Over a 6 year period in the US, 42 % of acute liver failure cases 
were due paracetamol overdose, of which 48 % were unintentional, 44 % were intentional 
and the remaining 8 % were of unknown intent (Larson et al., 2005). In the UK, it is 
estimated approximately 90000 patients present with paracetamol overdose a year, 
resulting in 50000 hospital admissions and 150-250 deaths (Bateman et al., 2014; Hawton 
et al., 2013; Wong et al., 2014). Paracetamol is the second most common reason for a 
liver transplant. Overall, paracetamol is the single largest cause of acute liver failure in the 
US and the UK (Ostapowicz et al., 2002). At a therapeutic dose, that is 4 g/day, 
paracetamol is an antipyretic and an analgesic drug. The analgesic effect is due to the 
indirect activation of cannabinoid (CB1) receptors (Bertolini et al., 2006). Additional 
therapeutic mechanisms of paracetamol includes the inhibition of cyclooxygenase (COX) 
activity, in particular it is COX2 selective and a reduction in prostaglandin synthesis (Hinz 
et al., 2007; Lucas et al., 2005). Severe liver injury is likely to occur when a single dose of 
10-15 g of paracetamol is taken (Dart et al., 2006). The majority of paracetamol 
metabolism occurs in hepatocytes in the liver and therefore the liver is the target organ for 
paracetamol-induced toxicity, although it can be metabolised in the kidney and intestines 
too (Bessems and Vermeulen, 2001). Paracetamol is a frequently used drug in developed 
countries and so the mechanism of paracetamol-induced liver injury is well defined in the 
literature (Figure 4-1). In humans, paracetamol (APAP) is metabolised predominantly by 
UDP (uridine 5'-diphospho)-glucuronosyl transferse (UGT) into the APAP-glucuronide 
conjugate, which is more water-soluble than the parent drug. The humans the major 
UGTs involved are UGT1A1 and UGT1A6 (Court et al., 2001). The second common 
pathway is APAP conjugation to sulphate with the help of the sulphotransferase (SULT) 
enzyme. The SULT1A1, SULT1A3/4 and SULT1E1 isoforms are important for 
paracetamol metabolism in humans (Adjel et al., 2008). In adult humans, approximately 
50-70% and 25-35 % of paracetamol is metabolised via the glucuronide and sulphate 
pathways respectively and are excreted safely. Less than 5 % of the parent drug is 
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excreted unchanged and the remaining 5-15 % is metabolised by CYP450 enzymes to N-
acetyl-p benzoquinone imine (NAPQI) (McGill and Jaeschke, 2013; Prescott, 1983).  The 
CYP450 isoform mainly involved in the production of NAPQI is CYP2E1, however 
CYP1A2, CYP3A4 and CYP2D6 contribute as well (Dong et al., 2000; Patten et al., 1993). 
When a therapeutic dose of APAP is taken, the NAPQI is converted to the APAP-GSH 
conjugate, via the cysteine sulfhydryl group on the GSH tripeptide, with the help of the 
glutathione-S-transferase (GST) enzyme. APAP-GSH is then further metabolised to 
mostly the APAP-cysteine and APAP-mercapturate metabolites, which are then excreted.  
 
 
Figure 4-1: Paracetamol metabolism with a therapeutic dose. 
Paracetamol (APAP) administered at a therapeutic dose (≤4 g/day) is metabolised to a 
number of metabolites in humans, the major metabolites are displayed in this schematic. 
Approximately 50-70 % of the APAP dose is converted to APAP-glucuronide through the 
action of uridine 5'-diphospho-glucuronosyltransferase (UGT). APAP-sulphate is the 
second major metabolite from APAP, contributing to approximately 25-35 % of all APAP 
metabolites and generated from sulphotransferase (SULT) enzymes. CYP450 enzymes 
convert 5-15 % of APAP to the reactive metabolite N-acetyl-p-benzoquinone imine 
(NAPQI), which is neutralised with the tripeptide glutathione (GSH). And <5 % of APAP is 
excreted unchanged or converted to the metabolite methoxy-APAP. 
 
The paracetamol metabolites are predominantly excreted through ABC transporters. 
These ATP-binding transporters are found in the membranes of hepatocytes and use the 
hydrolysis conversion of ATP to ADP to provide the energy required to move substrates 
across membranes, sometimes against the substrate gradient (Klaassen and Aleksunes, 
2014). The APAP-glucuronide and APAP-sulphate metabolites are excreted from the 
apical side of hepatocytes into the bile canaliculi through ABCC2 and ABCG2, also known 
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as multidrug resistance-associated protein-2 (MRP2) and cluster of differentiation w388 
(CDw388) or breast cancer resistance protein (BCRP) respectively. Both of these 
metabolites are excreted into the liver sinusoids via ABCC3 and ABCC4, which are found 
on the basolateral side of hepatocytes (Ghanem et al., 2009). The APAP-GSH metabolite 
is also a substrate for MRP2 efflux into bile (Chen et al., 2003) (Figure 4-2). 
 
 
Figure 4-2: Paracetamol metabolite hepatocyte transporters. 
Schematic of the hepatocyte transporters involved in the transport of major paracetamol 
(APAP) metabolites: APAP-glutathione (APAP-GSH), APAP- glucuronide and APAP-
sulphate. The multidrug resistance-associated protein-2 (MRP2) and breast cancer 
resistance protein (BCRP) transporters expressed on the apical surface of the hepatocyte, 
transport APAP-glucuronide and APAP-sulphate into the bile canaliculus. MRP2 also 
transports APAP-GSH. On the basolateral surface, the APAP-glucuronide and APAP-
sulphate metabolites are transported into the liver sinusoids via the MRP3 and MRP4 
transmembrane proteins. BSEP, bile salt export pump. 
When an overdose of APAP has been taken, the supply of GSH is saturated and so there 
is more free, unconjugated NAPQI (Figure 4-3). NAPQI is a reactive metabolite, and can 
bind to the sulfhydryl groups on cellular proteins such as mitochondrial proteins, or ion 
channels (Prescott, 1980). The NAPQI protein adducts formed can lead to mitochondrial 
dysfunction, nuclear DNA fragmentation, oxidative stress, hepatocyte death and 
subsequent acute liver failure and potentially patient death. The major cell death pathway 
by far is necrotic, although some apoptotic cell death also occurs. The initial ROS 
formation, exacerbates mitochondrial damage and cell death by activating the MAPK 
(mitogen-activated protein kinase) –JNK (c-Jun N-terminal kinase) pathway, which in turn, 
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amplifies oxidative stress (Jaeschke et al., 2012). Oxidative stress can activate the 
formation of the mitochondrial membrane permeability transition (MPT) pore. This allows 
solutes up to 1500Da to be able to pass through the inner mitochondrial membrane, the 
mitochondrial membrane potential is lost and mitochondrial proteins are released from the 
mitochondria and are able to fragment nuclear DNA (Kon et al., 2004). The mitochondrial 
proteins released include endonucleases such as AIF (apoptosis inducing factor) and 
endoG (endonuclease G) (Jaeschke et al., 2012; McGill and Jaeschke, 2013). 
Subsequently, necrotic cell death occurs. The exact mechanism for the initial incidence of 
oxidative stress, and it’s relationship to NAPQI production is not yet understood (Jaeschke 
et al., 2012). 
In the clinic, patients are administered N-acetyl cysteine (NAC) to prevent severe 
paracetamol-induced liver injury. The NAC replenishes the GSH stores, scavenges ROS 
in mitochondria and enhances the sulphation APAP metabolic pathway. The NAC 
therapeutic effect is more useful at preventing liver injury if it is taken less than 8 hours 
after the APAP overdose (Smilkstein et al., 1988; Waring, 2012). Some of the ABC 
transporters, in particular those involved in the efflux transport of paracetamol metabolites 
such as MRP2, BCRP and MRP4, are upregulated with paracetamol overdose (Barnes et 
al., 2007; Gu and Manautou, 2010). This is thought to be in a bid to reduce to 
accumulation of reactive metabolites inside the hepatocyte. Paracetamol-induced liver 
injury is an example of CRM-mediated DILI that is a result of the combination of CRM 
accumulation and a decline in cellular neutralising ability. The NAPQI protein adducts 
formed can by quantified by measurement of APAP-cysteine that is released into the 
protein fraction of the blood following a protease enzyme treatment (unlike the APAP-
cysteine derived from APAP-GSH, which is present in the non-protein fraction of 
circulation) (Vliegenthart et al., 2017). The site of hepatotoxicity associated with 
paracetamol overdose is the zone 3 perivenous zone where there is more CYP450 
bioactivation and more GSH generally available for detoxification. Paracetamol-induced 
liver injury has been recapitulated in several rodent and non-rodent animal models. 
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Figure 4-3: The mechanism for paracetamol-induced liver injury.  
The majority of paracetamol metabolism occurs in hepatocytes, in the liver. The major 
reactive metabolite responsible for paracetamol-induced liver injury is N-acetyl-p-
benzoquinone imine (NAPQI) that is produced from paracetamol (APAP) through the 
enzyme CYP2E1. In paracetamol overdose, the amount of glutathione (GSH) is reduced 
which allows NAPQI to covalently bind to the cysteine residues on mitochondrial proteins. 
This leads to the generation of reactive oxygen species (ROS), which exacerbates 
oxidative stress via the induction of the mitogen-activated protein kinase/c-Jun N-terminal 
kinases (MAPK/JNK) pathway. Mitochondrial dysfunction causes mitochondrial membrane 
permeability transition (MPT), which allows the translocation of proteins such as Bax into 
the mitochondria and release of endonucleases into the cytosol, which enter the nucleus 
and cause nuclear DNA fragmentation. All these mechanisms contribute to hepatocyte 
necrosis and liver injury. N-acetyl cysteine (NAC) is administered to paracetamol 
overdose patients. It replenishes GSH and scavenges ROS. 
4.1.1 Animal Models for Paracetamol-Induced Liver Injury 
A good animal model for the prediction of drug safety should be translatable to humans. 
However, a good way to determine the validity and limitation of a new animal model such 
as the Xenopus can be through comparison with existing animal models as well as to 
humans. Many animal models have attempted to mimic the paracetamol-induced liver 
injury phenotype. For rats, the paracetamol dose that has been used for studying 
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paracetamol overdose, ranges from 1500 to 2500 mg/kg (Bushel et al., 2007; Hadi et al., 
2013; Kienhuis et al., 2009). The wildtype F344/N and Wister male rats are the most 
popular, and the method of paracetamol administration is often oral gavage. Wildtype 
CB57BL/6 mouse models are treated with a toxic dose of paracetamol within the range 
300-375 mg/kg, also administered by oral gavage (McGill et al., 2012; Qin et al., 2016). 
Rats are less sensitive to hepatotoxicity associated with paracetamol overdose than mice 
(Davis et al., 1974). Rats do not form as much mitochondrial protein adducts, generate as 
much oxidative stress or activate the MAPK-JNK pathway unlike mice (McGill et al., 
2012). Although rats metabolised APAP similarly to mice, the steps that mice carry out but 
rats don’t, appear to be essential for the generation of APAP hepatotoxicity. The 
significant differences in response to a toxic APAP dose between the rat and mouse 
demonstrates the necessity for more than one animal species in drug development to pick 
up drug-induced toxicity reactions that could potentially be relative i.e. translatable to 
humans. It also indicates the complexity of decision-making in drug development: if APAP 
were a new drug candidate and the rat and mouse generated results that included 
conflicting hepatotoxicity incidence – which result should be considered? Would APAP be 
deprioritised? In this case, a drug that is very commonly used in the world today may not 
have made it to the market.  
The zebrafish (Danio rerio) is an increasingly popular non-mammalian animal model to 
use for research and toxicology studies. It has been used by different laboratory groups to 
investigate paracetamol-induced liver injury. Similar to Xenopus, zebrafish liver 
development is very rapid in comparison to mammalian liver development and occurs in 
the embryo ex utero. In zebrafish, liver budding starts at 28 hours post-fertilisation (hpf), 
primary liver morphogenesis is completed by 48 hpf, hepatic organogenesis is finished at 
72 hpf including blood perfusion and functionality. The liver is considered to be fully 
functional by 120 hpf (Isogai et al., 2001; McGrath and Li, 2008; Vliegenthart et al., 
2014b). Whereas mice do not have a mature liver until embryonic day 18.5, in utero (Zhao 
and Duncan, 2005). Zebrafish larvae models for paracetamol overdose were treated with 
within the range 1-10 mM APAP. This dose is administered into the media the embryos 
are swimming in, usually from the age of 72 hpf and harvested at or before 120 hpf (He et 
al., 2013; North et al., 2010; Verstraelen et al., 2016; Vliegenthart et al., 2014b). 
Vliegenthart and colleagues (2014) used adult zebrafish aged 5-24 months post-
fertilisation and administered a higher concentration range of paracetamol: 20-40 mM. 
Although, the survival rate of the fish began to decline at the 30 mM concentration 
(Vliegenthart et al., 2014a). Zebrafish are arguably the closest animal model to Xenopus. 
Subsequently, in order to determine the validity of paracetamol-induced liver injury in 
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Xenopus, the zebrafish paracetamol overdose model could be a useful model to compare 
results to. 
4.2 Aim 
Characterisation of Xenopus laevis as a model for paracetamol-induced liver injury and 
investigating the effects of additional compounds often affiliated with paracetamol toxicity 
models. 
4.3 Hypothesis 
Stage 38-45 Xenopus laevis embryos treated with paracetamol will exhibit characteristics 
of paracetamol-induced liver injury similar to other non-mammalian and mammalian 
animal models and humans. 
4.4 Paracetamol Results 
4.4.1 Paracetamol dose response in Xenopus laevis 
To test Xenopus laevis as a model for paracetamol-induced liver injury, I first investigated 
at what concentration paracetamol is toxic to the Xenopus laevis embryos.  A 
concentration that is too high may not elicit paracetamol-specific toxicity, but the resultant 
phenotype could be due to general toxicity that occurs from overexposure to any 
chemical. The phenotypes observed in chapter 3 for stage 38 to stage 45 embryos 
treated with a paracetamol concentration range 0-100 µM did not indicate toxicity. 
Consequently, for this chapter, I began with a higher paracetamol concentration range of 
0-5 mM. This range is consistent with zebrafish and in vitro models.  
The Xenopus laevis embryos are transparent at these stages and so the liver is visible, 
however the aim of this experiment was to see if we could detect an obvious change in 
phenotype in the whole embryo (not just the liver) with increasing paracetamol treatment 
concentration. For the concentration range of 0-5 mM there was no significant change to 
overall embryo phenotype (Figure 4-4). This dose response was performed with 4 groups 
of embryos from 4 different Xenopus laevis mothers (n=4). The untreated embryos were 
similar to the known stage 45 wildtype phenotype for Xenopus laevis. The resultant 
phenotype observed was due to the paracetamol treatment alone. Embryos were 
separated in the screens to 1 embryo per well of a 96-well plate, therefore spontaneous or 
drug-induced death of an embryo did not affect the probability of another embryo’s death. 
The incidence of oedema around the gastrointestinal region was higher with increasing 
concentration. The percentage survival decreased at the higher concentrations, for 
example, 4.5 mM and 5 mM to an average of 95 % and 90 % respectively (Figure 4-5). At 
all other concentrations the average survival percent remained at 100 %, with the 
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exception of 0.125 mM, where the 97.5 % average is due to the death of 1 embryo in all 
the dose response screens performed. 
I decided to investigate a higher dose response range, that is 5.5-10 mM paracetamol 
(Figure 4-6). The occurrence of gastrointestinal oedema was higher in the 5.5-10 mM 
than the 0-5 mM paracetamol concentration range. In the 5.5-10 mM range, the intestines 
look abnormal in the higher concentrations compared to the untreated control embryos. 
From 6-10 mM, there were some embryos with elongated intestines along the sagittal 
plane; the intestines were less compact. This elongation often coincided with oedema in 
the same anatomical region. The survival rate decreased with increasing paracetamol 
concentration to 40 % at 8 mM and below 5 % from 9-10 mM, which reflected the survival 
of only 1 embryo in all the screens carried out (Figure 4-7). 
It is from these sets of dose response concentration ranges, that it was decided to 
continue with the 0-5 mM range for the investigation of paracetamol-induced DILI for the 
remainder of the experiments in this chapter. The reduced survival rate for the 5.5-10 mM 
range, suggests non-specific toxicity. 
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Figure 4-4: Paracetamol dose response 0-5 mM. 
Xenopus laevis embryos were treated with a paracetamol concentration in the range 0-5 
mM (n=4). The embryos were treated with paracetamol from stage 38 and harvested at 
stage 45. The surviving embryos at stage 45 were photographed and the different 
phenotypes found for each paracetamol concentration are shown and the percentage of 
embryos that had that phenotype. Phenotypes include wildtype (w), damaged tail (dt), 
bent tail (bt), oedema (o) and abnormal gut (ag). The percentage is calculated from the 
total number of embryos treated. Where possible, the embryos were photographed to 
show the lateral view and the ventral view.  
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Figure 4-5: The percentage of Xenopus embryo survival with 0-5 mM paracetamol 
treatment. 
The average (±SEM) amount of embryos that survived until the age of stage 45 to be 
harvested and photographed for Figure 4-4 (n=4). 
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Figure 4-6: Paracetamol dose response 0, 5.5-10 mM.  
Xenopus laevis embryos were treated with a paracetamol concentration in the range 5.5-
10 mM (n=3) from stage 38 and harvested at stage 45. The surviving embryos at stage 45 
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were photographed. In this figure are the different phenotypes found for each paracetamol 
concentration and the percentage of embryos that had that phenotype. Phenotypes 
included wildtype (w), oedema (o), abnormal gut (ag), damaged tail (dt) and small (s). The 
percentage is calculated from the total number of embryos treated. Where possible, 
embryos were photographed to show the lateral view and the ventral view. 
 
Figure 4-7: The percentage of Xenopus embryo survival with 5.5-10 mM 
paracetamol treatment. 
The average (±SEM) amount of embryos that survived until the age of stage 45 to be 
harvested and photographed for Figure 4-6  (n=3). 
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4.4.2 Free GSH content in Paracetamol Treated Embryos 
In humans, the generation of the reactive metabolite, NAPQI, and the reduction of the 
neutralising agent, GSH, mediate paracetamol-induced liver injury. Consequently, the 
amount of free GSH can indicate the metabolism pathway of paracetamol and be an 
indirect measurement of paracetamol-induced liver injury.  Existing in vivo or in vitro 
assays that imitate human paracetamol overdose and the associated acute liver failure, 
show a reduction of free GSH in the assay system (Goldring et al., 2004; Howell et al., 
2014; Shenton et al., 2004; Vliegenthart et al., 2017). 
Embryos at stage 38 were treated with a paracetamol concentration within the range 0-5 
mM, harvested at stage 45, and processed to measure the amount of free GSH in them 
(n=10) (Figure 4-8A), normalised to the protein content using the Bradford assay. The 
amount of free GSH decreased from 47 nmol/mg to 22 nmol/mg with increasing 
concentration of paracetamol (0-5 mM). Embryos treated with a paracetamol 
concentration within the range 3-5 mM had statistically significantly less free GSH 
compared to untreated embryos (P<0.05). Xenopus laevis embryos that are incubated at 
23°C take 72h to develop from stage 38 to stage 45. In order to explore the time-
dependency of the decline in free GSH, I treated stage 38 embryos with the same 
paracetamol concentration range (0-5 mM) and harvested them after 24h, at stage 41 
(Figure 4-8B). There was no significant change in the relationship between paracetamol 
treatment and amount of free GSH when the embryos are treated for 24h.  
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Figure 4-8: The amount of free GSH inside Xenopus embryos treated with 
paracetamol. 
Xenopus laevis embryos were treated with 0-5 mM paracetamol from the age of stage 38, 
and harvested at stage 45 (A, n=10) or at stage 41 (B, n=3). The amount of free GSH 
(nmol/mL) was measured inside the embryos and normalised to the amount of protein 
(mg/mL). A one-way ANOVA compared each treatment group to the untreated group (0 
mM). For the embryos treated until stage 45 (A), the amount of free GSH for 3, 3.5, 4 and 
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4.5 mM paracetamol treatment groups was statistically significant compared to the 
untreated group (P<0.05). The 5 mM paracetamol treatment group was also statistically 
significantly different (P<0.01). There was no significant difference between treated and 
untreated embryos that were harvested at stage 41 (B). 
4.4.3 Liver expression pattern in Xenopus laevis and liver injury biomarker 
expression 
4.4.3.1 Wholemount in situ hybridisation 
The location of the liver is not always obvious in the Xenopus laevis embryo, it is <0.5 mm 
at its widest diameter, and the colour of it is not notably different to the intestines. Thus, 
we used a probe to identify the liver using a wholemount in situ hybridisation (WISH) 
protocol. The location of the liver in a whole Xenopus embryo, at stages 38 and stage 45, 
has been described in the literature (Blitz et al., 2006; Zorn and Mason, 2001) and is 
illustrated in Figure 4-9. Alpha-1-microglobulin/bikunin precursor (AMBP) is a protein 
specifically expressed in the Xenopus liver (Zorn and Mason, 2001) and so I used it as a 
positive control for the WISH. Stage 38 and stage 45 embryos expressed AMBP in the 
presumed location of the liver (Figure 4-10A) (n=10).  
Next, I decided to investigate the expression of miR-122 in the Xenopus embryos using 
the WISH assay. MiR-122 expression is specific to the liver in humans as well as rodent 
and zebrafish animal models (Figure 4-10B) (n=10). As previously mentioned in chapter 
1, the presence of miR-122 in the circulation is abnormal, and it can indicate liver injury 
and therefore, miR-122 can be a good biomarker for DILI. The WISH for miR-122 stained 
the same area as AMBP in stage 38 and stage 45 embryos, so miR-122 expression in 
Xenopus laevis is specific to the liver tissue, comparable to rodent and zebrafish species. 
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Figure 4-9: Illustration of the location of the liver in Xenopus embryos. 
The Xenopus embryos at the age of stage 38 (A) and stage 45 (B and C) have liver tissue 
(red). This schematic displays the location of the liver as seen from a lateral view (A and 
B) and ventral view (C). Modified from Nieuwkoop & Faber (1994) 
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Figure 4-10: Wholemount in situ hybridisation (WISH) for liver markers. 
WISH assay for AMBP (A) and miR-122 (B) at stage 38 (Ai and Bi) and stage 45 (Aii and 
Bii). The stage 38 embryos are shown in lateral view and the stage 45 embryos are shown 
ventrally. These embryos are representatives of the typical expression patterns seen 
(n=10). 
4.4.3.2 Sections of WISH miR-122 
When a liver is damaged, the expression of miR-122 in liver tissue becomes fragmented 
as the cells release it into the circulatory system. Consequently, I hypothesised that 
paracetamol-induced liver injury could be determined in the Xenopus embryos using 
fragmented miR-122 staining as an end-point. To test this hypothesis, I took untreated 
embryos that had been processed with the miR-122 probe using the WISH protocol, and 
sectioned them transversely; this was our negative control. I could clearly identify the liver 
in the transverse sections. Next, I treated the tissue sections with hematoxylin and eosin 
(H&E) that stain the nuclei and cytoplasm respectively. The H&E could help characterise 
the surrounding tissue in the sections. However, the WISH stain was not as easy to 
identify in these sections (Figure 4-11Aii). Finally, I treated embryos with paracetamol, 
then put them through the WISH protocol for miR-122 identification (Figure 4-11B), and 
sectioned them. It was difficult to observe paracetamol-induced liver damage in the 
results. 
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Figure 4-11: Sections of miR-122 WISH stage 45 embryos. 
WISH using miR-122 probe stage 45 Xenopus embryos untreated (A) or treated (B) with 5 
mM paracetamol from stage 38 until stage 45. 10 µm sections were either left without 
additional histology staining (Ai and Bi) or stained with H&E (Aii and Bii). Representative 
sections are displayed. The location of the liver (L) is attained purple. 
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4.4.3.3 The expression of miR-122 in the different tissues of embryos treated with 
paracetamol 
Stage 38 old embryos were treated with a paracetamol concentration within the 0-5 mM 
range, harvested at stage 45 and then processed to measure the expression of miR-122 
using qRT-PCR. Embryos were dissected to obtain gut tissue that included the liver and 
tail tissue to represent the blood. The miR-122 expression levels were normalised to a 
miRNA (miR-103), which is not effected by paracetamol treatment. The miR-122 
expression was also normalised to untreated (0 mM paracetamol) embryos (Figure 4-12). 
The expression of miR-122 increased in the tail tissue with increasing paracetamol 
concentration. In untreated wildtype embryos, the miR-122 expression in the tail was 
minimal. MiR-122 expression in the tail of embryos treated with 3 mM and 4 mM 
paracetamol was significantly different compared to the expression of miR-122 in the gut 
tissue from the same embryos treated with the same paracetamol treatment. In the gut 
tissue, the expression of miR-122 appears to be slightly reduced in treated embryos 
compared to untreated embryos, but the miR-122 expression does not change in relation 
to the paracetamol concentration, it remains level.  
 
Figure 4-12: Expression of miR-122 in paracetamol-treated embryos. 
Stage 38 embryos were treated with paracetamol (0-5 mM) and harvested at stage 45. 
The expression of miR-122 in gut (purple) and tail (red) was measured using qRT-PCR 
(log (fold change ± SEM)) and normalised to untreated embryos (0 mM). The statistical 
significant difference of miR-122 expression between tissues from embryos treated with 
the same paracetamol concentration was measured using the Mann-Whitney test 
(P<0.05) (n=5). 
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4.4.4 Characterisation of the metabolic profile of paracetamol-treated Xenopus 
laevis embryos 
As shown in Figure 4-1, paracetamol is metabolised into several small molecules in 
humans. I selected some of the major metabolites that are known to be produced in 
humans from paracetamol and investigated their production in our Xenopus paracetamol 
model. The metabolites I measured were: APAP-glucuronide, APAP-sulphate, APAP-
GSH, APAP-cysteine, APAP-NAC and APAP-methoxy (Figure 4-14). I measured the 
metabolic profile present inside the embryos themselves and within the media the 
embryos were swimming in using mass spectrometry protocol already established for 
paracetamol metabolites in the laboratory. As per the previous experiments in this 
chapter, stage 38 embryos were treated with a concentration of paracetamol within the 
range 0-5 mM and harvested at stage 45. The concentration of the parent drug, 
paracetamol, was measured to check the dosing of the stage 38 embryos (theoretical 
APAP dose) was correct (Figure 4-13). The concentration of paracetamol actually in the 
media the embryos were incubated within, was correct for the 0-3 mM theoretical doses 
however the 3.5, 4, 4.5 and 5 mM theoretical doses were actually measured as 5.2, 2.1, 
5.2 and 4.8 mM respectively. The APAP-sulphate metabolite is the dominant paracetamol 
metabolite produced in the Xenopus embryos and excreted into the incubation media. 
There were very small amounts of APAP-glucuronide and APAP-NAC detected in the 
media. The dominant metabolites present within the embryos were APAP-cysteine and 
APAP-GSH. Minimal amount (0-9.4 nmol/embryo) of the parent drug, paracetamol, was 
detected inside the embryo (Figure 4-13A).   
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Figure 4-13: Mass spectrometry detection of paracetamol. 
Embryos were treated with a paracetamol concentration (0-5 mM) in the embryo media. 
The embryos were pooled and mass spectrometry was carried out to measure the actual 
concentration of paracetamol in the media (orange) after 72h incubation (n=1). The 
amount of paracetamol was measured in nmol/embryo (A) and for ease, was then 
converted into mM (B). Minimal paracetamol was found inside the embryos (pink). 
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4.1.1  
Figure 4-14: Mass spectrometry detection of paracetamol metabolites. 
The amount of paracetamol metabolite present in the media (orange) and inside the 
embryo (pink) was measured after a 72h incubation with paracetamol (0-5 mM) (n=1). 6 
major metabolites involved in human paracetamol metabolism were identified: sulphate 
(A), glucuronide (B), methoxy (C), NAC (D), cysteine (E) and glutathione (F) paracetamol 
conjugates.  
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4.4.5 Analysis of time-dependent and dose-dependent multidrug resistance-
associated protein 2 (MRP2) expression 
MRP2, also known as ABCC2, has 17 hydrophobic transmembrane regions, of which 3 
span the membrane. In humans it is most highly expressed in the liver, however it is also 
found in the small intestine and kidney (Kool et al., 1997). APAP-glucuronide and APAP-
sulphate are substrates for this transporter, MRP2 translocates them from inside the 
hepatocyte into the bile canaliculi (Klaassen and Aleksunes, 2014). I treated stage 38 
Xenopus embryos with 5 mM APAP and harvested them at either stage 42, stage 44 or 
stage 45, that is 28 h, 48 h and 72 h respectively post-fertilisation (n=3, n=4 and n=4. 
respectively) (Figure 4-15). The mRNA expression for MRP2 was investigated in 
dissected gastrointestinal regions, and all results were normalised to untreated (0 mM 
APAP) embryos. The stage 42 harvested embryos had reduced MRP2 expression in 
comparison to untreated. The stage 44 and stage 45 embryos both had an average of 
increased MRP2 expression when compared to untreated embryos. The expression of 
MRP2 was greater in the stage 44 embryos than in the stage 45. There was not a 
statistically significant linear trend between MRP2 expression and increasing Xenopus 
embryo age.  
 
Figure 4-15: Expression of MRP2 in paracetamol-treated embryos. 
Embryos were treated with 5 mM paracetamol at stage 38 and harvested at stage 42, 44 
and 45, equivalent to 28 h, 48 h and 72 h incubation periods (n=3, n=4 and n=4. 
respectively). The gastrointestinal region was dissected and the expression of MRP2 
measured in that tissue by qRT-PCR (log (fold change ± SEM)) and normalised to 
untreated embryos (0 mM). No statistical significance was seen between samples. 
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4.4.6 Treatment with acetyl-meta-aminophenol (AMAP) 
AMAP is supposedly the non-toxic regioisomer version of APAP, but this appears to be 
species-dependent. I briefly investigated the Xenopus response to AMAP. Following the 
decline of survival percentage for the higher concentration range of APAP (5.5-10 mM), 
we decided to treat the embryos with that same concentration range and look at the 
resultant AMAP phenotype and survival percentage in comparison to APAP (Figure 4-16). 
The AMAP-treated embryos were increasingly more difficult to physically manipulate with 
increasing AMAP concentration to obtain the photographs. The embryos at the higher 
concentrations were more delicate, however they appeared similar to the stage 45 
wildtype untreated embryos when I took photographs. The survival percentage decreased 
with increasing AMAP concentration (Figure 4-17). In comparison to the APAP survival 
for the same concentration range, less AMAP-treated embryos survived overall, and more 
embryos died at the AMAP lower concentrations. Finally, I compared the affect of GSH 
depletion, which was determined by measuring the amount of free GSH in embryos from 
the same mother, treated with either AMAP or APAP in the same concentration range (0-5 
mM, n=3). These biological replicates for APAP produced the same depleting effect as 
shown with the previous result in this chapter; the amount of free GSH decreased with 
increasing APAP concentration. The embryos treated AMAP also produced a negative 
correlation: as the concentration of AMAP increased, the amount of free GSH detected 
decreased. The amount of GSH between embryos treated with the same concentration of 
either AMAP or APAP was not significantly different (Figure 4-18). 
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4.1.2  
Figure 4-16: AMAP dose response 0, 5.5-10 mM. 
Xenopus laevis embryos were treated with a AMAP concentration in the range 5.5-10 mM 
(n=3) from stage 38 and harvested at stage 45. The surviving embryos at stage 45 were 
photographed. There were no surviving embryos for 8 and 10 mM AMAP. In this figure are 
the different phenotypes found for each paracetamol concentration and the percentage of 
embryos that had that phenotype. The percentage is calculated from the total number of 
embryos treated. Where possible, the embryo was photographed to show the lateral view 
and the ventral view. 
 
Figure 4-17: The percentage of Xenopus embryo survival with 5-10 mM AMAP 
treatment. 
The average (±SEM) amount of embryos that survived until the age of stage 45 to be 
harvested and photographed for Figure 4-16 (n=3). 
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Figure 4-18: The amount of free GSH inside Xenopus embryos treated with 
paracetamol (APAP) or N-acetyl-meta-aminophenol (AMAP). 
Xenopus laevis embryos were treated with 0-5 mM paracetamol (APAP) or 0-5 mM N-
acetyl-meta-aminophenol (AMAP) from the age of stage 38, and harvested at stage 45 
(n=3). The amount of free GSH (nmol/mL) was measured inside the embryos and 
normalised to the amount of protein (mg/mL). There was no significant difference between 
embryos treated with the same concentration of APAP and AMAP. 
4.4.7 Characterisation of the metabolism of paracetamol in Xenopus 
I attempted to determine the key steps of paracetamol metabolism in the Xenopus 
embryos that are crucial for the development of the paracetamol-associated DILI reaction 
seen in humans. To do this, I used 1-aminobenzotriazole (1-ABT), a known non-selective 
CYP450 inhibitor in humans and other mammalian models. The dose response with 1-
ABT showed that significant oedema around the gastrointestinal region started developing 
at the 4 mM 1-ABT concentration and the incidence increased with increasing 1-ABT 
concentrations. The survival graph shows that death started occurring significantly at 6 
mM 1-ABT. Subsequently, I decided to use the highest concentration of 1-ABT that did not 
cause death or a notably different phenotype, I decided to use 3 mM 1-ABT for the co-
incubation with the APAP range of 0-5 mM. 
At stage 38, Xenopus embryos were treated with 3 mM 1-ABT for 2h and then a 
concentration of APAP within the range 0-5 mM was added to the 1-ABT-containing 
incubation media and the embryo was harvested at stage 45 (Figure 4-19). The 3 mM 1-
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ABT concentration was maintained throughout the entire incubation. The amount of free 
GSH was measured and compared between embryos treated with 1-ABT and APAP and 
embryos treated with APAP alone. As previously seen in this chapter, the amount of free 
GSH decreased in embryos treated with APAP alone with increasing APAP concentration. 
The same trend occurred for the embryos treated with 3 mM 1-ABT and APAP. However, 
the lower concentrations of the combined 1-ABT/APAP embryos had a lower free GSH 
compared to the APAP treated embryos of the same concentration. The embryos treated 
with 0-1 mM paracetamol and incubated with 3 mM 1-ABT, had less free GSH than the 
embryos treated with 0-1 mM paracetamol only. 
 
 
Figure 4-19: The amount of free GSH in embryos treated with 1-aminobenzotriazole 
(1-ABT) and paracetamol. 
Xenopus laevis embryos were treated with 3 mM 1-ABT (red) and without 1-ABT (blue) 
with a concentration of paracetamol (0-5 mM) from the age of stage 38, and harvested at 
stage 45 (n=4). The amount of free GSH (nmol/mL) was measured inside the embryos 
and normalised to the amount of protein (mg/mL). The embryos treated with or without 1-
ABT for the same concentration were not statistically significantly different. 
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4.4.8 Xenopus incubation with the human clinical treatment for paracetamol 
overdose 
As mentioned in the earlier text of this chapter, NAC is used as the treatment for humans 
that have overdosed on paracetamol. I identified the highest dose of NAC that Xenopus 
embryos could tolerate by doing a dose response and noting the survival percentage. To 
begin with, I started with a concentration range of 0-10 mM NAC and the embryos were 
treated from stage 38 to stage 45. However all of the embryos treated with a 
concentration within 0-10 mM did not survive. So I lowered the dose range to 0-1 mM 
NAC. The survival percentage significantly decreased from 0.6-1 mM NAC. I decided to 
co-incubate Xenopus embryos with 0.5 mM NAC and a concentration within the range 0-5 
mM APAP. Initially, I co-incubated NAC and APAP through 2 conditions: (1) incubation of 
the stage 38 embryos with 0.5 mM NAC for 2h and then the APAP concentration was 
added to the media and (2) concurrent 0.5 mM NAC and APAP (n=10) (Figure 4-20A). 
The embryos were harvested at stage 45 and compared to embryos treated with APAP 
alone. The free GSH concentration was measured and normalised to the untreated 
embryos for each condition which I denoted as a percentage of the 0 mM treatment 
group. Embryos treated with 0.5 mM NAC alone did not have a significantly different 
amount of free GSH to the untreated wildtype embryo (data not shown). Embryos that 
were pre-incubated with NAC before the APAP addition, had a decrease in free GSH with 
increasing APAP concentration, however the gradient was smaller in comparison to their 
counterparts that were treated with APAP only. The concurrent NAC and APAP co-
incubation also had a negative correlation between free GSH and APAP concentration, 
but this gradient was, on average, smaller than the pre-incubation treatment.  
Next, I decided to add the 0.5 mM NAC to APAP-treated embryos 24h, prior to their 
harvest at stage 45 (n=5) (Figure 4-20B). I saw that the free GSH measured in the 
embryos treated with NAC was, on average, higher than the counterpart embryos treated 
with the same APAP concentration but APAP alone. However the amount of free GSH 
measured in NAC-treated embryos did decrease with increasing APAP concentration. 
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Figure 4-20: Free GSH in embryos treated with paracetamol and N-acetyl cysteine 
(NAC). 
Embryos were treated with paracetamol (0-5 mM) for 72h with or without the addition of 
0.5 mM NAC, they were harvested at stage 45. For the initial experiments (A) there were 
3 conditions: treatment with paracetamol alone (blue), 2h incubation with NAC prior to the 
addition of paracetamol (red) and concurrent treatment with NAC and paracetamol (green) 
(n=10). The embryos were also treated with APAP and then with NAC for 24h prior to 
harvest (orange) or with paracetamol alone (blue) (B) (n=5). The amount of free GSH 
inside the embryos was measured and normalised to the amount of protein. This value 
was then normalised to the embryos treated with 0 mM paracetamol of the treatment 
group. The amount of free GSH measured was calculated as a percentage of the 0 mM 
paracetamol treatment group (±SEM). 
4.5 Investigating an alternative drug known to be associated with 
drug-induced liver injury 
4.5.1 Diclofenac-induced liver injury 
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is taken for it’s 
analgesic, antipyretic and anti-inflammatory properties for diseases such as ankylosing 
spondylitis and rheumatoid arthritis (Boelsterli, 2003). However, it is the most commonly 
used NSAID that is still on the market but is also associated with drug-induced liver injury 
(DILI) (Thompson et al., 2012). The US Food and Drug Administration (FDA) have 
diclofenac under black box warning for it’s potential to cause mitochondrial damage, 
cardiovascular toxicity and hepatotoxicity (Dykens and Will, 2007). The majority of 
patients tolerate diclofenac but cases of hepatotoxicity and liver failure have been 
reported. Diclofenac is associated with idiosyncratic hepatotoxicity, and although the exact 
mechanisms of toxicity are unknown, the metabolites derived from diclofenac are thought 
to play a crucial role. 4’-OH-Dic and 5’-OH-Dic are diclofenac metabolites generated from 
phase I oxidation drug metabolism reactions from the activity of CYP2C9 and CYP3A4 
respectively. Both of these oxidation products have the potential to be further oxidised to 
ρ-benzoquinone imines, which are very electrophilic and can covalently bind to non-
protein and protein sulfhydryl groups (Syed et al., 2016). The phase II metabolite 
diclofenac 1-O-acyl glucuronide and its derivative diclofenac glutathione thioester have 
also been implicated in diclofenac-mediated liver injury. The acyl glucuronide metabolite is 
a product of the UGT2B7 (uridine 5'-diphospho-glucuronosyltransferase 2B7) isoenzyme 
and can covalently bind to hepatocellular proteins and impair their activity (Kretz-Rommel 
and Boelsterli, 1993). Diclofenac glutathione thioester is thought to be involved in 
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diclofenac-induced liver injury because it is highly reactive with thiol groups, even more so 
than the glucuronide metabolite (Grillo et al., 2003; Syed et al., 2016). Overall, studies 
suggest that diclofenac and its metabolites mediate hepatotoxicity via mitochondrial 
dysfunction (Figure 4-21) (Boelsterli, 2003; Gómez-Lechón et al., 2003; Masubuchi et al., 
2002; Syed et al., 2016). 
  
 
Figure 4-21: Diclofenac mechanism of toxicity 
Diclofenac metabolites contribute to the generation of diclofenac-induced liver injury. 
Phase I metabolism produces hydroxyl metabolites via the CYP450 isoenzymes CYP2C9 
and CYP3A4. The phase II metabolism enzyme uridine 5;-diphospho-
glucuronosyltransferase 2B7 (UGT2B7) produces diclofenac 1-O-acyl glucuronide 
(DicGluA), which is conjugated to glutathione via glutathione S-transferase (GST) to 
produce diclofenac glutathione thioester (DicSG). 
4.6 Diclofenac Results 
4.6.1 Diclofenac dose response in Xenopus laevis 
In the initial screens conducted with diclofenac in chapter 3 using stage 38 to stage 45 
embryos, the survival appeared to decrease after the 12.5 µM concentration. 
Consequently, I decided to start with a dose range of 0-10 µM (n=3) (Figure 4-22). For all 
of the concentrations in this range, the majority phenotype was the same as the untreated 
(0 µM diclofenac) embryos. One incidence of oedema in the gastrointestinal region 
occurred in the 1 µM diclofenac concentration group. A common phenotype that occurred 
in most of the concentrations was a damaged tail. The survival percentage did not 
significantly decrease for the 1-10 µM diclofenac concentration range (Figure 4-23), I 
decided to look at a higher range of 11-20 µM (n=1, data not shown). For this range, the 
survival significantly decreased to 0 % after 12 µM diclofenac, from 13-20 µM. 
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Figure 4-22: Diclofenac dose response 0-10 µM. 
Xenopus laevis embryos were treated with a diclofenac concentration in the range 0-10 
µM (n=3) from stage 38 and harvested at stage 45. Surviving embryos were 
photographed at stage 45. The different phenotypes are shown for each diclofenac 
concentration and the percentage of embryos that had that phenotype. The percentage is 
calculated from the total number of embryos treated. Phenotypes include wildtype (w), 
damaged tail (dt), bent tail (bt), oedema (o) and abnormal gut (ag). The percentage is 
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calculated from the total number of embryos treated. Where possible, the embryos were 
photographed to show the lateral view and the ventral view.  
 
 
Figure 4-23: The percentage of Xenopus embryo survival with 1-10 µM diclofenac 
treatment. 
The average (±SEM) amount of embryos that survived until the age of stage 45 to be 
harvested and photographed for Figure 4-21 (n=3). 
4.7 Discussion 
As stated earlier the overall aim of the project is to assess the use of Xenopus as a model 
to predict drug-induced toxicity and this chapter predominantly focuses on one known 
hepatotoxic drug, paracetamol. Consequently, ultimately I have investigated the effect of 
paracetamol overdose on Xenopus embryos and can now compare the model to humans 
as well as mammalian and non-mammalian animal models. The results generated here 
can suggest the suitability of Xenopus as model to predict drug-induced hepatotoxicity. 
4.7.1 Paracetamol Overdose Concentration Range and Phenotypes 
In in vitro safety studies, the concentration of a drug candidate that exerts drug-specific 
toxicity mechanisms is defined as the highest concentration that induces approximately 20 
% cell death. At least 80 % viability is required at this concentration. The ratio between 
this high concentration and the peak serum concentration of the drug candidate should be 
at least ten-fold, this ratio is called the safety margin (SM). A drug candidate with a value 
of SM<10, is identified as a compound that has a high probability of causing a DILI 
reaction (Richert et al., 2016). In drug development, it is important to use the correct 
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concentration that is relative to the toxicity safety studies to be performed in higher-order 
animal models and humans. 
The photographs in Figure 4-4 depict the embryos that were alive at the harvest age, 
stage 45. The phenotypes of the embryos that died before stage 45 were not recorded. 
Therefore I was looking for a paracetamol concentration that was toxic, but did not kill the 
embryos, thus a concentration that would produce the pathophysiology of paracetamol-
specific toxicity, not general toxicity that could occur if a system is given too many of any 
xenobiotic.  
Despite the fact that they were sometimes difficult to manipulate, the embryos were 
photographed true to how they were found at their harvest age. The phenotype observed 
is a consequent of the paracetamol treatment. The gastrointestinal oedema phenotype in 
the Xenopus embryos was also observed in response to paracetamol in zebrafish larvae 
(Verstraelen et al., 2016). The paracetamol concentration range 0-5 mM is consistent with 
the dose used to investigate paracetamol-induced hepatotoxicity in zebrafish in the 
literature. Unlike the initial dose response screenings in chapter 3, the paracetamol used 
in this chapter was dissolved in the Xenopus media without the use of DMSO. This is 
important because DMSO is a known CYP450 inhibitor, and the pathophysiological 
mechanism of paracetamol-induced hepatotoxicity requires the generation of the reactive 
metabolite using CYP450 activity (Yoon et al., 2006). Overall the high mortality in the 
range 5.5-10 mM paracetamol coupled with some incidence of gastrointestinal oedema in 
the 0-5 mM range established the 0-5 mM concentration range as a sufficient dose to 
perform the following characterisation assays in this chapter, to observe Xenopus 
embryos and their response to a paracetamol overdose. 
4.7.2 Characterising the Xenopus embryo response to paracetamol overdose 
4.7.2.1 Free GSH 
For a long time, it was thought that a significant reduction of free GSH upon drug 
candidate administration is indicative of oxidative stress and covalent binding and 
modification of proteins that leads to liver toxicity and activation of the innate immune 
system. A 90 % reduction of free GSH compared to the untreated normal value is 
considered significant (Geenen et al., 2013). However it has been argued that a reduction 
in free GSH is not necessary for covalent binding to proteins to occur (McGill and 
Jaeschke, 2013). In HepaRG cells treated with paracetamol, protein binding occurred 
before the GSH depletion (McGill et al., 2011). Furthermore, humans that have been 
administered therapeutic doses of paracetamol have protein adducts in their serum but 
their GSH level remains normal (Heard et al., 2011). Consequently the relationship 
between free GSH reduction and liver injury is not definitive. However, for paracetamol-
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induced liver injury in humans, the reduced amount of free GSH is part of the 
pathophysiology mechanism as it allows the accumulation of the reactive metabolite 
NAPQI. Therefore it is an important assay to perform with the Xenopus embryos in order 
to determine if paracetamol is metabolised via the same pathway as mammals, and this 
would imply the embryos can be susceptible to a paracetamol-induced liver injury 
reaction. 
The reduction of free GSH observed in the Xenopus embryos (Figure 4-8A) implies they 
have generated a small molecule from paracetamol, which depletes the free GSH store. 
The absence of the reduction in the embryos treated for only 24h shows the GSH 
depletion is time-dependent. Although statistically significant, the GSH depletion with the 
highest paracetamol concentration tested (5 mM) is a 52.1 % reduction compared to the 
untreated embryos, not the 90 % significant reduction as favoured by researchers that 
suggests a high risk DILI compound. It would be interesting to see if such a great 
reduction occurs with embryos treated with higher paracetamol concentrations. 
4.7.2.2 The use of miR-122 as a biomarker for DILI in Xenopus embryos 
The Xenopus miR-122 has the same nucleotide sequence as zebrafish, humans and 
rodents and the WISH results show that miR-122 is liver-specific in the Xenopus, much 
like these animal models as well (Vliegenthart et al., 2014a; Wienholds et al., 2005). 
Fragmented WISH miR-122 staining in the liver indicates hepatocyte injury. However, I 
could not detect a difference between the sections from paracetamol-treated embryos and 
untreated. The WISH protocol can make the embryo tissue more delicate and the size of 
the embryo can also contribute to the difficulty of obtaining good quality sections. To 
optimise the quality, I tried different embedding, sectioning and fixation techniques, such 
as embedding in OCT compound, sectioning using a cryostat, and fixing in a 
formaldehyde-containing solution for a longer period of time (data not shown). The best 
quality sections, shown here, were produced with wax embedding with a microtome and 
the fixation method stated in chapter 2. The incidence of holes in the tissue sections was 
similar in the untreated and treated embryos. In conclusion, we believe the holes seen in 
the sections were not paracetamol-specific, but possibly due to the technique. 
Subsequently, I attempted to identify liver necrosis using the Terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay using a 12-UTP fluorescein label 
which has been shown to label necrotic cells as well as apoptosis (data not shown). The 
results were inconclusive and further work is needed to optimise this assay for use with 
Xenopus embryo sections. 
The presence of miR-122 in the blood in humans is an indication of hepatotoxicity. The 
Xenopus embryos have a circulatory system at the age I was treating them, but the size of 
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the embryos is too small to be able to easily obtain a blood sample, and the volume of 
blood within the embryo is very little. Consequently, in order to measure the expression of 
miR-122 with paracetamol treatment, we decided to use the tail tissue to represent the 
blood. The tail contains a good vasculature and the liver tissue is not present in this body 
compartment. Under healthy circumstances there should not be a significant amount of 
miR-122 expression found in the tail. The size of the embryos means dissecting the liver 
alone would be difficult and time consuming. I therefore decided to dissect the whole 
gastrointestinal or gut region, including the liver, to represent the liver miR-122 
expression. I normalised the miR-122 expression against miR-103 expression in the 
tissue of the embryos. Unlike U6, which is a small nuclear RNA (snRNA) that is 
traditionally used for miRNA quantification in qRT-PCR, miR-103 is not affected by 
paracetamol treatment (Wang et al., 2013). Vliegenthart and colleagues (2015) identified 
a comprehensive list of endogenous miRNAs unaffected by paracetamol in humans, 
however unfortunately none of the best miRNAs mentioned are expressed in Xenopus 
laevis (Vliegenthart et al., 2015). 
The increase of miR-122 expression in the tail with increasing paracetamol concentration 
in Figure 4-12 implies paracetamol-induced hepatotoxicity. The slight reduction of miR-
122 expression in RNA isolated from gut tissue is indicative of liver damage, however 
there is no linear trend of miR-122 expression in the gut with regards to paracetamol 
concentration. This may be because miR-122 expression in the liver is so abundant, that a 
slight depletion cannot be detected.  
4.7.2.3 Detection of Paracetamol Metabolites using HPLC-MS/MS 
The mass spectrometry analysis was performed by Dr. Mark Bayliss at the MRC Centre 
for Drug Safety Science in the University of Liverpool using tissue samples generated in 
our laboratory. Unfortunately only one set of samples could be analysed (n=1) therefore I 
cannot perform statistical analysis on this data. The difference observed between 
theoretical and measured paracetamol concentrations must be taken into account when 
we interpret the detection of the paracetamol metabolites. Where the ratio of the analyte 
inside the embryo versus the analyte in the media is less than 0.02, the results for embryo 
represented the concentrations in residual media that was still attached to the outside of 
the embryo. For future experiments, I would suggest we washed the embryos with 
phosphate buffered saline (PBS) to remove this media and consequently ambiguous 
results. The detection of the presence of all the paracetamol metabolites we looked for is 
promising in so far as it suggests the embryos took up the parent drug from the media 
they were swimming in. The ratios of the paracetamol metabolites in the Xenopus 
embryos are more similar to the paracetamol metabolism observed in children than in 
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human adults (Figure 4-14). As previously described in this chapter, in human adults the 
ratio of the APAP-glucuronide to APAP-sulphate metabolites is approximately 2:1. 
Children produce more of the APAP-sulphate the ratio to APAP-glucuronide is more akin 
to 1:1. The reasons for the differences have not been established however it is thought 
that a more active SULT enzyme activity in children compared to adult, contributes to the 
different metabolic profiles (Barshop et al., 2011). In addition, although not that much data 
is available, the incidence of paracetamol-induced hepatotoxicity is lower in children than 
adults (W.M. Lee, 2003; Squires  Jr. et al., 2006). But the oxidative pathway is more active 
in children than adults; children generate more of the reactive metabolite. The lower 
paracetamol-associated DILI incidence coupled with a higher production of NAPQI 
suggests children have more efficient detoxifying pathways (Penna and Buchanan, 1991). 
Furthermore, young mice are less susceptible to paracetamol-induced toxicity than their 
adult counterparts. This is thought to be attributed to a 4-fold higher GSH turnover and a 
more active GST system compared to adult mice (Adamson and Harman, 1989; 
Lauterburg et al., 1980). In summary, the results of the mass spectrometry analysis 
suggest the Xenopus embryos could be more similar to children and consequently they 
could be more adept at detoxifying xenobiotics. As stated, more experiments need to be 
carried out. 
4.7.2.4 Investigating the expression of a transporter involved in paracetamol metabolite 
excretion: MRP2 
For this experiment, all of the embryos were treated with 5 mM paracetamol at stage 38 
and the gastrointestinal region was isolated and processed to investigate the change in 
MRP2 mRNA expression. Some of these embryos were harvested at stage 42, some at 
stage 44 and some at stage 45. The stage 45 harvested embryos were treated with 
paracetamol for the same amount of time as the dose response assays in this chapter. 
The expression of Xenopus laevis MRP2 was normalised to untreated embryos. The 
different harvest stages allowed us to analyse the expression of MRP2 over time following 
a single toxic dose of paracetamol. In male C57BL/6J mice, Mrp2 expression in the liver 
was significantly induced with a paracetamol dose ≥400 mg/kg (Aleksunes et al., 2006, 
2005). This expression did not follow a time-dependent trend. The Mrp2 liver protein 
expression was upregulated in male Wister rats treated with 1 g/kg paracetamol (Ghanem 
et al., 2004). Studies involving the expression of MRP2 with paracetamol overdose in 
zebrafish are not available in the literature.  
MRP2 expression increases in the stage 44 and stage 45 embryos compared to stage 42 
and untreated embryos. However the absence of a positive linear correlation implies the 
expression is not time-dependent, indeed the expression of MRP2 appears to decrease 
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from stage 44 to stage 45. One explanation for this could be that the peak MRP2 
expression is at stage 44 and by stage 45, the embryos have managed to control the 
accumulation of metabolites that require exportation from the hepatocyte via MRP2 
activity. Perhaps the Xenopus have an alternative neutralising agent in their metabolic 
capacity to be able to do this. In order to clarify these results, further work should be done 
to explore the protein expression of MRP2. I would also suggest a greater range of 
harvest stages could help to establish the MRP2 expression pattern, and using a range of 
paracetamol doses would be interesting to ascertain the dose-dependent expression of 
MRP2. Characterising the expression of all the major efflux transporters involved in 
paracetamol excretion, for example MRP3, MRP4 and BCRP, could help determine the 
similarities or differences of paracetamol overdose in Xenopus and other animal models 
or humans. 
4.7.2.5 Intervention with 1-ABT to elucidate the mechanisms of paracetamol-induced 
liver injury in Xenopus embryos 
I hypothesised that 1-ABT will inhibit the CYP450 activity in the Xenopus embryos and 
consequently reduce the amount of reactive metabolite (NAPQI) produced. Therefore less 
GSH will be required to neutralise this reactive metabolite and a higher amount of free 
GSH will be detected in the GSH assay, compared to embryos not incubated with 1-ABT. I 
used 3 mM 1-ABT, which was the highest concentration of 1-ABT that the embryos could 
tolerate without any obvious phenotypic effects. All the embryos in the 1-ABT treatment 
group (Figure 4-19 red bars) were incubated with 3 mM 1-ABT in addition to the 
paracetamol concentration noted on the X-axis. As per the previous GSH assay 
experiments in this chapter, the whole embryo was processed to measure the amount of 
free GSH. The amount of free GSH in 0 mM paracetamol control groups differed, although 
the difference is not statistically significant (P=0.34). However this difference suggests 
that the 1-ABT compound alone reduces the amount of free GSH available in the embryo. 
We do not understand the mechanism for this. The average free GSH for 0.5 mM and 1 
mM paracetamol treatment also appears to be different for the 1-ABT group compared to 
paracetamol alone, but not statistically different (P=0.34 and P=0.11 respectively). I 
questioned if the 1-ABT compound has the same inhibitory affect in the non-mammalian 
Xenopus embryos as is established in mammalian models. To investigate this, I attempted 
to isolate Xenopus microsomes from adult liver homogenate that is available in our 
laboratory. In mammals, microsomes contain high concentrations of the CYP450 
enzymes, I hypothesised the same traditional high centrifugation isolation method will 
obtain Xenopus microsomes that also contain CYP450s in abundance. The substrate ρ-
nitrophenol is converted to 4-nitrocatechol in a hydroxylation reaction catalysed by 
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CYP450 enzymes (Monostory et al., 2004). This reaction can be used to measure 
CYP450 inhibition with 1-ABT. In the future I would like to optimise this experiment to 
determine the effectiveness of 1-ABT inhibition of Xenopus CYP450. This could help 
interpret the 1-ABT results I generated in this chapter. 
4.7.2.6 Treatment with NAC, the clinical treatment for paracetamol overdose in humans 
Overall 3 incubation conditions were carried out with 0.5 mM NAC and 0-5 mM 
paracetamol: (1) 2h NAC incubation prior to paracetamol addition (2) concurrent NAC and 
paracetamol treatment and (3) NAC incubation in paracetamol-treated embryos for 24h 
prior to harvest. Of the 3 conditions performed, the 24h incubation prior to harvest is the 
most clinically relevant to humans. However in all of the treatment conditions, the amount 
of free GSH measured is greater in the embryos of the NAC treatment group compared to 
the embryos without NAC, of the same paracetamol concentration group. This smaller 
decline of free GSH with NAC treatment suggests the embryos are metabolising 
paracetamol to generate a small molecule that depletes GSH, and this pathway can be 
reversed through the administration of NAC. This rescue mechanism implies but cannot 
confirm, that the reactive metabolite generated in the Xenopus embryos could be NAPQI, 
the same reactive metabolite produced in humans and animal models. The results are 
similar to the NAC response observed in zebrafish paracetamol overdose. In adult 
zebrafish treated with paracetamol, the amount of free GSH increased with NAC 
administration compared to zebrafish treated with paracetamol alone (North et al., 2010). 
Overall these NAC response results indicate that Xenopus embryos are a promising 
model as they exhibit reactivity to human treatments, which is similar to another promising 
non-mammalian model, the zebrafish.  
4.7.3 AMAP: the non-toxic regioisomer of APAP 
AMAP is the controversial, supposedly less toxic positional isomer to paracetamol. It has 
similar therapeutic indications to paracetamol, such as analgesic properties. Initially, I 
decided to use AMAP in comparison with paracetamol in chapter 3 to determine if the 
Xenopus embryos can distinguish a non-toxic drug from a toxic drug. However literature 
suggests the AMAP lower risk of toxicity is species-dependent. Hadi and colleagues 
(2013) investigated the different AMAP toxicity susceptibility between rat, mouse and 
humans using precision-cut liver slices (PCLS). PCLS are an ex vivo tool that can be used 
in small studies to research drug-induced hepatotoxic reactions. In PCLS the liver 
structure and cell interactions are maintained and the gene expression profile is very 
similar to a functional, intact liver (Boess et al., 2003; Lerche-Langrand and Toutain, 2000; 
Olinga et al., 1997; Vickers and Fisher, 2004). In this study, the mouse PCLS incubated 
with paracetamol had a lower ATP content and lower histomorphological score than the 
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rat and human PCLS incubated with the same paracetamol concentration. This suggests 
mice are more susceptible to paracetamol than humans. Furthermore, AMAP showed a 
significantly lower toxicity profile than paracetamol in the mouse PCLS, whereas in rat and 
human PCLS, the AMAP toxicity phenotype appeared to be equal to or more toxic than 
the paracetamol. The mouse differential response to AMAP and paracetamol has been 
replicated in in vitro and in vivo experiments and is also true for the hamster model 
(Nelson, 1980; Rashed et al., 1990; Roberts et al., 1990; Tirmenstein and Nelson, 1989). 
The difference in toxicity in mouse is attributed to the lower production of reactive 
metabolite from AMAP compared to paracetamol, the GSH depletion is greater with 
paracetamol than AMAP, and the reactive metabolites produced do not bind to as many 
mitochondrial proteins as paracetamol (Howell et al., 2014; Rashed et al., 1990; Salminen 
et al., 1997; Tirmenstein and Nelson, 1989). But the absence of a difference for AMAP 
and paracetamol toxicity in rat and human models highlights the importance of using 
animal models that are relevant to humans and understanding the limitations of an animal 
model in order to improve drug toxicity prediction. 
In our Xenopus embryos, the lack of significant difference between AMAP and 
paracetamol for the depletion of GSH indicates Xenopus could have a similar toxic 
reaction to AMAP as paracetamol. The embryos also have a similar concentration-
dependent survival percentage for AMAP and paracetamol. Unfortunately, I could not find 
any literature researching AMAP versus paracetamol toxicity in zebrafish, which could be 
a useful comparison for our fellow non-mammalian animal model. I do not think this result 
diminishes the integrity of the Xenopus toxicity prediction model because toxicity 
associated with AMAP is not consistent across the existing animal models in drug 
development. 
4.7.4 Investigating an additional hepatotoxin: diclofenac 
In order to characterise the Xenopus embryos as a model of detecting hepatotoxicity, not 
just the paracetamol-specific phenotype, I decided to look at another drug known to cause 
hepatotoxicity, diclofenac. The concentration of diclofenac that did not cause a high 
percentage of mortality was approximately 1000-fold lower than the concentration of 
paracetamol the embryos received. I would like to compare the lipophilicity of diclofenac 
versus paracetamol, as this physicochemical property could be an important factor that 
contributes to the amount of drug that can pass from the Xenopus media into the embryo 
through the embryonic membrane. Unfortunately I did not have enough time to investigate 
the diclofenac phenotype further. It would be interesting to research the mechanism that 
caused the diclofenac-induced tail damage displayed in the phenotype photographs 
(Figure 4-22).  
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4.8 Conclusion 
The scope for future work has been mentioned for individual experiments throughout the 
discussion. Overall our Xenopus embryo model appears to have the ability to react to 
paracetamol in a dose-dependent manner. The depletion of GSH with paracetamol 
treatment suggests the Xenopus embryo metabolic pathway is similar to that observed in 
humans and rodent paracetamol-induced liver injury models. Going forward it would be 
good to confirm the mechanism of toxicity using a CYP450 inhibitor that is valid for 
Xenopus. Furthermore, I would like to determine the CYP450 isoform that could be 
involved in the Xenopus metabolism of paracetamol. Although the dominant isoform in 
humans that generates the reactive metabolite NAPQI is the CYP2E1, in zebrafish the 
CYP3A65 isoform is predominantly responsible for NAPQI generation (Chng et al., 2012). 
In summary, these results represent the initial steps towards determining the advantages 
and limitations of our Xenopus embryo model as a predictive tool for drug-induced 
hepatotoxicity. It is promising that the embryos can react to paracetamol, a frequently 
used drug that is responsible for the largest proportion of drug-induced liver injury in 
humans.  
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5 Chapter 5: Assessing the use of Xenopus as a model 
for the prediction of Drug-induced Cardiotoxicity 
using doxorubicin and terfenadine as the model 
cardiotoxins 
5.1 Introduction 
5.1.1 Doxorubicin-induced cardiotoxicity 
Doxorubicin is an anthracycline antibiotic that targets haematogenous and solid 
malignancies (Gu et al., 2015). The exact anti-cancer therapeutic mechanisms of 
doxorubicin are not completely understood but theories include: (1) inhibition of 
topoisomerase II which results in DNA damage so the cell cannot replicate, (2) 
interference with the separation of DNA strands and helicase activity, and (3) DNA 
alkylation (Hortobagyi, 1997). There are 2 topoisomerase enzymes: α and β. The 
topoisomerase IIα enzyme is thought to be the main therapeutic target for doxorubicin as 
it is overexpressed in tumour cells (Zhang et al., 2012). Topoisomerase IIβ is expressed in 
quiescent cells (Capranico et al., 1992). Patients taking doxorubicin have a significantly 
high incidence of cardiovascular side effects including hypotension, tachycardia, 
arrhythmias and congestive heart failure (Singal and Iliskovic, 1998). In part, some of the 
doxorubicin-induced cardiotoxicity has been attributed to the inhibition of the 
topoisomerase IIβ in quiescent cardiomyocytes. Topoisomerase IIβ inhibition can cause a 
reduction of antioxidant enzyme gene transcription and a reduced activation of the p53 
pathway for apoptosis (Zhang et al., 2012). Doxorubicin-induced cardiotoxicity can occur 
after a single dose, or after repeated administration for weeks or months. The acute 
cardiotoxic effects manifest within minutes to a week from the initial doxorubicin 
administration. They are normally reversible and include arrhythmias and inflammation of 
the heart muscle and the membrane surrounding the heart (myocarditis and pericarditis 
respectively) (Bristow et al., 1978). The temporary arrhythmias that occur in approximately 
20-30 % of patients can be detected in the clinic by changes to the ECG. These 
electrophysiological abnormalities include T-wave flattening, a reduced QRS voltage and 
QT prolongation (Singal and Iliskovic, 1998). Chronic doxorubicin treatment is associated 
with congestive heart failure that correlates to a morality rate of up to 50 % (Chatterjee et 
al., 2010). This mortality percentage increases with doxorubicin doses that are higher than 
500 mg/m2. A cardiotoxic phenotype associated with doxorubicin can also persist and 
progress after discontinuation of the drug. Chronic dilated cardiomyopathy, that is an 
enlarged and weakened left ventricle, can develop in patients 10 years after doxorubicin 
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treatment was stopped (Steinherz et al., 1991). It is unlikely that doxorubicin is still present 
in a patient body decades after treatment was stopped. The exact mechanisms of 
severely delayed doxorubicin-induced toxicity are unknown. The progressive impairment 
of the ability of the sarcoplasmic reticulum to regulate cellular calcium homeostasis could 
be a contributing factor (Chugun et al., 2000). A reduction of Ca2+ ATPase mRNA 
expression causes a reduction of cardiac contractility (Arai et al., 2000).   
The intracellular characteristics of doxorubicin-induced cardiotoxicity include an increase 
of ROS production, a reduction of myocardial endogenous antioxidants, peroxynitrite 
formation, mitochondrial dysfunction and apoptosis (Vejpongsa and Yeh, 2014a). 
Doxorubicin-induced myocardial cell apoptosis can cause left ventricular thinning, an 
elevated afterload and subsequent increased stress on the heart (Wouters et al., 2005). It 
is thought that mitochondrial dysfunction is the major contributing factor towards the 
development of doxorubicin-induced cardiotoxicity. Doxorubicin is a favourable substrate 
for reduction, in particular, the NADH-dehydrogenase of mitochondrial complex I 
(Doroshow, 1983; Wallace, 2003). This reduction produces a highly reactive semiquinone 
radical that causes an increase of ROS generation which negatively impacts mitochondrial 
function: the mitochondrial transmembrane potential is disrupted, ATP production declines 
and the mitochondrial membrane permeability transition (MPT) pore forms allowing the 
release of pro-apoptotic proteins cytochrome c and AIF into the cytosol (Carvalho et al., 
2013). These proteins activate caspase-mediated apoptosis. Doxorubicin also forms 
adducts with the circular DNA in mitochondria and consequently damages the 
mitochondrial DNA (Ashley and Poulton, 2009). The strong association with oxidative 
stress and mitochondrial dysfunction can explain why doxorubicin toxicity affects the heart 
in particular. The heart has a large density of mitochondria, this organelle accounts for 
approximately 35 % of the cellular volume of cells in the heart tissue. Mitochondria are a 
source and target for ROS and in heart cells, they have an elevated rate of oxygen 
consumption. Relative to the liver, the heart also has less antioxidant activity including a 
low expression of catalase (Doroshow et al., 1980; Quiles et al., 2002). Furthermore, 
doxorubicin-induced mitochondrial DNA alterations are only found in heart not skeletal 
muscle cells, in mice and in humans (Lebrecht et al., 2005, 2003).  
Doxorubicin is a powerful iron chelator, the iron-doxorubicin complex can generate a large 
amount of ROS through iron cycling between Fe(II) and Fe(III) forms (Ichikawa et al., 
2014). Doxorubicin contributes to the accumulation of iron inside mitochondria and the 
iron-doxorubicin complex can catalyse hydrogen peroxide to a reactive hydroxyl radical 
(Myers, 1998). The altered distribution of iron could be a result of doxorubicin interacting 
with iron regulatory proteins 1 and 2, which are involved in the regulation of proteins 
transferrin receptor 1 and ferritin. Transferrin receptor 1 is involved in iron uptake and 
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ferritin contributes to the regulation of cellular iron storage (Xu et al., 2005). Overall, iron 
plays a role in doxorubicin cardiotoxicity and exerts a considerable contribution to the 
generation of ROS.  
Doxorubicin is a very effective anti-cancer drug, and it is an example of how in some 
circumstances, patients would prefer not to withdraw treatment that is causing 
inappropriate drug-induced toxicity. This can be because of the severity of their disease or 
the lack of alternative therapeutic treatment that is as effective. In this case, the 
risk/benefit of a drug for an individual patient must be weighed up and the drug implicated 
for toxicity is not always discontinued; if possible, a compound that can counter-act the 
toxic effects will be administered at the same time. Drugs with antioxidant properties can 
be used in conjunction with doxorubicin and have been proven to reduce doxorubicin-
associated cardiac mitochondrial damage. One such drug is dexrazoxane. Dexrazoxane 
is the only drug that is approved by the FDA to prevent cardiotoxicity associated with 
doxorubicin (Swain and Vici, 2004). Dexrazoxane is hydrolysed inside cardiomyocytes to 
its metabolite ADR-925 (Popelova et al., 2008). This metabolite is a good iron chelator 
and this characteristic has been proposed as the dexrazoxane cardioprotective 
mechanism for reducing doxorubicin cardiotoxicity (Hasinoff and Herman, 2007). An 
additional mechanism is that dexrazoxane binds to topoisomerase IIβ, protecting it from 
doxorubicin and consequently reducing topoisomerase IIβ-mediated doxorubicin 
cardiotoxicity (Lyu et al., 2007). Other compounds that are associated with 
cardioprotective mechanisms, including neuregulin-1β, a ErbB2 receptor agonist, and 
Cdk4/6 inhibitors (Cross et al., 2015). 
5.1.2 Animal models for doxorubicin-induced cardiotoxicity 
It is clear that the mechanism of doxorubicin-induced cardiotoxicity is multifactorial. 
Consequently, attempting to mimic the human pathophysiology in an animal model is 
difficult. Most of the animal models in the literature for doxorubicin-induced toxicity, or 
general anthracycline-induced cardiotoxicity, are altered to try to establish the mechanism 
of doxorubicin-induced cardiotoxicity and recapitulate the drug-induced phenotype 
manifested in humans. One example is the mouse model that has deleted the expression 
of topoisomerase IIβ in cardiomyocytes. This model appeared to be protected from 
anthracycline-induced cardiomyopathy (Vejpongsa and Yeh, 2014b). Furthermore, Li et al 
(2014) found that a nuclear factor erythroid-2 related factor 2 (Nrf2) knockout mouse  
(Nrf2-/-) had a more exaggerated doxorubicin-induced cardiotoxicity phenotype, including 
cardiomyocyte necrosis and cardiac dysfunction, compared ro the doxorubicin-treated 
wildtype mouse (Li et al., 2014). Nrf2 is a transcription factor that regulates the expression 
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of antioxidant proteins. Therefore, this model confirms the involvement of oxidative stress 
in the generation of cardiotoxicity induced by doxorubicin.  
As mentioned in chapter 4, the closest animal model to the Xenopus that is frequently 
used in drug-induced toxicity research is the zebrafish. Ultimately, we would ideally want 
the Xenopus model to illicit a similar response as humans to drugs known to be 
cardiotoxic in humans. However it is useful to compare the Xenopus response to 
cardiotoxic drugs, for example doxorubicin, to zebrafish cardiotoxicity models, to help 
determine the validity of the model. Chang et al (2014) exposed 4 hpf zebrafish embryos 
to 0-100 mg/mL (approximately 0-170 µM) doxorubicin and measured the effect the drug 
had on the heart rate, hatching rate, body length and survival. At 60 hpf, the zebrafish 
embryos treated with ≤10 mg/mL doxorubicin had a slightly increased heart rate however 
this declined significantly in embryos treated with ≥25 mg/mL doxorubicin (Chang et al., 
2014). This small study indicates non-mammalian animal models can present a 
cardiotoxic phenotype to doxorubicin. Furthermore Huang et al (2013) treated zebrafish 
embryos that were 6 hpf, until 96 hpf, with 0-100 µM doxorubicin. The doxorubicin-treated 
zebrafish developed cardiac-specific phenotypes that included cardiac oedema and an 
elongated heart (Huang et al., 2013).  
Overall it is important to remember that the majority of in vivo doxorubicin studies reflect 
acute doxorubicin treatment. In general, not enough studies have been done to look at 
delayed doxorubicin-induced cardiotoxicity (Carvalho et al., 2013). One example of the 
chronic doxorubicin cardiotoxicity model is a study which treated normotensive and 
spontaneously hypertensive rats with 0-1 mg/kg doxorubicin every week for 12 weeks 
(Herman et al., 1985). The spontaneously hypertensive rats had higher arterial pressure, 
higher mortality rate and were overall more sensitive to doxorubicin cardiotoxic effects 
than the normotensive rats. However the normotensive rats did develop heart lesions 
such as cytoplasmic vacuoles and loss of myofibrils, but these were just less severe than 
the normotensive rats and developed at a later stage in the doxorubicin treatment course. 
A variety of animal and human studies have been conducted to investigate the 
mechanism of action of the cardioprotective agent dexrazoxane in combination with 
doxorubicin treatment. Rats treated with doxorubicin and dexrazoxane, had less adverse 
cardiac effects compared to doxorubicin-treated rats that did not receive dexrazoxane 
(Zhang et al., 2015). Wiseman & Spencer (1998) summarise the key studies conducted in 
humans that demonstrates a reduction of cardiotoxicity in patients that have received 
dexrazoxane and doxorubicin combined, compared to doxorubicin alone (Wiseman and 
Spencer, 1998). As mentioned previously in this chapter, the FDA eventually supported 
these findings and implemented the use of dexrazoxane as a cardioprotective agent. 
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5.1.3 Terfenadine-induced cardiotoxicity 
Terfenadine is a second-generation, non-sedating, H1 antagonist antihistamine that was 
in the top 10 most prescribed drug in the US in 1991 (Simonsen, 1992). However in the 
1980s there was an increase in reports that associated terfenadine with QT prolongation, 
ventricular arrhythmia and Torsade de Pointes, although the incidence overall was still 
quite rare (Monahan et al., 1990; Zimmermann et al., 1992). Originally, it was proposed 
that terfenadine primarily causes cardiotoxicity through the inhibition of the KV1.5 channel. 
When the channel is open, the parent drug can enter the mouth and block it (Yang et al., 
1995). The KV1.5 channel contributes to the ultrarapid potassium ion efflux current (Kur) 
(Crumb  Jr. et al., 1995). However this channel is expressed more in the atrium than the 
ventricle, and it is ventricular arrhythmia that contributes to Torsade de Pointes more so 
than the atrium. The hERG channel is involved in the delayed rectifier current (IKr) in 
ventricular myocytes and it is more susceptible to terfenadine inhibition than the KV1.5 
channel. Roy and colleagues (1996) found that the hERG channel was 10-fold more 
sensitive to terfenadine block compared to KV1.5. Furthermore the parent drug is 
responsible for the cardiotoxic effects whereas the major metabolite, terfenadine 
carboxylate, does not as great an affinity for the hERG and KV1.5 channels (Woosley et 
al., 1993). Drug-drug interactions and environmental factors can inhibit the CYP450 
isoenzyme CYP3A4, which reduces the amount of terfenadine carboxylate metabolite 
generated and cause an accumulation of the parent drug. Terfenadine patients that are 
also taking the antibiotic erythromycin or the antifungal agent ketoconazole, are more 
likely to develop terfenadine-induced cardiotoxicity because both of these drugs inhibit 
CYP3A4 activity (Crumb  Jr. et al., 1995). Grapefruit is a well known CYP450 inhibitor that 
could also affect the toxicity of terfenadine. An accumulation to the extent of 0.2 µM 
terfenadine plasma concentration can result in cardiotoxicity (Zünkler et al., 2000). The 
therapeutic mechanism of terfenadine is attributed to the terfenadine carboxylate 
metabolite (Roy et al., 1996). This metabolite, known as fexofenadine, is used to treat 
allergic conditions and has markedly reduced incidence of cardiotoxicity compared to 
terfenadine. In addition, terfenadine inhibits L-type calcium current and induces 
spontaneous calcium release from the sarcoplasmic reticulum thus altering the 
intracellular calcium-handling in cardiomyocytes (Hove-Madsen et al., 2006). The increase 
of calcium ions in the cardiomyocytes induces apoptosis (Fearnley et al., 2011). 
5.1.4 Animal models for terfenadine-induced cardiotoxicity 
Terfenadine is frequently used as a model cardiotoxic drug in animal models, to compare 
other potentially cardiotoxic compounds to.  One example is the Batey and colleagues 
(2002) laboratory group. They used an open-chest anaesthetised rabbit to compare the 
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cardiotoxicity mechanisms of the anti-malarial drug halofantrine, clofilium, a K+ channel 
blocker, and terfenadine (Batey and Coker, 2002). Clofilium and halofantrine caused TdP 
whereas terfenadine did not in this animal model. ECG analysis was used with this animal 
model to detect proarrhythmic activity. Another example is for the evaluation of a zebrafish 
embryo cardiotoxicity model, which analysed terfenadine alongside 6 other human 
cardiotoxic drugs including aspirin, clomipramine hydrochloride, cyclophosphamide, 
nimodipine, quinidine and verapamil hydrochloride (Zhu et al., 2014). In their project, 
terfenadine induced bradycardia and reduced the conduction from the atrium to the 
ventricle (atrioventricular block) in zebrafish embryos treated for 4h. In another project, 
transgenic zebrafish embryos that have GFP-labelled cardiomyocytes, showed reduced 
cardiac contractility, reduced heart rate and cardiomyocyte apoptosis when treated with 5-
20 µM terfenadine for 24 h (Gu et al., 2017). The zebrafish treated with 20 µM terfenadine 
had an increased rate of arrhythmic beats. An arrhythmic beat was identified as an 
irregular atrium to ventricle contraction ratio. Survival of the zebrafish for Gu and 
colleagues (2017) decreased with embryos treated with more than 40 µM terfenadine for 
24 h. It would be interesting to see if our Xenopus model generates similar results to the 
zebrafish models mentioned here as well as the human terfenadine toxicity phenotype. 
Zebrafish are the closest animal model to Xenopus and any drug response similarities 
could help validate the results of the following experiments. 
5.2 Aim 
Examine the use of Xenopus laevis embryos as a model for drug-induced cardiotoxicity. 
5.3 Hypothesis 
The Xenopus laevis embryos can be used to detect some markers of drug-induced 
cardiotoxicity that are in use in other animal models and humans. 
5.4 Results 
5.4.1 Doxorubicin dose response in Xenopus laevis embryos 
In order to test doxorubicin-induced cardiotoxicity in Xenopus laevis embryos, I carried out 
a dose response experiment to determine the concentration range at which the embryos 
have drug-specific toxicity. Further to the initial doxorubicin screens in chapter 3. I 
performed dose response screens in the concentration range 0-100 µM doxorubicin, in 10 
µM increments (Figure 5-1). The embryos were incubated with doxorubicin from stage 38, 
harvested at stage 45 and photographed to investigate the presence of a visual 
phenotype (n=3). With increasing concentration, embryos have a red stain; this is 
particularly noticeable in 25 % of the embryos treated with 100 µM doxorubicin. I believe 
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this is because the doxorubicin solid compound is an orange-red powder and when 
dissolved in the Xenopus embryo media, it forms a orange-red solution. Therefore this is 
not a toxicity phenotype but it is a useful visual aid that confirms the Xenopus embryos 
are taking up the doxorubicin they are immersed within. By eye, the staining appears to 
be interior and the method of embryo processing to obtain the photograph of the embryos 
denotes the unlikelihood that the staining is just on the outside of the embryos. The most 
common phenotype observed with the doxorubicin-treated embryos is damage to the tail 
or a change in the tail shape. The incidence and variety of this tail phenotype increases 
with increasing doxorubicin concentration. From these photographs, I could not detect a 
significant heart-specific phenotype. The corresponding survival graph for these 
photographs shows that at 0-60 µM doxorubicin, the embryos survived, whereas from 70-
100 µM there was a concentration-dependent decline in survival from 96 % to 75 % 
(Figure 5-2). I decided to perform further dose response screens to investigate the 
survival at higher concentrations, from 0-150 µM doxorubicin (n=4) (Figure 5-3). I 
observed a repeat of the concentration-dependent decline in survival, but this from an 
early concentration of 50 µM until 100 µM (96 -0 % survival respectively). 
It was decided to continue with the 0-100 µM doxorubicin concentration range for the 
investigation of doxorubicin-induced cardiotoxicity for the remainder of the doxorubicin 
experiments in this chapter. The reduced survival rate for the 100-150 µM range suggests 
non-specific toxicity. 
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Figure 5-1: Doxorubicin dose response 0-100 µM 
Xenopus laevis embryos were treated with a doxorubicin concentration in the range 0-100 
µM (n=3). The embryos were treated with doxorubicin from stage 38 and harvested at 
stage 45. The surviving embryos at stage 45 were photographed. The different 
phenotypes found for each doxorubicin concentration and the percentage of embryos that 
had that phenotype are shown. The percentage is calculated from the total number of 
embryos treated. Where possible, the embryo was photographed to show the lateral view 
and the ventral view.  
 
Figure 5-2: The percentage of Xenopus embryo survival with 0-100 µM doxorubicin 
treatment. 
 
 
163 
The average (±SEM) amount of embryos that survived until the age of stage 45 to be 
harvested and photographed for Figure 5-1 (n=3). 
 
Figure 5-3: The percentage of Xenopus embryo survival with 0-150 µM doxorubicin 
treatment. 
The second set of doxorubicin dose response screens (n=4) to establish the average 
survival rate (±SEM) until the age of stage 45 for embryos treated from stage 38. 
5.4.2 Dexrazoxane dose response in Xenopus laevis embryos 
Dexrazoxane is a cardioprotective agent, administered to patients to minimise the 
cardiotoxic effects of their doxorubicin therapy. I hypothesised that the Xenopus embryos 
treated with the combination of dexrazoxane and doxorubicin will elicit a reduced amount 
of cardiotoxic effects compared to doxorubicin alone. I performed a dose response with 
the dexrazoxane alone, to determine if this compound alone produces any phenotypes 
(Figure 5-4). Stage 38 embryos were incubated with dexrazoxane (0-1 mM) and 
harvested at stage 45 (n=3). I did not detect any significant phenotype from the 
photographs. A minority of embryos displayed a damage tail phenotype, this did not 
appear to be concentration-dependent. The survival rate did not significantly reduce for 
the concentration range I tested (Figure 5-5). 
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Figure 5-4: Dexrazoxane dose response 0-1 mM. 
Xenopus laevis embryos were treated with a dexrazoxane concentration in the range 0-1 
mM (n=3). The embryos were treated with dexrazoxane from stage 38 and harvested at 
stage 45. The surviving embryos were photographed at stage 45. The different 
phenotypes found for each dexrazoxane concentration shown and the percentage of 
embryos that had that phenotype. The percentage is calculated from the total number of 
embryos treated. Where possible, the embryos are photographed to show the lateral view 
and the ventral view.  
 
 
Figure 5-5: The percentage of Xenopus embryo survival with 0-1 mM dexrazoxane 
treatment. 
The average (±SEM) percentage of embryos treated with dexrazoxane (0-1 mM) that 
survived until stage 45 to be photographed in the dose response assay in Figure 5-4 
(n=3).  
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5.4.3 Treatment with combined doxorubicin and dexrazoxane incubation 
Stage 38 embryos were treated with doxorubicin (0-100 µM and dexrazoxane (0-1 mM) at 
a concentration ratio of 1:10 (doxorubicin:dexrazoxane) (Figure 5-6). The embryos were 
harvested at stage 45, photographs were taken and we noted the survival rate. Damage 
to the tail was the most common alternative phenotype. The majority of the embryos 
appeared similar to wildtype, untreated embryos. The amount of embryos that survived 
declined with increasing concentration of the combined drugs from 100 to 33 % for the 
0.04 mM doxorubicin and 0.4 mM dexrazoxane treatment to the 0.1 mM doxorubicin and 
1 mM dexrazoxane treatment groups respectively (Figure 5-7).  
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Figure 5-6: Doxorubicin (0-100 µM) and Dexrazoxane (0-1 mM) treatment. 
Xenopus embryos were treated with a combination of doxorubicin and dexrazoxane in the 
ratio 1:10 from stage 38 until stage 45. The embryos that survived at stage 45 were 
photographed. The percentage is calculated from the total number of embryos treated. 
Where possible, the embryos were photographed to show the lateral view and the ventral 
view (n=3). 
 
 
 
 
 
 
171 
 
Figure 5-7: The percentage of Xenopus embryo survival with doxorubicin (0-100 
µM) and dexrazoxane (0-1 mM) treatment. 
The average (±SEM) percentage of embryos treated with doxorubicin (0-100 µM) and 
dexrazoxane (0-1 mM) in the ratio 1:10, that survived until stage 45 to be photographed in 
the dose response assay in Figure 5-6 (n=3).  
 
5.4.4 Identification of the anaesthetic concentration suitable for the experiments 
that will investigate Xenopus embryo heart rate  
To investigate drug-induced cardiotoxicity, I decided to examine the heart rate of the 
Xenopus embryos at stage 45 after drug treatment. At stage 45 the embryos are very 
active in their incubation media, consequently, to be able to measure the heart rate I had 
to add a compound to make them stationary. I used tricaine, a soluble anaesthetic 
commonly used to anaesthetise Xenopus adults and tadpoles (see chapter 2 for more 
detail). For the adult Xenopus, a concentration of 0.5 mg/mL tricaine is used for 1h to fully 
anaesthetise the frog. Consequently, I tested the Xenopus embryos with 0-0.5 mg/mL 
tricaine (n=3) (Figure 5-8). Stage 45 embryos were incubated with a concentration of 
tricaine for 1h and the heart rate was measured via the method described in chapter 2. 
For obvious reasons, the heart rate could not be measured for the 0 mg/mL tricaine group 
of embryos, however embryos from the same mother were incubated in untreated 
Xenopus media in parallel to the treated embryos for negative control. For all 3 biological 
replicates, the untreated embryos (0 mg/mL tricaine) appeared normal. The heart rate 
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increased from an average of 148 to 164 beats per minute (bpm) for 0.1-0.2 mg/mL 
tricaine respectively. The heart rate decreased for embryos treated with 0.3-0.5 mg/mL 
tricaine. At 0.1 mg/mL the embryos were not completely stationary (data not shown) and 
all the embryos treated with 0.5 mg/mL tricaine did not survive after the 1h incubation. I 
concluded that the best anaesthetic concentration for the following heart rate experiments 
was 0.2 mg/mL.  
 
 
Figure 5-8: Investigation of anaesthetic concentration and heart rate. 
The heart rate assay was used to measure the heart rate (±SEM) of stage 45 Xenopus 
embryos (n=3) that had been incubated with tricaine, an anaesthetic, for 1h before 
measurement. The embryos had not been treated with any other drugs. 
5.4.5 Video analysis 
An example of a heart rate assay video, video analysis and representative graphs for 
normal heart beat rhythm and arrhythmia is shown in the Appendix Figures 8-1 and 8-2. 
5.4.6 Investigating the effect of doxorubicin treatment on Xenopus embryo heart 
rate 
Embryos were treated with doxorubicin at stage 38 and their heart rate was measured at 
the age of stage 45 1 h after the addition of 0.2 mg/mL tricaine (n=3) (Figure 5-9). Of the 
embryos treated with 100 µM doxorubicin, 0 % survived. The heart rate increased with 
increasing concentration of doxorubicin treatment from 0-80 µM (110-141 bpm). However 
between 80-90 µM doxorubicin, the heart rate decreased from an average of 141 to 107 
bpm. The embryos treated with 30, 50-80 µM doxorubicin had a statistically significantly 
difference heart rate compared to the untreated (0 µM doxorubicin) embryos (P<0.05). 
The heart rates plotted on this graph include regular and irregular heartbeats. The amount 
of embryos that survived to have their heart rates measured is plotted against the amount 
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of arrhythmias identified in the embryos that survived. The embryo survival decreased 
with increasing doxorubicin treatment: 50-100 µM saw a decline from 95-0 %. There does 
not seem to be a definitive pattern between incidence of arrhythmias and the 
concentration of doxorubicin (Figure 5-10). A regular rhythm was identified from the 
graphs generated, as having opposite peaks and troughs for the atrium and ventricle 
lines, which represents the heart chamber filling and emptying with blood respectively. An 
irregular rhythm can have 2 atrial peaks to 1 ventricular peak, the ventricular peak height 
can vary or the heart chambers can contract and relax simultaneously. A series of short 
and tall peaks can indicate sporadic filling of the heart chamber to its maximum capacity 
(Appendix Figure 8-2). For example, a tall peak occurs with a darker colour and 
therefore more blood in the chamber whereas a short peak is associated with less blood 
and often this is accompanied with a less dynamic contraction that is apparent in the 
video. 
After this initial heart rate was measured, the same embryos were put into fresh media, 
that did not contain doxorubicin or tricaine, and incubated for 72 h (Figure 5-11, red). The 
heart rate was measured at 72 h and plotted against the primary heart rate measurement. 
The heart rates of the post-treatment embryos positively correlated with the doxorubicin 
concentration they received in their initial incubation. The gradient of the post-treatment 
heart rate looks similar to the gradient of the initial heart rate measurements. There is a 
shift of approximately +20 bpm for all the post-treatment measurements compared to the 
initial heart rate readings of the same doxorubicin concentration, including the untreated 0 
µM doxorubicin treatment group. This will be discussed in more detail in the discussion 
later in this chapter. 
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Figure 5-9: The effect of doxorubicin treatment on heart rate. 
Xenopus embryos were treated with doxorubicin from stage 38 until stage 45 (n=3). The 
heart rate assay was used to measure the heart rate of the treated embryos after 1 h 
incubation with 0.2 mg/mL tricaine. The average heart rate (±SEM) of treated embryos 
was compared to untreated embryos (0 µM doxorubicin) using a one-way ANOVA 
(P<0.05). 
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Figure 5-10: Heart rate assay embryo survival and incidence of arrhythmias with 
doxorubicin treatment. 
The average survival rate (±SEM) (blue) of doxorubicin-treated Xenopus embryos that 
were used in the heart rate assay (Figure 5-9, n=3) and the amount of arrhythmias (red) 
as a percentage of the embryos that survived (±SEM).  
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Figure 5-11: Characterisation of heart rate for doxorubicin-treated embryos after 3 
days without treatment. 
The Xenopus embryos that were treated with doxorubicin from stage 38 until stage 45 
(n=3, blue) were left in fresh Xenopus media for 3 days. After 3 days the heart rate 
(±SEM) was measured after 1 h treatment with 0.2 mg/mL tricaine (red). The heart rates 
at stage 45 and 3 days post-treatment for a given doxorubicin concentration were 
compared using a paired T test (P<0.05). 
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5.4.7 Terfenadine dose response in Xenopus laevis embryos 
Xenopus embryos were treated with a concentration of terfenadine within the dose range 
0-100 µM at stage 38 and harvested at stage 45 (n=3) (Figure 5-12). I took photographs 
and looked for a distinctive phenotype in the stage 45 embryos. A change in tail shape or 
tail damage was a frequent occurrence throughout the concentration range. At the high 
concentrations, from 20-80 µM, oedema around the heart and gastrointestinal region was 
a common phenotype. The embryos treated with 90 and 100 µM terfenadine did not 
survive to be photographed at the age of stage 45. The survival percentage began to 
decrease at 30 µM in a concentration-dependent manner. 90 % of the total embryos 
treated survived at 30 µM terfenadine, this decreased to 0 % at 100 µM terfenadine 
(Figure 5-13). I decided that the following experiments that explore terfenadine-induced 
cardiotoxicity would be performed in the range of 0-50 µM terfenadine. 
5.4.8 Investigating the effect of terfenadine treatment on Xenopus embryo heart 
rate 
I treated stage 38 embryos with 0-50 µM terfenadine and measured their heart rates at 
stage 45 following 1h incubation with 0.2 mg/mL tricaine anaesthetic (n=3) (Figure 5-14). 
This is the same concentration of anaesthetic used for the embryos treated with 
doxorubicin earlier in this results chapter. Overall, the heart rates decreased in a 
concentration-dependent correlation from an average of 125 bpm to 82 bpm for untreated 
embryos (0 µM terfenadine) to embryos incubated with 30 µM terfenadine respectively. 
The average heart rates were statistically and significantly different compared to the 
untreated embryos (0 µM terfenadine) for the 10-30 µM terfenadine embryos (P<0.05). 
The embryos treated with 40 and 50 µM terfenadine did not survive to the age of stage 45 
therefore we did not obtain heart rate measurements for these treatment groups. 
For the terfenadine-treated embryos that were to be processed through the heart rate 
measurement method, the survival percentage decreased at 20 µM to 50 µM. On 
average, 76 % of embryos treated with 20 µM terfenadine survived until stage 45 and had 
their heart rates measured. This decreased to 0 % survival in embryos treated with 50 µM 
terfenadine. The frequency of arrhythmias occurring in embryos that survived does not 
appear to correlate with the concentration of terfenadine they were incubated with (Figure 
14). 
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Figure 5-12: Terfenadine dose response 0-100 µM. 
Xenopus laevis embryos were treated with a terfenadine concentration in the range 0-100 
µM (n=3). The embryos were treated with terfenadine from stage 38 and harvested at 
stage 45. The surviving embryos at stage 45 were photographed. The different 
phenotypes found for each terfenadine concentration and the percentage of embryos that 
had that phenotype were photographed. The percentage is calculated from the total 
number of embryos treated. Where possible, the embryo was photographed to show the 
lateral view and the ventral view.  
 
 
Figure 5-13: The percentage of Xenopus embryo survival with 0-100 µM terfenadine 
treatment. 
The average (±SEM) amount of embryos that survived until the age of stage 45 to be 
harvested and photographed for Figure 5-12 (n=3). 
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Figure 5-14: The effect of terfenadine treatment on heart rate. 
Xenopus embryos were treated with terfenadine from stage 38 until stage 45 (n=3). The 
heart rate assay was used to measure the heart rate of the treated embryos after 1 h 
incubation with 0.2 mg/mL tricaine. The average heart rate (±SEM) of treated embryos 
was compared to untreated embryos (0 µM terfenadine) using a one-way ANOVA 
(P<0.05). 
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Figure 5-15: Heart rate assay embryo survival and incidence of arrhythmias with 
terfenadine treatment. 
The average survival rate (±SEM) (blue) of terfenadine-treated Xenopus embryos that 
were used in the heart rate assay (Figure 5-14, n=3) and the amount of arrhythmias (red) 
as a percentage of the embryos that survived (±SEM).  
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5.4.9 Heart expression pattern in Xenopus laevis 
5.4.9.1 Wholemount in situ hybridisation and transverse sections 
The heart in the Xenopus embryo is easier to locate compared to the liver (Figure 5-16). 
The embryo retains its transparency for the duration of the stages I was observing for the 
drug-induced cardiotoxicity experiments. However I decided to use a probe that could 
stain the Xenopus embryo heart in order to investigate the expression pattern of miR-208. 
MiR-208 is a promising cardiotoxicity marker that is expressed in humans, zebrafish and 
rodents. I wanted to see if this expression pattern is conserved in the Xenopus embryos. 
First, I carried out a WISH assay on untreated stage 38 and stage 45 embryos using 
cardiac troponin 1c, a known Xenopus gene that is specific to the heart (n=5). These 
embryos were then sectioned and I could see the cardiac troponin 1c probe has stained 
the heart tissue (Figure 5-17). 
Next, I conducted WISH assays using a probe for miR-208 (Figure 5-18). From the 
wholemount photographs I identified the probe stained the heart tissue in the stage 38 
and stage 45 untreated embryos (n=10). Furthermore, the heart tissue is clearly stained in 
the sections taken from these same embryos in stage 38 and stage 45 embryos (Figure 
5-19). 
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Figure 5-16: Illustration of heart location in Xenopus laevis embryo. 
The Xenopus embryos at the age of stage 38 (A) and stage 45 (B and C) have heart 
tissue (red). This schematic displays the location of the heart as seen from a lateral view 
(A and B) and ventral view (C). Modified from Nieuwkoop & Faber (1994). 
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Figure 5-17: Cardiac troponin 1c sections. 
Representative sections from stage 38 (A) and stage 45 (B) untreated embryos that had 
been processed through the WISH assay using a probe for cardiac troponin 1c (n=5). The 
heart (H) was stained purple in the WISH assay. 
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Figure 5-18: Wholemount in situ hybridisation (WISH) for miR-208. 
A WISH assay with a probe for Xenopus miR-208 on stage 38 (A) and stage 45 (B and C). 
The stage 38 embryos were photographed to see the lateral view and the lateral (B) and 
ventral (C) view has been photographed for the stage 45. These embryos represent the 
stain (arrows) seen consistently for the embryos tested (n=10). 
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Figure 5-19: miR-208 sections for stage 38 Xenopus embryos. 
Representative sections from stage 38 (A) and stage 45 (B) untreated embryos that had 
been processed through the WISH assay using a probe for Xenopus miR-208 (n=10). The 
heart (H) was stained purple in the WISH assay. 
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5.5 Discussion 
In this chapter, we set out to explore the suitability of the Xenopus embryos for the 
prediction of drug-induced cardiotoxicity. To do this, I decided to use 2 drugs that are 
associated with cardiotoxicity in humans: doxorubicin and terfenadine. The mechanism of 
toxicity for doxorubicin is less certain and more multifactorial than terfenadine. Indeed, I 
deliberately chose to use these different drugs to see if our non-mammalian animal model 
is favourable to one or the other, or potentially neither. In order to conclude if the Xenopus 
embryos are a good model for the prediction of drug-induced cardiotoxicity in humans, a 
more comprehensive list of cardiotoxic and non-cardiotoxic drugs should be evaluated. 
However, this chapter can give an indication of the usefulness of the Xenopus embryo 
model for cardiotoxicity prediction. 
5.5.1 Doxorubicin dose range and phenotype 
The 0-100 µM doxorubicin concentration range I used to assess drug-induced 
cardiotoxicity in this chapter is similar to the dose used in zebrafish embryos. Huang  and 
colleagues (2013) used doxorubicin to induce a heart failure model in zebrafish. Mild 
cardiac defects were detected in 20 % of the zebrafish given 50 µM doxorubicin and 60 % 
of the zebrafish given 90 µM doxorubicin developed heart failure. The zebrafish embryos 
Huang and colleagues used were of a similar age to the Xenopus embryos we used. All 
the zebrafish embryos given 100 µM doxorubicin, did not survive to the end of the 72h 
treatment period (Huang et al., 2013).  
In the initial 3 screens of doxorubicin treatment I performed for this chapter, 75 % of the 
embryos survived with 100 µM doxorubicin for the 72 h period of treatment from stage 38 
until stage 45. However, when I extended the dose range from a maximum of 100 µM 
doxorubicin to 150 µM in the second set of screens, the survival at 100 µM was 0 %. The 
reason for this difference is not clear. The first set of screens comprised of 3 biological 
replicates and the second set took an average of 4 biological replicates. The survival rate 
for the embryos in the experiments that followed these initial screenings in this chapter all 
showed 0 % survival with 100 µM treatment. It could be that the embryos treated for the 
first set of photographs were anomalies. I decided to use 0-100 µM doxorubicin because I 
believed this range incorporated the dose for which embryos that are likely to have a drug-
specific cardiotoxic effect. A concentration of drug for which none of the embryos survive 
has an ambiguous causality. But a drug associated with toxicity is likely to reduce the 
survival rate because, for example, some embryos will not be able to tolerate the adverse 
effects and some embryos will. I believe the 0-100 µM doxorubicin concentration range 
takes into account these criteria and includes the dose that could cause doxorubicin-
specific cardiotoxicity in the Xenopus embryos. 
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The embryos that survived the 72h treatment time were photographed. From the 
photographs we could not detect a phenotype that I could instinctively associate with 
heart pathophysiology in the Xenopus embryos. As mentioned in chapter 4, much like the 
liver, the heart is a very small organ in stage 38 – stage 45 Xenopus laevis embryos; it is 
difficult to detect microscopic changes to the heart structure. In future work it would be 
beneficial to use a marker for structural damage such as TUNEL, which can label necrotic 
cells with a fluorescent tag. Unintentionally, I was able to observe Xenopus embryo 
doxorubicin ingestion because the dissolved drug has a strong red pigment that is visible 
inside the transparent embryo body. For future work with the Xenopus embryos and drug 
toxicity, it could be useful to use drugs that have a natural pigment or label the drugs with 
a pigment that would not interfere with the drug toxicity mechanism. This could be an easy 
method to detect and maybe quantify drug uptake in the Xenopus embryos that doesn’t 
require complex and expensive equipment, just a microscope colour camera.  
5.5.2 Terfenadine dose range and phenotype 
I used a dose range 0-50 µM to treat our stage 38 Xenopus embryos (72 hpf at 23°C) until 
stage 45 (72 h incubation). This is similar to the terfenadine concentration the 48 hpf 
zebrafish embryos were exposed to for 24 h in the Zhu et al (2014). And Gu et al (2017) 
also used similar terfenadine concentrations for 72 hpf zebrafish embryos, which were 
exposed to terfenadine for 24 h. The 24 h terfenadine exposure in both of these zebrafish 
models is considered acute exposure. In comparison, our Xenopus embryos were 
incubated in terfenadine for 72 h. However I observed similar phenotype endpoints such 
as some cardiac oedema. Overall, we chose to continue with the 0-50 µM terfenadine 
concentration range for the heart rate experiment because it incorporates treatment that 
produces phenotypes that are not dissimilar to untreated embryos, and a gradient of 
phenotypes across the middle concentrations, ending with a high mortality rate at the high 
concentrations. I concluded the 0-50 µM terfenadine concentration range should include 
terfenadine-specific effects. In future experiments I would like to identify any 
cardiomyocyte apoptosis in the wholemount embryos using a fluorescent label such as 
TUNEL or acridine orange staining. 
5.5.3 The heart rate assay 
An example of a heart rate assay video, video analysis and representative graphs for 
normal heart beat rhythm and arrhythmia is shown in the Appendix Figures 8-1 and 8-2. 
A change in heart rate can indicate a problem with the heart cellular components. It is also 
a very good method of identifying and quantifying heart function. A drug that alters the 
structure of an organ does not always correlate with a functional change. Sometimes the 
body has mechanisms that can compensate for the structural damage and keep the 
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function of the organ in tact. Often, drug-induced toxicity and adverse drug reactions are 
not detected in patients until they affect the organ function. Furthermore, as long as the 
drug does not affect the organ function, it can be argued that one can continue to 
administer the drug to the patient. Overall it is when the organ function is impaired, not 
necessarily the structural integrity, that the patient should consider withdrawal and seek 
alternatives. Consequently, I think heart rate is a good measure of cardiotoxicity. 
A major advantage of Xenopus embryos is their transparency. This characteristic is useful 
because it means that we do not have to attach the embryos to an electrocardiograph to 
get the number of heart beats per minute. My heart rate protocol is adapted from Bartlett 
and colleagues (2004), I used the equipment available in our laboratory to update their 
protocol. Bartlett and colleagues compared cardiac recordings measured using fine glass 
microelectrodes to non-invasive digital video image analysis. They found that the non-
invasive method was sufficient to obtain accurate cardiac cycle length readings (Bartlett et 
al., 2004). The full details of the heart rate protocol are described in chapter 2. Briefly, the 
stage 45 embryos were arranged ventral side up, I made sure the heart was in view down 
the microscope which translated to on the computer screen, and I obtained a 30 s black 
and white video of the heart beating using a camera that captured 50 frames per second 
(fps). I used my knowledge of the Xenopus laevis heat anatomy to identify an atrium and 
the ventricle to create the regions of interest (ROIs). The change in the shade of grey 
within the region corresponded to the blood flow; a darker shade indicates the heart 
chamber filling with blood, and a lighter shade is the heart chamber emptying. The heart 
rate (bpm) was calculated by counting the number of peaks in the graph created from the 
ROIs manually, I could not find a computational algorithm that could calculate this 
accurately. Consequently, this experiment is quite labour intensive and more work would 
be needed in order to make it an automated system that would be beneficial for drug 
safety studies in industry. It is important to note that through this method we can create a 
graph that illustrates the heart beat frequency, it does not show the changes in electrical 
activity, and consequently it is not an ECG. We cannot, for example, see the separate 
waves that are associated with the different stages of a heartbeat including the P and T 
waves and the QRS complex.  
The heart rates recorded and plotted on the graphs included those that appeared to have 
an arrhythmic beat. A heart beat trace that depicted irregular peaks and troughs of 
greyscale intensity was identified as an arrhythmia. I verified this by going back to look at 
the video and deduce if the beat looks arrhythmic. It is possible that a heart with an 
arrhythmic beat will beat the same amount of times as a heart that has a regular rhythm 
and consequently produce a heart rate that is the same. However analysing the heart rate 
can still indicate cardiotoxicity. An increased heart rate can be caused from an increase of 
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stress on the heart that is a result of cardiomyocyte apoptosis and the loss of myofibrils. 
Drug-induced cardiomyocyte apoptosis can therefore be detected through changes in the 
heart rate. In research, commonly the left ventricular ejection fraction (LVEF) is used to 
identify heart stress or heart dysfunction. LVEF or ejection fraction is the volume or blood 
ejected from the heart with each heart beat. A shortened left ventricular ejection fraction 
can be an indication of a heart that is struggling to pump and move blood effectively 
because it has less of it’s functional subunits i.e. cardiomyocytes, due to cardiomyocyte 
apoptosis. I hypothesise, that with more time, our heart protocol can be adapted to 
measure the change in LVEF.  
One problem with my heart rate assay was that I needed to be able to immobilise the 
embryos to get an accurate heart rate video, to do this I used anaesthetic. Consequently I 
was not able to measure the heart rate in completely untreated stage 45 embryos. The 
effect of the drug on the heart rate measurements can be determined by comparing the 
change relative to the embryos that have not received drug treatment but have still been 
anaesthetised; therefore I may not have measured the “true” heart rate of the stage 45 
embryos. Ideally in the future, I would like to be able to conduct this assay without the 
anaesthetic to reduce the intervention with the embryos that could affect the drug-induced 
cardiotoxicity results. Suggestions for this include minimising the space in which the 
embryo can swim and Bartlett and colleagues (2004) used superglue. However these 
methods could also cause the embryos stress and affect the heart rate results. More work 
needs to be done to improve this part of the method. When I was investigating which 
concentration of anaesthetic to use for my heart rate assay, I was looking for the 
concentration at which the embryo is stationary for the videos but it was not so high so as 
to slow down the heart rate. In our laboratory, it is known that 0.5 mg/mL tricaine slows 
and sometimes stops the heart beating altogether in adult male Xenopus laevis. So I 
started with 0.5 mg/mL as the highest concentration to test on the embryos. I concluded 
0.2 mg/mL was the tricaine concentration best to use for the heart experiments. When I 
created the ROIs to determine the change of grey intensity, the ROI area is fixed, it does 
not move with the embryo. Therefore the 0.1 mg/mL tricaine concentration was not 
sufficient because although the Xenopus embryos stopped swimming at this 
concentration, they still twitched, and the heart chambers would move in and out of the 
ROIs set on the screen. When the embryos were incubated in 0.2 mg/mL tricaine for 1 h I 
did not want to give them the chance to recover from the doxorubicin treatment before we 
filmed them. Therefore I decided to incubate them in a combination of 0.2 mg/mL tricaine 
and fresh doxorubicin of the same concentration they had been incubated in since stage 
38.  
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5.5.3.1 Investigating the effect of drug treatment on the Xenopus embryo heart rate: 
Doxorubicin 
The concentration-dependent increase of heart rate for embryos treated with doxorubicin 
indicates that the drug has had an effect. The same result was achieved with zebrafish 
embryos treated with doxorubicin (Chang et al., 2014). Although the change in heart rate 
with doxorubicin treatment implies there is a cardiotoxic effect, the incidence of 
arrhythmias can provide a better indication of drug-induced cardiotoxicity. The occurrence 
of arrhythmia was concentration-dependent for doxorubicin-treated Xenopus embryos, but 
as the concentration of doxorubicin increased the survival of the embryos decreased. It 
could be possible that the embryos that didn’t survive to stage 45 have had an arrhythmic 
heart beat and therefore the arrhythmia incidence could be higher. A useful experiment to 
carry out in the future would include the monitoring and characterisation of the heartbeat 
at more than 1 time point to include the embryos that don’t survive to the age of stage 45. 
The increase in heart rate for all of the doxorubicin concentrations and untreated embryos 
(0 µM doxorubicin) at 3 days post-treatment was also observed by Chang and colleagues 
in zebrafish embryos. This heart rate increase is likely to be as a result of the ageing of 
the embryos over the 3 days. It is a time-dependent increase irrespective of the 
doxorubicin concentration. The heart has developed further and become stronger from 
stage 38 to stage 45 in the Xenopus embryos. In future experiments this should be taken 
into account when analysing the results. 
5.5.3.2 Investigating the effect of drug treatment on the Xenopus embryo heart rate: 
Terfenadine 
Terfenadine is a known hERG blocker that is associated with QT-prolongation, 
arrhythmias and TdP in humans. My results suggest that our Xenopus model correlates 
with the human terfenadine-induced cardiotoxicity response. The incidence of arrhythmia 
is not dose-dependent in my results, but this could be explained by the decline in survival 
at higher concentrations, therefore I could be missing arrhythmic heart rates in embryos 
that did not survive until stage 45. The concentration-dependent reduction in heart rate 
with our Xenopus model was also observed in zebrafish embryos exposed to acute 
terfenadine cardiotoxic concentrations (Gu et al., 2017). I used DMSO as a solvent for 
terfenadine, the final incubation concentration contained 0.5 % DMSO. DMSO is a known 
human CYP450 inhibitor (Chauret et al., 1998). As I have mentioned previously in this 
chapter, the presence of a CYP450 inhibitor can reduce the amount of terfenadine that is 
metabolised to terfenadine carboxylate, a known non-cardiotoxic molecule, and lead to 
terfenadine accumulation. The accumulation of the parent drug terfenadine increases the 
risk of drug-induced cardiotoxicity. The terfenadine was not soluble in the Xenopus media 
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alone, but in future experiments I would like to use a different solvent to DMSO to remove 
possible pro-cardiotoxic effects.  
5.5.4 Doxorubicin and dexrazoxane combined treatment 
In humans taking doxorubicin, dexrazoxane is a cardioprotective agent often prescribed to 
help minimise the doxorubicin cardiotoxic effects. Our aim was to explore this using the 
heart rate assay. In the literature, the ratio of doxorubicin to dexrazoxane used in dug 
safety models varies. Zhang and colleagues (2015) used a doxorubicin to dexrazoxane 
ratio of 1:50 to investigate the combined effects of doxorubicin, dexrazoxane and 
trastuzumab on the cardiotoxicity in rats. They found that the rats that had dexrazoxane in 
their treatment had a bigger LVEF than the rats that did not (Zhang et al., 2015). Lyu and 
colleagues (2007) used a ratio range of 1:20 to 1:2000 doxorubicin to dexrazoxane to 
treat H9C2 cardiomyocytes. A retrospective study looked at cardiotoxicity in children and 
teenagers treated with doxorubicin alone or in combination with dexrazoxane in a ratio of 
1:10 (Paiva et al., 2005). In another retrospective study, children received doxorubicin 
alone, or in combination with dexrazoxane in a ratio of 1:10 (Lipshultz et al., 2012). In 
conclusion, I decided to use a ratio of doxorubicin to dexrazoxane 1:10 to treat the 
Xenopus embryos. The doxorubicin concentration range was 0-100 µM (10 µM integrals), 
therefore the dexrazoxane concentration range was 0-1 mM (100 µM integrals. Before I 
performed the dose response with the combination of doxorubicin and dexrazoxane 
treatment, I examined the phenotype and survival rate of the embryos with the 0-1 mM 
dexrazoxane treatment alone. Unlike the majority of the dose response assays performed 
in this project, I did not want a change in survival rate with dexrazoxane treatment. There 
was no change in survival for embryos treated with 0-1 mM dexrazoxane; therefore I 
concluded that changes in the combined doxorubicin and dexrazoxane treatment are 
likely to be due to the doxorubicin compound. I hypothesised the survival rate for the 
combined doxorubicin and dexrazoxane treatment would be higher than the survival rate 
for embryos treated with doxorubicin alone. However in the combined treatment the 
survival rate was similar to the doxorubicin alone treatment. In future experiments I would 
like to explore the reason for this result. As mentioned above, dexrazoxane binds to 
topoisomerase IIβ in humans, this is one of the cardioprotective mechanisms proposed 
that reduces doxorubicin cardiotoxicity. The Xenopus laevis topoisomerase IIβ protein has 
84 % homology to the human protein. Therefore it could be that the dexrazoxane cannot 
carry out the cardioprotective mechanism in the Xenopus embryos. 
5.5.5 MiR-208 expression in Xenopus embryos 
The Xenopus laevis miR-208 mature sequence has 95 % homology to the mature human 
miR-208a-3p sequence; 1 out of the 22 nucleotides differs. My results clearly show that 
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the Xenopus miR-208 is specifically expressed in the heart (Figure 5-18), this is similar to 
humans and other animal models such as rats. I did perform qRT-PCR to identify the 
expression of miR-208 in the Xenopus heart compared to the tail (tissue that does not 
express miR-208) in doxorubicin-treated embryos (data not shown). However 
unfortunately I did not have enough time to optimise the primers. In future work I would 
like to investigate the change of miR-208 expression in Xenopus plasma for embryos 
treated with known cardiotoxic drugs. This experiment would be similar to the miR-122 
qRT-PCR paracetamol experiment performed in chapter 4 and it would explore if the role 
of miR-208 as a drug-induced cardiotoxicity biomarker is conserved in Xenopus embryos. 
5.6 Conclusion  
In this chapter I have used 2 drugs that in rare cases, are known to cause cardiotoxicity in 
humans through different mechanisms. Unlike chapter 4, which focused on structural and 
metabolic changes to the target organ for toxicity, I was able to assess the effect of the 
drugs associated with toxicity on organ function in this chapter. There is room for 
improvement in heart rate assay, limitations and future experimental ideas have been 
mentioned in the text above. In addition, I would like to test more known cardiotoxic 
compounds and drugs that are not associated with heart-specific ADRs to validate the 
heart rate assay protocol. In chapter 3 I identified the expression of the Xenopus 
equivalent hERG gene in stage 38 and stage 45 embryos. However, in the future I would 
like to determine the activity of the Xenopus hERG channel when the embryos are treated 
with cardiotoxic drugs and if the drugs associated with significant hERG inhibition in 
humans, perform the same mechanism of action with the Xenopus hERG channel. With 
regards to the wholemount phenotype, I would like to add a more comprehensive 
specification of endpoints to look for that is decided on prior to the experiment, for 
example, haemorrhage and thrombosis. The transparency of the Xenopus implies it 
should be simple to spot the pooling of blood outside the heart and blood clots, however I 
think that this could be undetectable in the photographs I have taken due to the fixation 
process we perform prior to photographing. Indeed the red blood colour is not visible in 
the Xenopus embryos hearts in my photographs. 
Overall the arrhythmias and statistically significant changes in heart rate in Xenopus 
embryos treated with doxorubicin and terfenadine suggests that the Xenopus could be 
useful for identifying drug-induced cardiotoxicity that is applicable to humans. 
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6 Chapter 6: General discussion 
6.1 Project aims 
During this project our project aims were to: 
• Characterise the functional capacity of Xenopus laevis embryos functional capacity 
in relation to drug metabolism and drug toxicity 
• Optimise and adapt assays used in other drug toxicity models to the Xenopus 
system 
• Investigate organ-specific toxicity in Xenopus embryos with drugs that are 
associated with hepatotoxic, cardiotoxic and nephrotoxic reactions in humans 
6.2 Introduction 
Current drug safety assessment animal models do not reliably predict drug-induced 
toxicity events in man. In a large retrospective study of 150 compounds, 221 human 
toxicity events were generated, 63 % were detected in non-rodent models (mostly dogs) 
and there was a 43 % concordance with rodent models (mainly rats) (Olson et al., 2000). 
Improving the current models or finding better alternatives can help to reduce drug attrition 
in the later phases of drug development and therefore decrease the amount of time and 
money wasted in pharmaceutical companies for drugs that are not going to be approved. 
A more efficient and successful assessment of drug toxicity potential in animal models 
could improve drug development productivity, thus having a positive impact on hospitals 
and patients. If the drug candidates associated with toxicity were identified and terminated 
early in development, more effort can be put towards the safer drugs and a 
pharmaceutical company could potentially deliver more drugs to the market each year. 
This could benefit a larger number of patients and consequently hospitals.  
The use of traditional animal models, which in the past were sometimes used by default 
for safety predictions, is on the decline. There is increasing pressure to produce drug 
safety data that is as relevant to humans as possible. Researchers need to think about 
what the best animal model is for their experiments and not just use the one they have 
always used. In drug development, the best animal model for each safety assessment is 
chosen carefully. In particular, in the UK the NC3Rs, which was launched in 2004, 
encourages the development of research methods that can replace, reduce and refine the 
use of animals in scientific research (NC3Rs, 2017). The replacement principle refers to 
using a technology or alternative tool that is just as good or better than the animal model 
to be able to replace the animal entirely. Good experimental design and analysis can 
reduce the number of animals used, whilst still generating accurate and reproducible data 
that has good statistical power. Finally, animal welfare can affect the validity of the results 
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produced and so by refining the experiment to minimise animal suffering, it is not only 
considered more ethical, but the results can be interpreted more accurately (Prescott and 
Lidster, 2017). This project was funded by the NC3Rs. We hypothesised that a non-
mammalian Xenopus laevis embryo model for drug-induced toxicity prediction could 
contribute to the reduction principle. A successful Xenopus laevis model could aid lead 
drug candidate prioritisation and reduce the number of toxic compounds getting through to 
the mammalian animal models as well as reduce the number of mammalian animal 
models to be used. 
The Xenopus laevis embryo model has several characteristics that are in line with an ideal 
animal model for the prediction of drug toxicity. It can also help bridge the gap between 
the in vitro and the first mammalian in vivo studies conducted in drug development.  
A large number of Xenopus embryos can be produced from an adult female Xenopus, 
approximately 1000 a day. The embryos develop quickly ex utero after in vitro fertilisation 
(IVF) and the cost for keeping adult females is relatively low compared to mammalian 
models. Furthermore, the embryos are small and up to 5 can comfortably fit into 1 well of 
a 96-well plate. This makes them amenable for medium to high throughput compound 
screening and advantageous for early preclinical studies, as they require only a small 
amount of the test compound. Xenopus laevis embryos are transparent, a useful 
characteristic for imaging techniques and phenotype analysis. Unlike other mammalian 
models, the Xenopus model does not necessarily require time-consuming dissection to 
visualise the effect of the test compound and we can obtain real-time information. 
However it is likely the Xenopus laevis embryo model does have some limitations that are 
possibly similar to other non-mammalian models such as zebrafish. For this project we 
decided to characterise the Xenopus laevis embryos capability to act as a model for the 
prediction of drug toxicity, exploring the model’s advantages and disadvantages using 
drugs associated with toxicity in humans. The results are summarised in Figure 6-1. 
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Figure 6-1: Summary of project results. 
A schematic to summarise the main results generated in this project including the 
expression of the Xenopus laevis gene equivalent to the hERG (human Ether-à-go-go-
Related Gene) also known as KCNH2. Stage 38 embryos incubated with a drug for 72 h, 
until the age of stage 45, measures drug-induced toxicity as opposed to teratogenicity, as 
organogenesis is near completion. CYP450, cytochrome P450; GSH, glutathione; GST, 
glutathione S-transferase; miR-122, microRNA-122; NAC, N-acetylcysteine; SULT, 
sulphotransferase; UGT, Uridine-5'-triphosphate-glucuronosyl transferase. 
 
 
 
200 
6.3 Characterisation of the Xenopus laevis embryo as a model for 
drug-induced toxicity 
In chapter 3 we conducted preliminary dose response assays with 2 different Xenopus 
embryo age groups: stage 15 to stage 38 and stage 38 to stage 45. Overall, we proved 
our chapter 3 hypothesis is correct, that is that the stage 38 to stage 45 embryos were 
suitable for drug-induced toxicity screening. In the dose response assays for the embryos 
incubated with the test drug at stage 38 and harvested at stage 45, the number of 
different abnormal phenotypes was less compared to the stage 15 - stage 38 screens. 
This indicates the stage 38 - stage 45 embryos have more functional organ systems 
compared to younger embryos. There is only 1 dominant abnormal phenotype generated 
from the stage 38 - stage 45 embryo screen, that is gastrointestinal oedema, which 
suggests the reaction drug-specific. It would be ideal if we could correlate specific organ 
toxicity to a visual phenotype. For example, oedema around the cardiac tissue would 
indicate cardiotoxicity. Unfortunately, there was not a clear correlation between this 
abnormal phenotype and the embryo treatment of drugs associated with cardiotoxicity 
such as doxorubicin. 
These screens also demonstrate that the drug is at least getting into the embryo and 
causing an effect. The Xenopus laevis embryos do not have an open mouth until stage 
40, however the gills are open and the skin is permeable to small molecules such as 
phenylthiourea (PTU) therefore, drugs present in the media the Xenopus embryos swim 
in, should still be able to enter the embryo system (Brandli, 2004; Chen et al., 2017). It is 
not known if the physicochemical properties of each individual drug will affect the 
efficiency of drug diffusion through the Xenopus embryo skin. For example, a more 
lipophilic drug could diffuse at a different rate to a hydrophilic drug. One of the 
disadvantages of using non-mammalian models for drug or chemical screens, is that it is 
difficult to determine what percentage of the dose they are exposed to translates to an 
internal concentration (van Vliet, 2011). We explored this with Xenopus embryos treated 
with paracetamol and using mass spectrometry in chapter 4. These mass spectrometry 
results revealed the presence of paracetamol metabolites APAP-cysteine and APAP-
glutathione inside the embryos, although the presence of the parent drug paracetamol 
was minimal. We hypothesise this is because paracetamol is quickly metabolised inside 
the embryos, or it could be that the parent drug is rapidly excreted. The internal 
concentration of the test drug inside the embryos should be relevant to the human Cmax 
(peak serum drug concentration after a dose) value in order for the model to be applicable 
for the prediction of drug-induce toxicity in humans. Consequently, we need to be able to 
measure the amount of drug inside the embryos. We believe mass spectrometry is the 
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best method to measure internal drug concentration inside Xenopus embryos. 
Vliegenthart and colleagues (2014) developed a method to extract blood from zebrafish 
through the retro orbital sinus. This could be useful to determine the Cmax of drug 
candidates in Xenopus. But this laboratory group used adult zebrafish aged 5 months to 2 
years old post fertilisation; we imagine it would difficult to apply the same technique to 
Xenopus embryos. This zebrafish laboratory group found that the zebrafish plasma 
concentration of paracetamol 4 h after an overdose was 962 mg/mL. They stated this was 
similar to the 10-340 mg/mL plasma concentration measured in humans that have taken a 
paracetamol overdose (Dargan et al., 2001; Prescott et al., 1979; Vliegenthart et al., 
2014a). The fact that a non-mammalian model can possess similar pharmacokinetics to 
humans means the Xenopus model could be useful too.  
 At the ages of stage 38 and stage 45, the embryos expressed phase I and phase II drug 
metabolism enzymes: (a) CYP450 isoenzymes 2D6, 3A4 and 2E1 (b) GST (glutathione-S-
transferase) P1, T1 and M1 (c) SULT (sulphotransferase) 1A1 and 2A1 and (d) UGT 
(UDP-glucuronosyltransferse) 1A1 and 1A6. The human drug metabolism enzymes of the 
same names metabolise a high percentage of drugs taken. We decided to look for the 
expression of these enzymes especially, because the CYP2E1 and all the phase II 
enzymes are known to be important for paracetamol metabolism, which is the main 
hepatotoxic drug we explored in chapter 4. The mRNA expression of these enzymes 
does not necessarily correlate with a functional CYP450 enzyme. In addition, the Xenopus 
CYP2E1 enzyme may not be the major enzyme involved in the generation of the 
paracetamol reactive metabolite NAPQI, as is the case in humans. Consequently it would 
be useful to measure the activity of the drug metabolism enzymes in Xenopus at stages 
38 and stages 45 to characterise their drug metabolism capacity. Possible methods for 
this are outlined in the future experiments sections below. 
6.4 Xenopus laevis embryos and the prediction of DILI: paracetamol 
Drug-induced liver injury (DILI) is the leading cause of drug attrition in the later phases of 
drug development. Each drug associated with DILI in man presents as a specific liver 
injury phenotype. In addition, a drug candidate that causes idiosyncratic DILI is rare and 
often not detected in the clinical phases of drug development because the size of the 
study cohorts are too small. Consequently, it is impossible for one animal model to be 
able to detect all DILI reactions. We proposed the Xenopus laevis embryos could be an 
additional animal model to detect drug candidates that are associated with DILI in the very 
early phases of drug development. They could bridge the gap between in vitro studies and 
the first in vivo studies. To investigate if the Xenopus embryos have the ability to detect 
DILI, we used the dose-dependent hepatotoxin paracetamol in chapter 4. Paracetamol 
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overdose is a major contributor to the incidence of acute liver failure in the US and the UK. 
We hypothesised that stage 38-45 Xenopus laevis embryos treated with paracetamol will 
exhibit characteristics of paracetamol-induced liver injury similar to other non-mammalian 
and mammalian animal models and humans. We established this hypothesis is correct 
according to our results that measured: (1) miR-122 expression, (2) free GSH 
concentration, (3) paracetamol metabolite generation and (4) NAC intervention. Xenopus 
embryos treated with paracetamol had an increased miR-122 expression in isolated tissue 
that does not normally express miR-122. In humans, other mammalian animal models, 
and non-mammalian models, miR-122 expression is abundant in the liver. Liver injury 
causes an increase of miR-122 expression in the blood. The Xenopus embryo tail was 
used as a substitute for mammalian blood in our experiment, as it is very difficult to obtain 
enough blood from a stage 45 to measure the serum miR-122 concentration. We also 
adapted an in vitro assay that measures free GSH concentration for paracetamol-treated 
Xenopus embryos. This adaptation produced results that show that as the concentration 
of paracetamol the embryos were incubated with increased, the concentration of free GSH 
inside the embryos decreased. In humans that take a therapeutic dose of paracetamol, 
the paracetamol reactive metabolite NAPQI is neutralised with GSH. A paracetamol 
overdose leads to a higher production of NAPQI and consequently less endogenous free 
GSH is available to reduce the toxic effects of NAPQI that provokes liver function 
impairment. The GSH result for Xenopus embryos implies they metabolise paracetamol 
via a similar pathway to humans. Moreover, the Xenopus embryos generate paracetamol 
metabolites that are also detected with human paracetamol metabolism. This is 
demonstrated in our HPLC-MS/MS results in chapter 4. Finally, when Xenopus embryos 
are treated with paracetamol for 72 h and NAC for the last 24 h of the incubation, the 
reduction of free GSH is not as considerable as without NAC treatment. NAC is the 
therapeutic treatment for humans that have taken a paracetamol overdose. These last 3 
experiments (free GSH reduction, HPLC-MS/MS and NAC treatment) indicate the 
Xenopus embryos have the ability to process paracetamol and therefore potentially other 
drugs as well, using the same metabolic pathways and mechanisms as humans. This is 
important for the detection of DILI, because often an adverse hepatotoxic reaction occurs 
due to a drug metabolite, not the parent drug. So a good animal model for the prediction 
of DILI should be able to generate the same or similar metabolites that will be produced in 
humans. 
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6.5 Xenopus laevis embryos and the prediction of cardiotoxicity: 
doxorubicin and terfenadine 
The second organ-specific toxicity we investigated with the Xenopus embryos was drug-
induced cardiotoxicity. The introduction of a compulsory evaluation of the potential for a 
drug candidate to cause delayed ventricular repolarisation has reduced the incidence of 
drug attrition due to cardiotoxicity associated with TdP. In the past, the majority of assays 
that assessed drug-induced cardiotoxicity analysed the drug candidate’s interaction and 
ability to block the potassium ion hERG channel and consequently the IKr current. But in 
2014, the CiPA initiative recognised that there are other ion channels that the drug 
candidate could interfere with and contribute to the generation of a cardiotoxicity reaction. 
As a result, the CiPA method was introduced which is comprised of 3 elements: (1) in vitro 
evaluation of drug effect on multiple individual currents, (2) in silico computational 
reconstruction to assess proarrhythmic liability and (3) confirm any effects found using in 
vitro electrophysiological techniques. The models to predict drug-induced cardiotoxicity 
are clearly still developing and we think there is room for the Xenopus embryo model at 
the early phases of drug development. Non-mammalian animal models can still be 
relevant to humans even though the heart structure does not have 4 chambers. For 
example, the zebrafish has a 2-chambered heart it has an average heart rate of 120-180 
bpm and the QT intervals are 400-500 ms (Hassel et al., 2008; Leong et al., 2010). 
Whereas mice have a much higher heart rate at 300-600 bpm and their QT intervals are 
shorter at 50 ms (Dhillon et al., 2013). Humans have an average heart of 60-100 bpm and 
a QT interval of 350-440 ms (Li et al., 2016). Thus, the non-mammalian zebrafish could be 
just as relevant as the mammalian models for the prediction of drugs that affect human 
heart rhythm. 
In chapter 5 we investigated if the Xenopus embryo could be a good model for the 
prediction of cardiotoxicity. To do this, we used doxorubicin and terfenadine, which are 2 
drugs known to be associated with cardiotoxicity in humans. The mechanism of toxicity is 
slightly different between doxorubicin and terfenadine, so by using these test drugs we 
were able to analyse if the Xenopus embryos can aid the identification of different types of 
drug-induced cardiotoxicity.  The generation of doxorubicin-induced cardiotoxicity is 
attributed to the production of free radical oxygen species that damage cardiac tissue. 
Terfenadine is known to block the hERG channel and therefore negatively impact on the 
delayed rectifier current and subsequently cause arrhythmia. One of the advantages of 
the Xenopus embryos, is their transparency, the heart can be observed beating in real 
time. We exploited this with our heart rate assay. The heart rate of treated embryos 
increased with increasing doxorubicin concentration and decreased with increasing 
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terfenadine concentration. The incidence of arrhythmias increased with increasing 
doxorubicin concentration. But for terfenadine-treated embryos, arrhythmias occurred at 
every concentration and were not dose-dependent. All of these results demonstrate that 
cardiotoxic drugs affect the Xenopus embryo hearts and the trends also correlate with 
other animal models. Overall, we reached the aim of chapter 5 and demonstrated that the 
Xenopus embryos can be useful for the prediction of cardiotoxicity. 
6.6 Limitations and future experiments 
We have addressed the majority of the aims for this project in chapters 3 – 5 and the 
advantages of the Xenopus embryos for the prediction of drug-induced toxicity are 
summarised in the sections above. However, we understand this non-mammalian model 
is not likely to correlate completely with humans and we discovered some limitations in 
this project. We think some of these limitations can be improved with future experiments 
(Figure 6-2). First of all, we did not have the time to explore a large number of drugs 
associated with organ-specific toxicity in the Xenopus embryos. To help further 
characterisation of the Xenopus embryo model, we would like to use a list of test drugs 
that have different mechanisms of toxicity for hepatotoxicity and cardiotoxicity. We also 
think it would be beneficial to add drugs to the list that are not associated with toxicity and 
conduct a blind experiment to determine if the Xenopus embryos can help differentiate 
between the toxic and non-toxic compounds. This is an important feature of an ideal 
animal model to be used in drug development.  
In chapter 3 we measured drug metabolism enzyme expression but not activity. It is 
important to characterise the Xenopus embryo drug metabolism capability because 
sometimes it is the drug metabolite, not the parent drug, which is vital for a drug-induced 
toxicity reaction to occur. In future experiments we would like to measure drug metabolism 
enzyme activity in the stage 38 to stage 45 Xenopus embryos to examine if they are 
functional at this age. Once we have established their functionality, we could also use 
enzyme inhibitors to decipher the mechanisms and pathways for drug-induced toxicity 
reactions in the Xenopus. We attempted to isolate microsomes from an adult Xenopus in 
chapter 4 to investigate CYP450 activity in the presence of 1-ABT, a known CYP450 
inhibitor in mammalian models. To quantify CYP450 activity, we used the substrate ρ-
nitrophenol and tried to measure the rate of the production of the product 4-nitrocatechol 
(Monostory et al., 2004). However the protocol required more time to be optimised for the 
Xenopus. We would like to measure SULT activity in the Xenopus embryos to determine 
their ability to process drugs using the sulphation metabolic pathway. Typically, the activity 
of the SULT enzymes is determined by measuring the transfer of a PAP35S sulpho group 
to a substrate, and then quantifying the 35S-labelled products (Paul et al., 2012). PAPS is 
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the coenzyme or conjugating agent involved in sulphotransferase reactions. We would 
also like to measure the activity of the UGT enzymes in the Xenopus embryos, as 
glucuronidation is a major drug metabolism pathway in humans for many drugs. There are 
compounds specific to UGT isoforms such as azidothymidine for UGT2B7 and propofol for 
UGT1A9. UGT activity can be quantified using fluorescence, HPLC and mass 
spectrometry techniques that detect the products of these substrates (Donato et al., 
2010). 
One of the major aims we did not achieve for this project was the evaluation of Xenopus 
embryos for the prediction of nephrotoxicity. Drug-induced nephrotoxicity accounts for 18-
27 % of acute kidney injury cases in the US (Taber and Pasko, 2008). It is responsible for 
2 % of drug attrition in preclinical studies and 19 % in the clinical phase of drug 
development (Jang et al., 2013). In the literature and to our knowledge, Xenopus embryos 
have not been characterised for the prediction of drug-induced nephrotoxicity. 
Christensen et al (2008) have detected the expression of megalin and cubilin in stage 35 
Xenopus tropicalis embryos. The expression was specific to the proximal tubule of the 
pronephric kidney (Christensen et al., 2008). Megalin and cubilin are endocytic receptors 
that are co-expressed in the apical membrane of the proximal tubule. In humans, they are 
predominantly involved in the reabsorption of albumin. However these receptors also play 
a pathophysiological role in the uptake of aminoglycosides, such as gentamicin. The 
accumulation of aminoglycosides in the proximal tubule is associated with the mechanism 
of drug-induced nephrotoxicity. In summary, Christensen et al indicate the Xenopus 
embryo has some of the mechanistic tools that suggest it could be a good animal model 
to help predict drug-induced nephrotoxicity, and it would be interesting to investigate this 
in the future. In chapter 3 we looked at 2 drugs associated with nephrotoxicity: cisplatin 
and gentamicin. In the stage 38 – stage 45 screens, a common abnormal phenotype 
observed in embryos treated with 0.78-100 µM gentamicin was gastrointestinal oedema. 
This indicates that the Xenopus embryo could be a promising model to help identify drug-
induced nephrotoxicity. However all of the embryos treated with cisplatin generated a 
wildtype phenotype, no abnormal phenotypes were identified. We hypothesise this is 
because the dose range 0.78-100 µM was not high enough to cause cisplatin-induced 
toxicity in the Xenopus embryos.  
It is difficult to determine what is the correct concentration range to use that can potentially 
cause drug-induced toxicity in a new animal model. For in vitro safety studies, the drug 
concentration that causes 20 % cell death is the highest concentration that should be 
used to test for drug-specific toxicity. A higher percentage of cell death could be caused 
by general toxicity mechanisms that occur if the cells were treated with too much of any 
compound. In addition, the highest concentration treatment that maintains 80 % cell 
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viability can be used to decide if the test drug is likely to generate a toxicity reaction in 
humans. The ratio between this high concentration and the Cmax of the drug candidate in 
patients should be at least ten-fold, this ratio is called the safety margin (SM). A drug 
candidate with a value of SM<10, is identified as a compound that has a high probability 
of causing a toxicity reaction (Richert et al., 2016). We applied the same principle to our 
Xenopus embryo toxicity studies and used a concentration range that we believe 
investigates drug-specific toxicity, not general toxicity. 
It would be useful to measure the Xenopus embryo Cmax of the drugs we researched in 
this project for 2 reasons: (1) we can establish how much of the drug the embryo has 
taken up (the “internal dose” mentioned previously in this chapter) and (2) we can see if 
this is similar to Cmax in humans and therefore deduce the relevance of the Xenopus 
embryo as a model for the prediction of drug toxicity. HPLC-MS/MS can be used to 
measure the Xenopus Cmax. The concentration of paracetamol metabolites inside and 
outside the Xenopus embryos treated with paracetamol was measured after a 72 h 
incubation using HPLC-MS/MS in chapter 4. However we could not perform a statistical 
analysis on this experiment because it was only conducted once (n=1). We would like to 
repeat this experiment in the future and modify it to include more time points so we can 
analyse the concentration of the parent drug and its metabolites throughout the stage 38 – 
stage 45 paracetamol screen. As explained in the discussion of chapter 4, the 1 set of 
results we did obtain from HPLC-MS/MS analysis of paracetamol-treated Xenopus 
embryos indicate the embryos could be more representative of a child than an adult 
human. The APAP-glucuronide to APAP-sulphate metabolite ratio in adult humans is 
approximately 2:1 whereas in children it is closer to a 1:1 ratio. The APAP-glucuronide 
and APAP-sulphate metabolites detected in Xenopus treated with a concentration of 
paracetamol within the range 0-5 mM were closer to the ratio for children. If this result is 
reproducible, we will conduct further experiments to determine if the Xenopus behaves 
more like a child in terms of drug metabolism and pharmacokinetics than an adult. This 
could impact upon what the Xenopus should be used for in drug development. For the 
most part, in drug development the drugs are assessed for adult administration. 
Finally, in future experiment we would like to determine the impact of the test drug on 
organ function in the Xenopus embryos. Our experiments in chapter 4 focused on 
characterising drug-induced liver injury, however we did not investigate if the liver function 
was impaired. This is important because in humans, the body sometimes has the ability to 
compensate for drug-induced toxicity reactions. The human liver is particularly capable of 
adapting to chemical insults and it is able to regenerate after liver resection (Eakins et al., 
2015; Riehle et al., 2011). Adverse drug reactions could go undetected in the clinic until 
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the toxicity reaction is reversible after administration stops and organ function is adequate, 
then it can be argued that the drug benefits outweigh the risks. We would to adapt the 
liver function tests used in other animal models and humans to measure liver function in 
Xenopus embryos treated with drugs associated with liver injury in humans. Typically, liver 
function impairment can be characterised by measuring the concentration of liver 
biomarkers in the plasma as previously mentioned in chapter 1 such as ALT, AST, ALP 
and total bilirubin. However 1 method to truly measure liver function is using Indocyanine 
green (ICG) dye, which is exclusively cleared from the body via the liver. The elimination 
rate of ICG has been used to measure hepatic blood flow, hepatosplanchnic 
haemodynamics, and liver function (Brillant et al., 2017; Imamura et al., 2005; Levesque 
et al., 2016; Sakka, 2007). In the future, we would like to investigate the use of ICG dye to 
evaluate Xenopus embryo liver function. 
Our heart rate assay assessed Xenopus embryo heart function in the presence of drugs 
associated with cardiotoxicity in humans. In particular, we think that the incidence of 
arrhythmias measured with our heart rate assay method, is a good reflection of drug-
induced cardiac injury. However in future experiments with the Xenopus embryos we 
would like to add more time points to assess the incidence of arrhythmia over the 72 h 
incubation period and detect embryos that had arrhythmic heart beats but died before 
they could be detected at 72 h. In addition, it would be interesting to see if we could adapt 
the heart rate assay to detect changes in left ventricular ejection fraction (LVEF), which is 
a common measure of heart function in other animal models for the prediction of drug-
induced cardiotoxicity. Our heart assay protocol includes a computational element that 
eliminates some personal bias but it is still requires further development to become a 
more automated experiment. Currently, we counted the peaks and troughs of the graph 
generated from the change in greyscale due to the movement of blood through the 
Xenopus embryo heart, in order to get the number of beats per minute. 
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Figure 6-2: Future experiments to be conducted 
A schematic that displays examples of future experiments that would be required to 
further characterise the Xenopus laevis embryo as a model for the prediction of drug-
induced toxicity. The internal dose the embryo receives from the dose they are exposed to 
should be characterised to determine Xenopus embryo pharmacokinetics and relevance 
to human peak plasma concentration. The paracetamol metabolite ratio was similar to that 
observed in children; future experiments should explore if this model is closer to human 
adults or representative of children. Finally, a more comprehensive list of compounds 
associated and not associated with toxicity reactions in humans should be performed in a 
blind study to see if this model can differentiate these groups. 
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Figure 6-3: Drug development with Xenopus laevis 
The proposed use of Xenopus laevis embryos in drug development would be in the early 
preclinical phase for the prediction of drug-induced toxicity. Xenopus embryos could 
bridge the gap between in vitro and in vivo safety studies. 
6.7 Conclusion and the ‘bigger picture’ 
In this project, we aimed to investigate the use of Xenopus embryos for the prediction of 
drug-induced toxicity in humans. We propose a non-mammalian animal model such as the 
Xenopus could be useful to bridge the gap between in vitro and in vivo drug safety studies 
in the early preclinical phase of drug development (Figure 6-3). Currently, our results 
indicate that the Xenopus embryos could be useful and relevant model. A lot of the 
methods for the detection of drug-induced toxicity are conserved. In particular, the organ-
specific expression of miR-122 and miR-208 for the liver and heart respectively suggests 
a simple qRT-PCR experiment with treated Xenopus embryos can indicate drug-induced 
toxicity. This experiment combined with the fact that at least 5 embryos can fit into 1 well 
of a 96 well plate, demonstrates Xenopus embryos could be useful for medium throughput 
screening. In addition, this is translatable to other animal models and humans that also 
express these organ-specific biomarker miRNAs. However we think that further 
characterisation is required to determine the limitations of the model and therefore 
understand the value of the data it generates. This animal model could adhere to the 
reduction principle defined by the NC3Rs. In research, much effort has been made to 
characterise the zebrafish as a model for drug-induced toxicity. However the Xenopus, an 
alternative non-mammalian model, has a closer anatomic proximity to humans than the 
zebrafish. The Xenopus has lungs, a 3-chambered heart (as opposed to the 2-chambered 
zebrafish heart) and amphibians have a common evolutionary history with mammals that 
is an estimated 100 million years longer than between zebrafish and mammals (Kälin et 
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al., 2009). Unfortunately commercial research tools for the Xenopus such as antibodies 
are currently not readily available. Consequently it can be difficult to adapt common drug 
toxicity experiments. However we believe that with time, further characterisation and by 
developing the experimental methods to be become more automated, the Xenopus 
embryo could be a useful tool for the prediction of drug toxicity in drug development. 
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8 Chapter 8: Appendix 
 
Genes were retrieved from GenBank (www.ncbi.nlm.nih.gov) and primers were designed 
using Primer3 (http://primer3.ut.ee/). 
 
The miRCURYTM LNA PCR Primer mixes used were: 
Table 8-1: miRNA qRT-PCR primer sets 
Xenopus laevis 
experimental target 
gene 
Product name 
(Exiqon) 
Target sequence 5’-3’ 
miR-122 ssc-miR-122 UGGAGUGUGACAAUGGUGUUU
GU 
miR-103 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAU
GA 
 
Custom designed miRCURYTM locked nucleic acid (LNA) probes 
Table 8-2 miRNA LNA probes 
Xenopus laevis 
experimental target 
gene 
Target sequence 5’-3’ 
miR-122 UGGAGUGUGACAAUGGUGUUUGU 
miR-208 AUAAGACGAGCAUAAAGCUUGU  
 
Table 8-3: mRNA qRT-PCR primers 
Gene Forward primer Reverse primer 
mrp2 CTGCACAACATCCTACGGG
T 
TCCAGCTGCGGAATGACA
TT 
odc CATGGCATTCTCCCTGAAG
T 
TGGTCCCAAGGCTAAAGTT
G 
 
Table 8-4: mRNA RT-PCR primers 
Gene Forward primer Reverse primer 
CYP2E1 CCGCTCATTGGAAATCTGCA CGGTGGTTGAGCAGTATG
TG 
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CYP2D6 TCACACTGGGCATCATCTGT TTTCCCCATGCCAAAATCC
C 
CYP3A4 ACCTACTCCATTGCCGTTCA TGAGGTGCTGGTGATGAC
AT 
GSTP1 set 1 GTATTCGGTCAGCTGCCTCA CGTTTATTGCGGGCATCTG
A 
GSTP1 set 2 GGCAGATCAGGGCATTTCC AAGGGTAGGCTGAAAGGG
AC 
GSTT1 set 1 TGGCCGATCTCACACTCTAC TGCCACAGAGATCTCATCC
C 
GSTT1 set 2 GTGTGCCCGTGTTGATGAAT GGGTAGAGGTTCACTTGC
CA 
GSTM1 set 1 CGATGGATTTTCGCATGGGT AGGACATCAGGTAGGGGA
GA 
GSTM1 set 2 CGTGGATGGTGATGTGAAG
C 
CCATGCGGTTGTTAATCG
GT 
SULT1A1 set 1 CCATTGCGTCAGACAGGAA
G 
TAAGACACCGCCACATCCT
T 
SULT1A1 set 2 GGCATCCCCTCGTATCATCA CATCACAGAGCTTGGAAC
CG 
SULT2A1 set 1 TGCTTTCTCGCTGTAGGTGA AAGAACCCTTGGGCTGGA
AA 
SULT2A1 set 2 CCCCAGGCTCATACTCACAA CTGACGTGCTCAAACCAA
GA 
UGT1A6 set 1 TCCTCTTGTTGGTGTTGGGT GGGATGGAAAGGTGTTCA
GC 
UGT1A6 set 2 TCCCAGACCTGTAATGCCAA ACTGAGAGTCAACCCTGC
TC 
UGT1A1 set 1 AGAATGCTCTGGTGTGGTCA CATGTGATCCAGCGTGAG
TG 
UGT1A1 set 2 CACTCACGCTGGATCACATG GCGAAAGACAAAAGTGCA
GC 
KCNH2 TGGTGGCAGCTATACCCTTT GTGTTGGGAGAGACATTG
CC 
AMBP CGACTATTTCAACGCACGGT CGCCATACTGAAACGTCTC
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G 
MRP2 CCTTCCCCTGTGCTTTGAAC CGCCTGGTGTGATGAATG
AG 
Cardiac 
troponin 1c 
AAAGAGCCCGGACAAGATG
T 
TCACTTCGGCTTCCATGTC
A 
 
8.1 Heart rate assay 
An example of a video used for the heart rate assay can be found at the following link: 
 
https://drive.google.com/drive/folders/1uoxGkKr1NsYniqqHgzIgQa4Bdf_HGEKg?usp=sha
ring 
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Figure 8-1: Heart rate analysis and an example of a physiological heart beat 
Schematic to show the analysis process of the videos taken for the heart rate assay. 
Shown here, is a screenshot of the video once it has been imported into the video 
analysis software, ImageJ (Panel A). A more detailed description of the method is in 
chapter 2. The heart is outlined with a black line and the three regions of interest (ROIs) 
are shown here in yellow circles that are 70 pixels in diameter. ROIs were placed in the 
Xenopus atrium (A), ventricle (V) and in an area outside of the heart for control (C). The 
average intensity for each ROI over time was plotted. Shown here is an example of a 
graph generated for a normal, physiological heart beat (Panel B). The intensity peaks and 
troughs are opposite for the ventricle (blue) and atrium (orange). 
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Figure 8-2: Graphs that indicate arrhythmic heart beats 
3 representative arrhythmic heart beat graphs generated from videos analysed using the 
heart rate assay. The average intensity within the ROI for the ventricle (blue line) and the 
atrium (orange line) were plotted against time. An abnormal heart beat pattern can be 
presented as irregular ventricular peaks or shallow atrium peaks (A and B). Alternatively, 
simultaneous atrial and ventricular peaks also indicates an arrhythmic beat (C).	  	  
